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Abstract 
 
The successful development of the human fetus during pregnancy depends on a tight 
regulation of the uteroplacental vasculature in order to allow sufficient provision of 
oxygen and nutrients from the mother to the placenta and fetus. To accomplish this, the 
fetoplacental circulation develops de novo, whilst the uterine vasculature undergoes 
dynamic remodelling. Such distinct features of these circulations suggest that regulation 
of their vascular function may differ. If so, then in vitro examination of these blood 
vessels may serve as a useful model for tissue-specific mechanisms of human vascular 
tone regulation. A reduction in intracellular Ca2+ ([Ca2+]i) in vascular smooth muscle 
cells leads to an increase of myosin light chain phosphatase (MLCP) activity, which 
induces myosin light chain dephosphorylation and vasodilation. Further molecular 
signal transduction mechanisms may serve to desensitise the myofilaments to changes 
in [Ca2+]i.  There is surprisingly little information on the nature of desensitisation to 
Ca2+ in human myometrial (MA) and placental arteries (PA). Therefore, this study 
aimed to primarily assess Ca2+-desensitisation mechanisms in MA and PA. Here, we 
showed (i) that the phenomenon of Ca2+-desensitisation occurred in MA and PA. (ii) 
That it was promoted by the activation of protein kinase G (PKG) and dependent upon 
an active MLCP. (iii) That MA displayed greater PKG-mediated Ca2+-desensitisation 
capabilities compared to PA. In addition, this sensitivity remained greater in MA and 
PA over the soluble guanylate cylase/PKG axis, but was, surprisingly, reversed at the 
NO level. Moreover, these differences were not the result of differing expression levels 
of PKG and PKG-interacting proteins involved in the vasodilatory pathway, as these 
were similar between the two artery types.  These results highlight a variation in 
vasodilatory responses between MA and PA, which may illustrate a difference in the 
regulation of vascular tone between the two circulations. Further investigation of the 
mechanisms involved may prove useful in the development of more tissue-specific 
therapies. 
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1. Chapter 1 
Introduction 
 2 
1.1. General overview 
 
During pregnancy, a tightly regulated exchange must develop between the mother and 
growing fetus and be kept throughout the gestational 40 weeks. A fetus may be 
considered a foreign body with increasing demands for oxygen and nutrients allowing 
its full development. The dependence of the fetus on the mother requires the latter to 
undergo several dramatic adaptations to provide for these expectations. These include 
immune, renal, pulmonary and, perhaps most importantly, vascular and allow the 
recognition of the fetus and a maternal endurance of the pregnancy. The importance of 
adequate vascular adaptations is highlighted in the fact that the only available delivery 
route from mother to fetus is vascular. The placental and uterine circulations play a vital 
role in this contraption. They represent the highly regulated circuits through which the 
fetus receives oxygen and nutrients from, and exports waste products to, the mother. 
The mechanisms involved in regulating tone of these two vasculatures are therefore 
likely to be complicated and discreet. However, despite the essential role of the two 
circulations, our knowledge of the biological processes involved in their regulation is 
limited.  
 
The placental vascular bed develops de novo into one of relatively low resistance 
(Boura, 1998) and the uterine circulation becomes extensively remodelled (Ramsey, 
1981), all to accommodate the increasing demands of a growing fetus. However, in 
pregnancy complications, such as preeclampsia, fetal growth restriction (FGR) and 
preterm birth, in vitro resistance of maternal and/or placental circulations is increased 
and blood flow is compromised (Poston et al., 1995, Wilson et al., 2003, Wallis et al., 
2008). The increased vascular resistance is thought to occur as a result of deficient 
remodelling of uterine spiral arteries, which are not transformed to low-resistance 
vessels, and hence restrict blood flow to the intervillous space and placental circulation 
(Khong et al., 1986) and, especially in preeclampsia, endothelial dysfunction within 
upstream uterine resistance arteries and/or placental arteries contributes to the pathology 
(McCarthy et al., 1993, Ashworth et al., 1997, Wareing and Baker, 2004). Indeed, 
aberrant endothelial function has been observed in small intact arteries dissected from a 
number of human vascular beds (placental, omental, myometrial) following functional 
assessments with endothelial-dependent vasodilators, such as bradykinin (McCarthy et 
al., 1993, Ashworth et al., 1997, Wareing and Baker, 2004). 
 
 3 
The only effective management option for severe complications of this nature, where 
fetal and/or maternal health is at risk, is the preterm delivery of the infant. Deliveries 
occurring before the 37th week of gestation are considered preterm and in developed 
countries, such as the United Kingdom, account for around 6 - 8 % of all deliveries 
(Goldenberg et al., 2008). The care of preterm infants puts a great burden on the 
healthcare infrastructure, with costs estimated at 1 billion pounds per annum (Petrou et 
al., 2011). Infants born pre-term are at increased risk of both immediate adverse 
neonatal outcomes, such as haemorrhage, neonatal sepsis, bronchopulmonary dysplasia 
and long-term disabilities, such as respiratory problems, learning difficulties, social and 
behavioural problems (Anderson and Doyle, 2003, Wen et al., 2004, Iams et al., 2008, 
Saigal and Doyle, 2008, Zhang et al., 2011). Current therapies for placenta-mediated 
disease are very limited. With respect to preterm labour tocolytic interventions, such as 
$-agonists, L-type Ca2+ channel blockers, vasopressin/oxytocin receptor antagonists are 
ineffective; studies have failed to demonstrate benefits in terms of prevention of preterm 
birth or improvement in neonatal outcomes (Hollier, 2005, Lyndrup and Lamont, 2007). 
This, in part, reflects the fact that they act on vasculature as well as the myometrium.  
 
Thus, it has never been more important to develop our understanding of the vascular 
mechanisms governing healthy pregnancies, in order to allow a better approach at 
developing more specific therapies. 
 
1.2. The physiological adaptations during human pregnancy 
 
The physiological adjustments that occur during pregnancy are specifically designed to 
promote an environment that supports fetal development and growth, whilst 
maintaining maternal wellbeing. Several major maternal adaptations are required during 
pregnancy in alliance with placental organogenesis and fetal development. 
 
1.2.1. Maternal changes in pregnancy 
1.2.1.1. Cardiovascular adaptations 
 
Perhaps the most profound and essential maternal adaptations during pregnancy occur 
in the cardiovascular system.  The uterine blood flow increases dramatically as the 
cardiac output (CO) rises from the 5th week of pregnancy, peaking around 32 weeks at 
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approximately 30 – 50 % above non-pregnant values (Figure 1.1) (Clark et al., 1989, 
Easterling et al., 1987, Robson et al., 1989). Preceding and enabling the increase of CO, 
the systemic vascular resistance (SVR) decreases during the first trimester of pregnancy 
and reaches a nadir at 14 - 24 weeks of gestation. Thereafter, SVR rises reaching pre-
pregnancy values by term (Clark et al., 1989, Bosio et al., 1999). The fall in SVR is due 
to peripheral and renal arterial vasodilation in early pregnancy, thought to be mediated 
by progesterone and oestrogen and by vasodilators such as nitric oxide (NO) (Weiner et 
al., 1994). These mechanisms of remodelling will be further discussed in Section 1.3.2. 
With the increase in CO but a greater relative decrease in SVR (Phippard et al., 1986), 
blood pressure, which is the product of CO and SVR, falls by approximately 10 % by 
mid-pregnancy and then increases thereafter reaching or exceeding pre-pregnancy 
values by term (Clapp et al., 1988, Clapp and Capeless, 1997, Robson et al., 1989). 
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Figure 1.1: Vascular changes during pregnancy. Diagrams highlighting the changes in 
cardiac output (A) and uterine blood flow (B) during pregnancy. Adapted from (Turnbull, 
2001). 
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1.2.1.2. Changes in the renal system 
 
Both renal blood flow and glomerular filtration rate increase by 35 – 60 % during 
pregnancy, which increases the functional capacity of the kidneys (Davison and Hytten, 
1975), allowing an increase in urea, creatinine and urate clearance (Higby et al., 1994). 
The activities of renin-angiotensin, aldosterone and progesterone are also increased, 
leading to an increase in water and sodium retention and a decreased plasma osmolarity 
(Davison et al., 1981, Lindheimer and Barron, 1998). Over-activation of renin-
angiotensin by a low-sodium diet attenuated maternal artery remodelling, impairing 
adequate neonatal development in pregnant rat (St-Louis et al., 2006). Additionally, in 
preeclamptic women, over-expression of the angiotensin I receptor has been 
documented, potentially contributing to the hypertensive state of the pathology 
(Mandala and Osol, 2012). 
 
1.2.2. Embryonic and placental development 
1.2.2.1. Embryonic development 
 
The first week of pregnancy results in implantation of the blastocyst, into the decidual 
endometrium, which is the inner-most layer of the uterine wall (Benirschke and 
Kaufmann, 1991, Pijnenborg, 1990). The blastocyst is composed of a fluid-filled cavity 
within a cell mass; the surface (outer) cells will become the trophoblast and give rise to 
the extra-embryonic structures, including the placenta; whilst the inner cell mass or 
embryoblast will form the embryo (Cross et al., 1994). By the 10th day post-fertilisation, 
the surface trophoblastic cells of the adhering blastocyst have differentiated into an 
inner cellular layer, the cytotrophoblast, and an outer syncytiotrophoblast (Boyd and 
Hamilton, 1966), which are important cell types for the establishment of placentation 
(Norwitz et al., 2001).  During the second week, the embryoblast becomes flattened to 
form the embryonic disc. This structure then differentiates into three germinal tissues, 
an ectodermal layer, mesodermal layer and endodermal layer, in which a small fluid-
filled cavity, the amniotic sac, forms (Gray, 1975, Elder, 2002). The dorsal ectoderm 
will develop into the entire nervous system, the skin and its appendages (hair and 
glands) and the other sensory organs, such as the eyes and ears. The intermediate 
mesoderm will form the supporting structures of the body – bones, joints, muscles, 
connective tissues – and the vascular and urogenital systems. Finally, the endoderm is 
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responsible for the gasto-intestinal tract and the remaining organs, such as the lungs and 
thyroid glands (Gray, 1975).  During the third week of pregnancy, the secretion of 
human chorionic gonadotrophin by the syncytiotrophoblast of the early formed placenta 
stimulates the maternal ovaries to produce progesterone and oestrogen (Foidart et al., 
1992).  Thus, it is the control of the maternal reproductive system by the embryo, which 
sustains the pregnancy state and inhibits menstrual cycles for the remainder of gestation. 
By the time the embryo is one month old, all the major organs have developed and for 
the remainder of the pregnancy, these organs will mature and grow in size. 
 
1.2.2.2. Placental Development 
 
The human placenta is a haemochorial structure, which means that the maternal 
circulation comes into direct contact with the placental surface (chorion), but not with 
the fetoplacental circulation itself (Benirschke and Kaufmann, 1991, Gray, 1975). The 
placenta is the first of the fetal organs to form and its development is characterised by a 
particularly invasive behaviour, analogous to a locally invasive tumour (Foidart et al., 
1992). It mediates implantation and establishes the interface for nutrient and gas 
exchange between maternal and fetal circulations. Additionally, it contributes to 
maternal recognition of pregnancy by altering the local hormonal and immune 
environment. 
 
Placentation begins at the end of the first week post-fertilisation with the implantation 
of the blastocyst (Benirschke and Kaufmann, 2000). Columns of proliferating 
cytotrophoblasts penetrate and invade the decidual endometrium (Boving, 1959a). 
These then assume the extravillous trophoblastic lineage and invade by two distinct 
routes – interstitial and endovascular. Both contribute to the invasion and 
transformation of the distal branches of the maternal uterine circulation, also known as 
spiral arteries, thereby promoting increase in blood flow to the site of implantation 
(Kilman, 2000, Kilman, 1993, Pijnenborg, 1990, Kaufmann et al., 2003). By the end of 
the second week post-fertilisation, an early intervillous space exists formed from the 
coalescence of maternal vascular spaces derived from dilated uterine capillaries (Boving, 
1959b, Dempsey, 1972).  
 
The trophoblast lining the intervillous space develops forming a series of villous 
structures from primary to tertiary villi (at the end of the third week), ultimately 
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developing into the chorionic villus network (Dempsey, 1972, Demir et al., 1989).  
From the fourth week, the maternal ends of villous stems start to subdivide and side 
branches develop off the main villous trunk (Boving, 1959a). Each villous stem forms a 
complex network consisting of a single trunk attached by its base to the chorion, and 
from which arise distally, second and third degree branches, making up the cotyledon 
(Figure 1.2). Each new terminal villous branch passes through primary, secondary and 
tertiary villous development stages (Castellucci et al., 1990, Castellucci et al., 2000). 
Most importantly, these terminal villi have a high degree of capillarisation (Feneley and 
Burton, 1991), which enables adequate maternal-fetal exchange of nutrients, oxygen 
and waste products.  
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Figure 1.2: Schematic diagram of tertiary chorionic villi. The uterine vessels in the decidua 
represent spiral arteries, which, once remodelled following invasion of trophoblasts, display a 
rather non-contractile phenotype, due to the loss of their smooth muscle cells (see Section 
1.3.2). Adapted from (Gray, 1975).  
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1.3. Characterisation of the placental and uterine circulations  
 
In human pregnancy, the de novo formation of the placental circulation and the 
remodelling of the uterine vasculature both occur during the first 20 weeks; however 
these processes take place separately. The two vasculatures do not physically meet and 
remain separated by the intervillous space. 
 
1.3.1. De novo formation and characterisation of the placental circulation 
1.3.1.1. The development of the placental circulation by vasculogenesis and 
angiogenesis 
 
The placental vasculature develops via two distinct processes, vasculogenesis, which is 
the formation of new blood vessels by de novo development of endothelial progenitor 
cells, and angiogenesis, which is the formation of new blood vessels from pre-existing 
ones (Kaufmann et al., 2004, Demir et al., 1989). The process of vasculogenesis 
involves (i) the production of haemangioblasts (the progenitors of hematopoietic cells) 
and angioblasts (the progenitors of endothelial cells), possibly induced by fibroblast 
growth factors, leading to the formation of primitive capillaries (Hanahan, 1997, Ribatti 
et al., 2002), (ii) the assembly of primordial vessels, a process, which is mediated by 
vascular endothelial growth factors (VEGF) (Demir et al., 2006) and (iii) the activation 
of VEGF receptors to induce the transition from vasculogenesis to angiogenesis (Demir 
et al., 2010).  
 
Angiogenesis occurs through both sprouting and non-sprouting processes (Kaufmann et 
al., 2004). The former is characterised by the development of branches, with each 
branch passing through primary, secondary and tertiary villous development stages, as 
described in Section 1.2.2.2, until a primitive feto-placental circulation is established. 
The latter is the formation of capillary loops through elongation of existing capillaries 
(Demir et al., 2006). The formation of novel capillaries by vasculogenesis followed by 
the expansion of the villous vascular system by angiogenesis is thought to occur 
throughout gestation (Benirschke and Kaufmann, 2000).  
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1.3.1.2. Characterisation of the fetoplacental circulation 
 
Studies on blood flow using Doppler ultrasound have described the placental 
vasculature as a “low-pressure circulatory system” (Rosenberg, 1998, Ferre, 2001, 
Kleiner-Assaf et al., 1999, Boura, 1998). Anatomically, the placental circulation is 
made up of three umbilical vessels (two arteries and a vein), vessels on the surface of 
the chorionic plate, vessels within the stem villi and vessels present in the terminal 
portions of the villus trees (Kaufmann, 1998). Arteries from the chorionic plate have the 
size characteristics of small arteries (less than 500 µm), which are thought to contribute 
to the resistance of peripheral vascular beds (Mulvany, 1987, Mulvany and Aalkjaer, 
1990, Wareing et al., 2002). However, it remains unclear to what extent the chorionic 
plate and downstream stem villi vessels each contribute to vascular resistance in the 
placental vascular bed (MacLean et al., 1992, Wareing et al., 2002).  
 
Small arteries (and arterioles) from the systemic vascular beds are controlled by the 
sympathetic and nervous systems, which contribute to the maintenance of basal tone 
(Mulvany and Aalkjaer, 1990, Mulvany and Korsgaard, 1983). However, evidence 
suggests that the placental (and umbilical) vasculature has no neuronal input (Reilly and 
Russell, 1977, Fox and Khong, 1990), suggesting that tone of the placental vessels is 
predominantly regulated by endocrine and paracrine factors (Boura, 1998, Poston et al., 
1995).  
 
1.3.2. Dynamic remodelling and characterisation of the uterine vasculature 
1.3.2.1. Effects of remodelling on the uterine vasculature 
 
As illustrated in Figure 1.3, the blood supply of the uterus is comprised of uterine radial 
arteries, which originate from a common arcuate (main) artery (Brosens et al., 1967). As 
radial arteries approach the inner myometrium and decidua, they become coiled (spiral 
arteries) (Brosens et al., 1967, Pijnenborg et al., 2006, Ramsey, 1981). During 
pregnancy, spiral arteries are transformed from high-resistance, low-flow vessels into 
dilated high flow, low resistance vessels (Osol and Mandala, 2009, Burton et al., 2009). 
These alterations occur as a result of loss of smooth muscle cell (SMC) and elastic 
lamina from the vessel wall (Pijnenborg et al., 2006, Pijnenborg et al., 1980). 
Breakdown of elastin within the internal elastic lamina (IEL) is crucial to allow 
expansion and abolish elastic recoil. The endothelium is temporarily replaced with a 
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trophoblast layer (restored later in pregnancy), which may account for the low oxygen 
tension in the fetal environment relative to maternal tissues (Huppertz and Peeters, 
2005). This ‘plugging’ by the trophoblast layer may be necessary as fetal organ 
differentiation is highly vulnerable to free oxygen radicals (Burton et al., 2003, Burton 
et al., 1999). These perturbations in the arterial wall result in a two-fold increase in 
arterial diameter, which characterizes the outward hypertrophic vasodilatory process 
during arterial remodelling (Osol and Mandala, 2009) and allows for a ten-fold increase 
in the blood supply to the fetoplacental unit (Hytten, 1985). This enlargement is usually 
accompanied by little or no thickening of the wall (Huppertz and Peeters, 2005, Osol 
and Mandala, 2009). 
 
1.3.2.2. The purpose of myometrial (basal and radial) arteries.  
 
While, spiral arteries are extensively remodelled and lose their SMC and elastic lamina, 
their vasoconstrictive/vasodilatory capacities are decreased. Although the basal and 
radial arteries supplying the myometrium do not undergo physical remodelling, they 
likely undergo vasodilatory adaptations to support the increase in blood flow throughout 
gestation. This vasodilatory process may be due both local factors associated with 
embryonic implantation and to systemic hormone changes, particularly elevated 
oestrogen and progesterone (Leiberman et al., 1993). Oestrogen may augment NO 
synthesis (Kim et al., 2008, van der Heijden et al., 2005); studies in rat uterine arteries 
have shown that endothelial NO synthase (eNOS) is upregulated during pregnancy, as 
eNOS ablation abrogated uterine vascular remodelling (Sladek et al., 1997). This 
supports a key role for NO as a primary mediator of human uterine vasodilation during 
pregnancy (Osol et al., 2009). In term pregnant rats, the equivalent of human 
remodelled spiral arteries did not constrict in response to intraluminal pressure elevation, 
possibly reflecting the loss of SMC in these arteries. Such observations were not made 
in non-pregnant rats (Gokina et al., 2003). Therefore, vascular tone in myometrial radial 
arteries may be a key determinant of overall vascular tone in the uterus (Gokina et al., 
2003). The importance of myometrial (radial) arteries is further illustrated by the 
evidence that they have impaired endothelium-dependent vasorelaxatory responses in 
preeclampsia (Ashworth et al., 1997). This study has therefore used radial myometrial 
arteries (Figure 1.3).  
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Figure 1.3: Overview of the uterine vasculature in a uterus from a pregnant woman. The 
radial arteries likely play a central role in the regulation of blood flow to the distal sites (such as 
spiral arteries/arterioles) and were the (myometrial) arteries used in this study (around 200 – 
400 µm). Adapted from (Brosens et al., 1967, Pijnenborg et al., 2006). 
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Thus, during human pregnancy, the significant increase in CO is facilitated by a 
dynamic remodelling of the uterine vasculature, which along with a complex de novo 
formation of the placenta and placental circulation, accommodate the growing fetus and 
its nutritional demands. One might, now, wish to consider the contributions, which the 
maternal and placental circulations make to match fetal nutrient demand and maternal 
provision thereof. To do so, it is necessary to understand what mechanisms regulate the 
vasoreactivity of these two circulations and it is therefore worth considering what, in 
general terms, is known about constrictive and dilatory mechanisms regulating blood 
vessel tone of the vasculature. 
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1.4. Signalling transduction mechanisms regulating vascular tone 
1.4.1. Blood vessel structure 
 
Arteries are usually composed of three main layers; the intima is made up of endothelial 
cells (EC) and IEL, the media is predominantly SMC and the adventia, the outermost 
layer, is formed of collagen fibers and fibroblasts.  
 
SMC contain a complex intracellular filamentous system consisting of cytoskeletal and 
contractile filaments. The cytoskeleton, which regulates cell shape and motility, is made 
up of three filamentous structures; actin thin filaments (~6 nm diameter), intermediate 
filaments (~10 nm diameter) and microtubules (~20-25 nm diameter) (Taggart and 
Morgan, 2007, Yu and Lopez Bernal, 1998). Thick myosin filaments and thin actin 
filaments make up the contractile filaments and their interaction governs the extent of 
the SM contraction. The principal determinant of contractile force is the level of free 
intracellular calcium ions ([Ca2+]i) with the rise and fall in [Ca2+]i being the primary 
mechanism initiating constriction and relaxation, respectively (Somlyo and Himpens, 
1989). 
 
1.4.2. Induction of contractile mechanisms in smooth muscles 
 
Contraction of SM is regulated by dynamic changes in [Ca2+]i and, partly, by the 
sensitivity of the myofilaments to any activating Ca2+ in response to changes in the 
environment surrounding the SMC.  
 
1.4.2.1. Ca2+-dependent contractile mechanisms 
 
Elevation in [Ca2+]i results in the co-operative binding of Ca2+ to the calcium-binding 
protein calmodulin (CaM). Subsequent association of the regulatory Ca2+-CaM complex 
with the catalytic subunit of the intracellular myosin light chain kinase (MLCK) 
activates it to cause phosphorylation of threonine and serine at positions 18 and 19, 
respectively, on the 20 kDa regulatory myosin light chain (MLC20) of myosin II (Figure 
1.4). This induces constriction of the myofilaments (Somlyo and Himpens, 1989). 
Calmodulin kinase II (CaMKII) also phosphorylates MLC20 at Ser-19 but at a much 
slower rate (1/20 of the Vmax of MLCK), which is unlikely to initiate contraction 
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(Edelman et al., 1990). A fall in [Ca2+]i leads to a reduction in activity of MLCK 
allowing dephosphorylation of MLC20 by myosin light chain phosphatase (MLCP). This 
leads to deactivation of actomyosin ATPase resulting in relaxation (Somlyo and Somlyo, 
1994).  
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Figure 1.4: Overview of the regulation of contraction/relaxation balance. MCLK: myosin 
light chain kinase, Ca-CaM: Ca2+-calmodulin, Myosin II RLC20: myosin light chain, MLCP: 
myosin light chain phosphatase. Adapted from (Somlyo and Somlyo, 2003). 
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Andrew and Avril Somlyo, pioneers in SM research, introduced the concept of 
excitation-contraction coupling over fifty years ago to explain the principal mechanisms 
leading to increases in [Ca2+]i and contraction of SMC. These mechanisms were termed 
as electromechanical and pharmacomechanical coupling (Somlyo and Somlyo, 1968).  
 
Electromechanical coupling operates through changes in the membrane potential. 
Positive potentials open voltage-gated Ca2+ channels (mainly L-type), leading to Ca2+ 
influx, an increase in [Ca2+]i and contraction. Membrane depolarization may be 
observed in both tonic and phasic SMC, however tonic SMC respond to excitatory 
stimuli resulting in delayed graded depolarisation through signal transduction 
mechanisms, whereas phasic SMC generate action potentials or electrical slow waves 
(Somlyo and Somlyo, 1968, Somlyo and Somlyo, 1994). Additional Ca2+ may be 
released through calcium-induced calcium-release (CICR) from the sarcoplasmic 
reticulum (SR) induced by increased [Ca2+]i (Figure 1.5, see Page 19).  
 
Pharmacomechanical coupling operates via multiple cellular signalling mechanisms, 
which can change the level of force production without necessarily changing the 
membrane potential. The major mechanisms of pharmacomechanical coupling occur 
following agonists, such as thromboxane A2, endothelin-1 (ET-1) or sphingosine-1-
phosphate (S1P), binding to G protein-coupled receptors (Figure 1.5, Page 19). Ca2+ 
release from the principal intracellular Ca2+ store, sarcoplasmic reticulum (SR), may 
also occur via CICR (Ogawa, 1994, Zucchi et al., 1994) or via inositol 1,4,5-
trisphosphate (IP3)-induced Ca2+-release (IICR) mechanisms (Somlyo and Somlyo, 
1968, Somlyo et al., 1988, Somlyo and Somlyo, 1990). CICR, which arises following 
activation of ryanodine receptors (RyR), is likely activated by Ca2+ influx through L-
type Ca2+-channels, as was shown in guinea pig aorta and rat portal vein (Ito et al., 1991, 
Ganitkevich and Isenberg, 1992) IICR results from IP3 binding to its receptors on SR. 
Activation of the membrane G protein-coupled receptors by agonists (thromboxane A2, 
ET-1 and/or S1P) induce the formation of IP3 and diacylglyerol (DAG) by 
phospholipase C (Somlyo et al., 1988). Enhancement of IICR by Ca2+ has been shown 
below 300 nM; above this concentration, IICR was inhibited as a negative feedback 
(Iino, 1990, Iino and Endo, 1992).  
 
Thus electromechanical and pharmacomechanical coupling likely work in synergy to 
regulate [Ca2+]i. 
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1.4.2.2. Ca2+-sensitisation mechanisms 
 
The regulation of contractile cellular mechanisms can be further modulated by Ca2+ 
sensitivity. The phenomenon of Ca2+-sensitisation has been defined as an increase in 
force production induced by agonist G protein-coupled receptor stimulation at constant 
suprabasal [Ca2+]i (Figure 1.5, Page 21) (Somlyo and Somlyo, 2003, Somlyo and 
Somlyo, 1992).  
 
The mechanism of G protein-coupled receptor-mediated Ca2+-sensitisation has been 
studied in several intact and permeabilised animal SM preparations. In intact porcine 
cardiac arteries, Ca2+-sensitive fluorophores were used to compare steady-state force to 
steady-state Ca2+ levels. It was found that the force/Ca2+ ratio was higher upon 
activation by agonists than by depolarization induced by high K+, indicating Ca2+ 
sensitizing potential and effect by agonists (Bradley and Morgan, 1987). 
Permeablisation of arteries allowed for [Ca2+]i to be clamped (with Ca2+ chelators) and 
controlled, thereby excluding the possibility of confounding effects due to the 
intracellular Ca2+ compartmentalisation and/or cytoplasmic Ca2+ gradients. !-Toxin 
permeabilised arteries seem to retain their G protein-coupled signalling pathways and 
receptor activity as activation of these receptors by agonist or guanosine 5-O-(3-
thiotriphosphate) (GTP"S) at constant, highly buffered [Ca2+]i led to an increase in 
MLC20 phosphorylation and force (Kitazawa et al., 1989, Himpens et al., 1990, 
Nishimura et al., 1990). This was indicative of Ca2+ sensitisation via a G-protein 
coupled mechanism and was shown in both rat and rabbit mesenteric and pulmonary 
arteries (Kitazawa et al., 1989, Himpens et al., 1990, Nishimura et al., 1990). Different 
agonists have been shown to induce different maximal Ca2+-sensitised force production 
(Hemmings et al., 2006, Wareing et al., 2005b). The mechanisms responsible have yet 
to be identified, but may result from variable coupling between agonists, G proteins and 
guanine nucleotide factors or the activation of distinct downstream intracellular 
effectors (Somlyo and Somlyo, 2003).  
 
One mechanism proposed to explain changes in Ca2+-sensitivity within SMC (vascular 
and non-vascular) relates to the fact that an increase in [Ca2+]i may activate CaMKII, as 
a negative feedback, which would phosphorylate MLCK and decrease its activity 
(Tansey et al., 1994, Stull et al., 1990). Agonists may somehow abolish this feedback. 
However, studies in airways and vascular smooth muscles (VSM) negated this 
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possibility (Tang et al., 1992, Van Riper et al., 1995); they showed that increases in 
[Ca2+]i increased MLCK phosphorylation regardless of the simulant. Somlyo and co-
workers asserted the second and most likely mechanism, in which Ca2+-sensitivity is 
induced by agonist-mediated MLCP inhibition (Kitazawa et al., 1991b, Somlyo and 
Somlyo, 1992). In addition, GTP"S was thought to decrease Ca2+-sensitivity of 
myofilaments by inhibiting MLCP (Kubota et al., 1992). Studies have shown that 
arachidonic acid enhanced Ca2+-induced constrictions in !-toxin permeabilised chicken 
gizzard SM, resulting in both MLCP activity and MLC20 dephosphorylation inhibition 
(Gong et al., 1992b, Gong et al., 1995).  
 
The signal for Ca2+-sensitisation was found to be communicated by the RhoA/ROK 
pathway. Studies in guinae-pig ileal SM and rat caudal arterial SM have shown that the 
serine/threonine Rho-kinase (ROK), activated by the GTP-bound form of RhoA (a 
small 20 kDa monomeric GTPase), induced phosphorylation of the regulatory subunit 
of MLCP inhibiting the catalytic phosphatase activity of MLCP and inducing 
contraction (Sward et al., 2000, Wilson et al., 2005a). The activity of MLCP may also 
be inhibited by the DAG-activated protein kinase C (PKC) (Jensen et al., 1996) or by 
CPI-17, a protein, which can be activated by phosphorylation by a variety of factors, 
such as PKC (Woodsome et al., 2001, Kitazawa et al., 2000) or ROK (MacDonald et al., 
2001, Koyama et al., 2000). Inhibition of MLCP activity is, therefore, likely to be the 
prime mechanism of Ca2+-sensitisation. 
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Figure 1.5: Mechanisms governing constriction and Ca2+-sensitisation in vascular smooth 
muscles. IL(Ca): L-type Ca2+-channels, GPRC: G protein-coupled receptors VSMC: vascular 
smooth muscle cell, Ca2+: calcium, CaM: calmodulin, SR: sarcoplasmic reticulum, SERCA: SR 
Ca2+-ATPase pump, RyR: ryanodine receptor, IP3: inositol 1,4,5-triphosphate, IP3R: IP3 
receptor, DAG: diacylglycerol, PLC: phospholipase C, PKC: protein kinase C, GDP: guanosine 
diphosphate, GTP: guanosine-5'-triphosphate, ROKI: RhoA kinase isoform I, MLCP: myosin 
light chain phosphatase, MYPT1: MLCP targeting subunit, MLCK: myosin light chain kinase, 
CaM: calmodulin, P-MLC20: phosphorylated myosin light chains. Grey lines: inhibited 
signalling. Black arrows: stimulation. Black stop: inhibition.  
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1.4.3. Induction of relaxatory mechanisms in smooth muscles 
 
Similarly to constriction, relaxation may be induced by two mechanisms. The first 
involves a dramatic decrease in [Ca2+]i, the second, experimentally at least, is observed 
without the prerequisite of reducing Ca2+ levels. 
 
1.4.3.1. Mechanisms inducing vascular smooth muscle relaxation 
 
Relaxation may be initiated through membrane repolarization resulting in reduction of 
[Ca2+]i via closing of the voltage-gated-operated channels and removal of Ca2+ from 
cytoplasm via membrane pumps/channels and uptake by the SR (Somlyo and Somlyo, 
1994). Studies in guinea-pig mesenteric veins have shown that the extent and rate of 
intracellular Ca2+ sequestration by the SR is sufficient to induce relaxation of SMC 
(Bond et al., 1984). ATP-dependent plasma membrane Ca2+ pumps and to a lesser 
extent Na+/Ca2+ exchanger also contribute to the removal of the cytoplasmic Ca2+ 
(Karaki et al., 1997, Somlyo and Somlyo, 1994).  
 
The tightly connected EC also act as regulators of the contractile system by producing 
vasodilators, which penetrate through the IEL to act on the underlying SMC to control 
their degree of contraction and relaxation.  
 
Endothelium-derived relaxant mechanisms  
The first pathway involves the endothelium-derived hyperpolarising factor (EDHF), 
which was first reported as a “new endogenous inhibitor from the vascular endothelium” 
in 1987 (Taylor and Weston, 1988). In fact, it rather defines an entity, than a single 
factor (Edwards et al., 2010). EDHF refers to a variety of signalling mechanisms 
involved in communications between the EC and VSMC. The classical EDHF pathway 
leads to an endothelial hyperpolarisation, followed by an increase in EC [Ca2+]i and the 
activation of the Ca2+-activated K+ channels (KCa), large KCa (BKCa), intermediate KCa 
(IKCa), and small KCa (SKCa), which are located in the membrane caveolae and in EC 
extensions through the IEL (Edwards and Weston, 1998). The endothelial 
hyperpolarisation can then either be transmitted to the SMC via EC-SMC gap junctions, 
without the involvement of another factor, or the K+ ions can escape through the 
activated KCa channels and activate endothelial Na+/K+-ATPases to generate SMC 
hyperpolarisation and vasodilation (Edwards et al., 1998).  The second major pathway 
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of relaxation is also endothelium-derived and involves Ca2+-dependent release of 
endothelium-derived vasodilators, such as NO (Edwards et al., 2010). 
Nitric Oxide  
NO is synthesized by the catalytic action of a family of NO synthases (NOS). 
Endothelial cells contain endothelial NOS (eNOS). These synthases convert the 
precursor amino acid, L-arginine, to NO and L-citrulline (Ignarro, 1999, Ignarro, 2005). 
NO synthesis and release from EC is increased in response to mechanical shear stress 
from blood passing through the vessel and to release of vasodilators, such as 
acetylcholine or bradykinin (Ignarro et al., 1987, Furchgott and Zawadzki, 1980). NO 
then diffuses into the intercellular space and traverses the plasma membrane of nearby 
cells, such as SMC, where it acts as a signal for subsequent biological processes, 
including relaxation (Ignarro, 2005). NO induces changes in target proteins by binding 
to their tyrosines or cysteines or by forming complexes with the associated heme groups 
of proteins such as the guanylate cyclase (GC) (Ignarro, 1999). In SMC, NO at 
nanomolar levels binds tightly to a prosthetic heme of the $-subunit of GC, also known 
as soluble GC (sGC), and causes a 100- to 200-fold increase in its activity (Friebe and 
Koesling, 2003). The activation of sGC induces the production of cyclic guanosine 
monophosphate (cGMP), a cyclic nucleotide deriving from guanosine triphosphate 
(GTP), resulting in an elevation of intracellular cGMP and relaxation (Waldman and 
Murad, 1987). The elevation in cGMP primarily activates protein kinase G (PKGI), 
though cGMP-gated channels, cyclic nucleotide (cN) phosphodiesterases (PDEs) and 
PKGII are also thought to be important targets of cGMP actions (Warner et al., 1994, 
Wang et al., 2002, Burnett, 1995).  
 
NO is the ‘first messenger’ in the NO/cGMP/PKGI signalling pathway. However, even 
if sufficient NO is generated by EC, an imbalance in the rates of cGMP production 
and/or degradation or abnormalities in sGC, PKGI or other mediators of the cGMP-
mediated signalling pathway, may lead to vascular pathology. Endothelial dysfunction 
leading to aberrant production of NO has been found in patients with metabolic 
syndrome, hypertension, diabetes, erectile dysfunction and pregnancy complications, 
such as preeclampsia (Celermajer et al., 1993, Knock and Poston, 1996, Knock et al., 
1997, Burnett, 2006). 
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Protein kinase G isoform I 
PKGI monomers contain a regulatory domain, located on the N-terminal portion of the 
protein and a catalytic domain, present in the C-terminal portion; each contains multiple 
sub-domains providing specific functions (Francis et al., 2010). There are two PKGI 
isozymes, PKI! and PKGI$, which are products of alternative splicing and differ by 100 
amino acids in their N-terminal region (Francis and Corbin, 1994). The sequence 
divergence affects a variety of parameters, such as cGMP affinity, cN analogue 
selectivity, protein-substrate specificity, state of activation and subcellular localisation 
(Wolfe et al., 1989b, Ruth et al., 1997, Surks et al., 1999). cGMP binds to the PKG 
regulatory domain and increases its activity 3- to 10-fold (Wolfe et al., 1989a, Francis 
and Corbin, 1994). The more N-terminal cN-binding site in PKGI isozymes has a 
higher affinity for cGMP compared to the C-terminal (Reed et al., 1997) and PKI! 
displays around 10-fold greater affinity for cGMP than PKGI$ (Wolfe et al., 1989a). 
cGMP analogues, such as 8-bromo-cGMP (8-br-cGMP), have been extensively used to 
investigate the biological effects elicited by PKGI!, as they traverse cell membranes 
freely and act directly on the target proteins (Francis et al., 1988, Poppe et al., 2008). 
Studies in Chinese hamster ovary cell lines have shown that PKGI! activation by 8-br-
cGMP suppressed increases in [Ca2+]i in response to thrombin receptor stimulation 
(Christensen and Mendelsohn, 2006).  
 
The regulatory domain of PKGI is made up of a dimerization and cell-localisation sub-
domain provided by an extended leucine-zipper motif, overlapping autoinhibitory and 
autophosphorylation sub-domains and two homologous cGMP-binding sites arranged in 
tandem (Figure 1.6). The catalytic domain contains an Mg2+/ATP binding domain and a 
substrate-binding domain (Lincoln et al., 1977, Lincoln et al., 1978). The respective 
leucine/isoleucine-zipper motif at the N-terminus of each PKGI monomer provides for a 
high affinity homodimerisation (Richie-Jannetta et al., 2003). The leucine/isoleucine 
zipper of PKGI! is made up of five heptad repeats, which are stabilised by hydrophobic 
residues and an extensive network of hydrogen bonds (Sharma et al., 2008), whilst the 
leucine/isoleucine zipper of PKGI$ contains eight heptad repeats involved in 
dimerization. This unique leucine zipper signature of PKGI isozymes regulate the 
interaction with cGMP-dependent protein kinase-interacting proteins (GKIPs), which 
localise PKG to certain cellular regions and also represent PKGI substrates (Surks et al., 
1999). One such GKIP is the targeting subunit of MLCP, MYPT1, which has been 
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found to interact with PKGI via their respective leucine-zipper motifs targeting PKGI to 
the SMC myofilaments (Surks et al., 1999, Sharma et al., 2008, Lee et al., 2007). 
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Figure 1.6: Schematic model of Protein Kinase G I. PKGI isozymes are homodimers, which 
are dimerised by an extended leucine/isoleucine zipper motif (ZZZZZ). These motifs provide 
for selective interaction (indicated by *+*+) with a variety of specific cellular proteins, 
including the targeting subunit of myosin light chain phosphatase, MYPT1. Multiple sites of 
autophosphorylation, as a negative feeback, are indicated by encircled P. The cGMP-binding 
sites are homologous, but the sites closest to the N-terminal domain present higher affinities for 
cGMP – these are indicated by heavy dark semi-circles. Adapted from (Francis et al., 2010). 
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Modulation of intracellular calcium 
Numerous targets of PKGI are implicated in modulating [Ca2+]i. The NO/cGMP/PKGI 
signalling pathways generally promote increased sequestration and decreased release of 
calcium from intracellular stores as a result of phosphorylation of target proteins (Figure 
1.7). PKGI phosphorylation of the G protein-activated phospholipase C$2/$3 at Ser-26 
and Ser-1105 leads to the inhibition of this enzyme, thereby decreasing the generation 
of IP3 and calcium influx from the SR, causing relaxation in intact SM (Xia et al., 2001). 
Similarly, PKGI$ phosphorylates the IP3-associated PKG substrate (IRAG) at Ser-696, 
which converts IRAG to an inhibitor of the IP3 receptor activity, thereby blocking 
calcium release from the SR (Schlossmann et al., 2000). PKGI is also thought to 
phosphorylate and activate BKCa, thereby promoting channel opening, which results in 
loss of potassium, hyperpolarisation of the plasma membrane and ultimately decreased 
calcium influx through L-type Ca2+ channels (White et al., 1993). Similarly, the PKG 
activator, cGMP, was found to be required for activation of Ca2+-activated Cl- -channels, 
now also known as cGMP-dependent Cl- -channels, and activation of these channels led 
to hyperpolarisation of rat mesenteric arteries plasma membrane and vasodilation 
(Matchkov, 2004). Further phosphorylation may occur on phospholamban at Ser-16, 
which would raise its inhibitory effect on the SR Ca2+/ATPase pump, increasing Ca2+ 
sequestration (Schlossmann et al., 2000). Finally, PKGI may also increase GTPase 
activity of G!q proteins and interfere with G protein-coupled receptor activation by 
agonists, such as thromboxane, thereby counteracting constriction of SM by 
pharmacomechanical coupling (Huang et al., 2007). 
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Figure 1.7: PKGI-mediated relaxatory mechanisms in vascular smooth muscles. IL(Ca): L-
type Ca2+-channel, IBK(Ca): large conductance Ca2+-activated K+-channel, IcGMP(Cl): cGMP-
dependent Cl—channel, GPCR: G protein-coupled receptor, VSMC: vascular smooth muscle 
cell, Ca2+: calcium, SR: sarcoplasmic reticulum, SERCA: SR Ca2+-ATPase pump, RyR: 
ryanodine receptor, PLN: phospholamban, P-Ser16: phosphorylation at Serine 16, IP3: inositol 
1,4,5-triphosphate, IP3R: IP3 receptor, DAG: diacylglycerol, PLC: phospholipase C, MLCP: 
myosin light chain phosphatase, MYPT1: MLCP targeting subunit, MLCK: myosin light chain 
kinase, CaM: calmodulin, deP-MLC20: dephosphorylated myosin light chains. Black arrows: 
stimulation. Grey lines: inhibited signalling. Red arrow: increase in activity. 
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1.4.3.2. Ca2+-desensitisation mechanisms in smooth muscles 
 
Ca2+-desensitisation is defined by a decrease in MLC20 phosphorylation and a reduction 
in force production at constant [Ca2+]i (Kitazawa and Somlyo, 1990). Conversely to 
Ca2+-sensitisation occurring via MLCP inhibition, desensitisation is thought to take 
place primarily via increase in the MLCP activity rather than the inhibition of MLCK. 
Although the primary mechanism inducing relaxation in VSM has been shown to 
involve lowering [Ca2+]i, additional regulation of vascular tone may be achieved via 
desensitisation of the contractile machinery to the effects of Ca2+ (Figure 1.8). 
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Figure 1.8: PKGI-mediated Ca2+-desensitisation mechanisms in vascular smooth muscles. 
IL(Ca): L-type Ca2+-channel, IBK(Ca): large conductance Ca2+-activated K+-channel, IcGMP(Cl): 
cGMP-dependent Cl—channel, GPCR: G protein-coupled receptor, VSMC: vascular smooth 
muscle cell, Ca2+: calcium, SR: sarcoplasmic reticulum, SERCA: SR Ca2+-ATPase pump, RyR: 
ryanodine receptor, IP3: inositol 1,4,5-triphosphate, IP3R: IP3 receptor, DAG: diacylglycerol, 
PLC: phospholipase C, PKC: protein kinase C, GDP: guanosine diphosphate, GTP: guanosine-
5'-triphosphate, ROKI: RhoA kinase isoform I, MLCP: myosin light chain phosphatase, 
MYPT1: MLCP targeting subunit, MLCK: myosin light chain kinase, CaM: calmodulin, deP-
MLC20: dephosphorylated myosin light chains. Black arrows: stimulation. Grey lines: inhibited 
signalling. Red arrow: increase in activity. 
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PKGI as a prime mediator in Ca2+-desensitisation 
cGMP-mediated Ca2+ desensitisation has been found to be mediated by both soluble and 
particulate (ie. membrane-bound) isoforms of PKGI. Production of cGMP by the sGC 
induces activation of soluble PKGI, which ultimately results in a decrease in the 
inhibitory state of MLCP activity via a variety of potential pathways, ultimately leading 
to relaxation of VSM.  
 
The significant role of PKG as vasodilatory mediator was shown in studies in PKG! 
null mice. These mice displayed a hypertensive phenotype, which was reversed after 
transfection of PKGI! into their SM. Jejunum and aorta strips from these ‘rescue’ mice 
relaxed significantly and to a similar extent to 8-br-cGMP, compared with wild-type 
mice (Feil et al., 2002, Weber et al., 2007). As described previously, direct stimulation 
of MLCP may also occur via interaction between the LZ motifs of PKGI! and MYPT1. 
In chicken gizzard, loss of the LZ motifs on MYPT1 blocked 8-br-cGMP-induced 
dephosphorylation of MLC20 and SM relaxation (Khatri et al., 2001). In addition, PKGI 
is thought to phosphorylate RhoA at Ser 188 (Sauzeau et al., 2000a), lifting ROK-
induced phosphorylation of MYPT1, known to inhibit MLCP activity (Kitazawa et al., 
2009, Sauzeau et al., 2000a, Gudi et al., 2002).  Further PKG-mediated desensitisation 
to Ca2+ may occur via interaction with a number of other actinomyosin filament-
interacting proteins discussed below.  
 
Vasodilator-Stimulated Phosphoprotein 
The actin binding protein, vasodilator-stimulated phosphoprotein (VASP), is another 
substrate of PKGI and known to inhibit actin polymerisation (Reinhard et al., 2001). 
This decreases actin and myosin filament interactions and thus induces SM relaxation. 
In addition, studies in rat and rabbit aortas have shown that prolonged exposure to 
nitroglycerin decreased phosphorylated VASP levels, whilst unphosphorylated VASP, 
sGC and PKGI levels remained unchanged and induced vasodilation (Oelze et al., 2000, 
Schulz et al., 2002, Mulsch et al., 2001, Schafer et al., 2003). This introduced VASP as 
a reliable marker for vascular vasodilatory activity via the NO-mediated cGMP/PKGI 
pathway and its effect on actin filaments. 
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Telokin  
Phosphorylation of the 17 kDa SM specific telokin protein has also been found to 
mediate Ca2+-desensitisation via PKA and PKG (activated following elevation of 
intracellular cAMP and cGMP, respectively) (Somlyo and Somlyo, 2003). Telokin is 
derived from the SM MLCK gene, shares identical COOH terminus with MLCK and is 
phosphorylated by PKGI (Ito et al., 1989, Wu et al., 1998). Depletion of endogenous 
telokin from permeabilised rabbit ileal SM was found to correlate with a loss of 8-br-
cGMP-induced relaxation and was rescued by the addition of recombinant telokin and 
further enhanced by PKGI (Wu et al., 1996, Wu et al., 1998, Walker et al., 2001). It was 
also shown that telokin null mice displayed normal expression of MLCK but a marked 
decrease in MCLP activity and an increase in MCL20 phosphorylation as compared to 
wild-type (WT) mice (Khromov et al., 2006). Finally, telokin was also shown to interact 
with inhibited MYPT1 to enhance MLCP activity and MYPT1 interaction with myosin 
filaments (Khromov et al., 2012), thus decreasing actinomyosin filament interactions. 
This highlights a role for telokin in Ca2+-desensitisation of force and cGMP-induced 
relaxation in telokin-rich SM.  
 
Heat-shock proteins  
Another PKA/PKG target, identified in SM, is the small heat shock protein 20 (HSP20), 
which was found to regulate relaxation of SM via its interaction with actin, 
independently of MLC20 dephosphorylation (Tyson et al., 2008b). HSP20 is abundantly 
expressed in smooth, skeletal and cardiac muscle and belongs to the small HSP (sHSP) 
family (Kato et al., 1994). Several studies have shown that phosphorylation of HSP20 
(phospho-HSP20) occurs during cGMP-induced relaxation of pre-constricted swine 
carotid arteries (Rembold et al., 2000, Stulc et al., 1994) and that this is cAMP/cGMP-
dependent in term human umbilical arteries (Bergh et al., 1995). Moreover, the 
application of a phospho-peptide HSP20 analogue (containing phospho-Serine 16) to 
permeabilised bovine carotid arteries has been shown to inhibit agonist-induced 
contraction, whilst an unphosphorylated peptide had no effect (Beall et al., 1999). A 
recent study has reported the presence of HSP20 in rat myometrium; mRNA and protein 
levels were highly expressed in early to mid-gestation and then decreased during late 
pregnancy and labour (Cross et al., 2007). Recent proteomics studies have identified the 
presence of phospho-HSP20 in human term labouring myometrium and co-
immunoprecipitation studies have revealed a specific association of HSP20 with !-SM 
actin and HSP27, a key regulator of actin filament dynamics. These studies indicate that 
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phospho-HSP20 modulates cGMP-mediated relaxation in term myometrium via its 
interaction with actin (Tyson et al., 2008b). 
 
1.4.3.3. Altered protein expression and tissue-specific differences in 
responsiveness to NO and/or PKG 
 
The expression levels of the relaxatory proteins telokin, HSP20 and MYPT1 have been 
suggested to differ between SM types, which is thought to influence their vasodilatory 
capacities. Visceral SM are thought to be predominantly fast phasic, with rapid 
constrictions and relaxations, whilst vascular SM are thought to display a rather slow 
tonic phenotype (slow constrictions or relaxations) (Owens et al., 2004). However, 
within vascular SM, SMC may also exhibit a more phasic or tonic phenotype (Owens et 
al., 2004). Differences in expression levels of relaxatory proteins have been reported by 
comparing visceral with vascular SM or within vascular SM (portal vein with large 
arteries and veins) to highlight wide differences between phasic and tonic SM 
phenotypes. However, no studies have, to my knowledge, reported expression levels in 
human tissues or artery types, such as myometrial and placental small arteries, which 
may also display more phasic and tonic phenotypes. 
 
Telokin has been suggested to be highly expressed in fast phasic SM with only small 
amounts in slow tonic SM (Choudhury et al., 2004). Studies in Ca2+-constricted tonic 
femoral arteries have shown that telokin induced maximal relaxations of 30 %, whilst 
relaxations in phasic ileum muscle reached 90 % and telokin expression levels were 
four fold higher in the ileum compared to arteries (Choudhury et al., 2004). Conversely, 
phospho-HSP20 was shown to slow the relaxation time course in guinea pig phasic 
taenia cecum SM through decreased actin-myosin interactions, whilst no effects were 
observed in tonic skinned carotid arteries (Hashimoto et al., 2009). Meanwhile, MYPT1 
LZ-positive isoforms have been identified predominantly in slow-tonic SM, whilst LZ-
negative isoforms are thought to be expressed in higher levels in fast-phasic SM (Payne, 
2004). The LZ-negative isoform is thought to result in a resistance to the calcium de-
sensitising effects of cGMP (Khatri et al., 2001). However, a switch from LZ-positive 
to LZ-negative isoforms has been reported during neonatal development of the rat portal 
vein, turning a slow-tonic SM at birth into a fast-phasic SM following development 
(Payne et al., 2006). Thus, within vascular SM, slow-tonic phenotypes may develop into 
fast-phasic SM. These studies highlighted wide differences in protein expression and 
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functional responses between phasic and tonic SM; however they also stressed the 
difficulty in determining the phenotypic profile of a SM type wholly from expression 
levels and vasodilatory capacities, as they may shift to change phasic into tonic or tonic 
into phasic SM. The phenotypic differences existing between phasic and tonic SM may 
be more difficult to underline and compare in SM of small resistance arteries, such as 
myometrial and/or placental arteries. 
 
1.5. Mechanisms involved in tone regulation of human uterine and placental 
arteries 
 
Ca2+-sensitisation and –desensitisation result from major physiological mechanisms 
regulating MCL20 activity, i.e. phosphorylation and dephosphorylation (Gong et al., 
1992a, Somlyo and Himpens, 1989, Tansey et al., 1994). However, the majority of the 
work on Ca2+-sensitisation and –desensitisation has been carried out on a variety of 
vascular and non-vascular tissues from animals. Our current knowledge of these 
signalling pathways in human SMC is limited, particularly in the reproductive 
vasculatures. 
 
1.5.1. Structural properties of myometrial and placental arteries 
 
Knowledge of the structural properties of human placental and uterine vascular SMC is 
limited. Studies have shown that placental arteries from the chorionic plate contain a 
thick medial layer with the SMC separated by an abundance of extracellular matrix 
(ECM), whilst (uterine) myometrial arteries displayed a more tightly packed SM layer 
with less ECM (Figure 1.9) (Sweeney et al., 2006a). A structure similar to chorionic 
plate placental arteries was also observed in placental arteries within the stem villi 
(Tanaka et al., 1999) and in human umbilical arteries at term gestation (Benirschke and 
Kaufmann, 2000). In addition, placental arteries, in contrast with myometrial arteries, 
lack a distinct IEL separating EC and SMC. As mentioned earlier, the placental 
vasculature offers little resistance to blood flow (Kleiner-Assaf et al., 1999), therefore 
placental blood vessels are likely exposed to lower pressures than myometrial blood 
vessels. It is possible that placental arteries evolved without an elastic component 
because of their exposure to low pressure/flow, in which case elasticity in these vessels 
may not have been an important requirement (Sweeney et al., 2006a). The placental 
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vasculature lacks innervation indicating that its regulation relies only upon paracrine, 
autocrine or mechanical stimuli (Fox and Khong, 1990).  
 
 
 
 
 
 
 
Figure 1.9: Electron micrographs of transverse sections of arterial walls from a 
myometrial (A) and placental artery (B). The myometrial artery consists of EC, an IEL and 
tightly packed SMC separated by little ECM compared to the placental artery, which does not 
display an IEL and whose SMC are interspersed with large amounts of ECM. The ECM is 
represented by collagen amounts. S: smooth muscle cell, E: endothelial cell, IEL: internal 
elastic lamina, C: collagen. Adapted from (Sweeney et al., 2006a). 
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1.5.2. Functional characteristics of myometrial and placental arteries 
 
Electromechanical and pharmacomechanical stimuli are known to play a role in the 
regulation of vascular tone of the uterus and placenta. Studies have shown both human 
myometrial and placental arteries constrict to solution with high potassium 
(electromechanical) (Sweeney et al., 2008), and to a variety of contractile agents 
(pharmacomechanical) such as the eicosanoid, thromboxane A2 (Sweeney et al., 2008, 
Wareing et al., 2006c), and the constrictive peptides ET-1 (Wareing et al., 2006c) and 
S1P (Hemmings et al., 2006, Hudson et al., 2007).  
 
The importance of the endothelium-derived NO in the placental circulation was first 
shown in studies in the isolated perfused cotyledon, which reported that inhibition of 
NO production led to an increase in perfusion pressure (Myatt et al., 1991, Myatt et al., 
1992). Tables 1.1 and 1.2 summarise our current knowledge of the effects of both 
endothelium-dependent and endothelium-independent vasodilators, respectively, on 
maternal and placental circulations. However, very few of these studies have compared 
effects between artery types, as a greater portion of studies seems to have been done on 
the placental vasculature and groups assessing one artery type rarely assessed the other. 
In a recent study, bradykinin-mediated endothelium-dependent relaxations induced 
minimal relaxations in placental arteries, in contrast to observations in myometrial 
arteries (Sweeney et al., 2008). It is unclear whether the difference in bradykinin 
response is the only dissimilarity within the NO/cGMP/PKG pathway between placental 
and myometrial arteries. 
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Table 1.1: Effect of receptor-coupled endothelium-dependent vasodilators on placental and maternal vasculatures. 
 
               Placental Vasculature                                              Myometrial Vasculature 
Vasodilators Comments References Comments References 
Acetylcholine  
No effect in perfused human 
placentas pre-constricted with 
U46619 or ET-1. No relaxation in 
small U46619-constricted human 
CPA. 
(Myatt et al., 1992),  
(McCarthy et al., 1994), 
(Hull et al., 1994), 
(Amarnani et al., 1999). 
 
Relaxation in U46619-
constricted MA from pregnant 
sheep and pre- and post-
menopausal UA constricted 
with 30 mM KPSS, MA from 
term pregnant women. 
(McCarthy et al., 1993), 
(Kublickiene et al., 1997), 
(Anwar et al., 1999), 
(Kublickiene et al., 2000), 
(Spitaler et al., 2002). 
Bradykinin 
 
Relaxation in perfused human 
placental cotyledon; small/no 
relaxation in CPA constricted with 
high K+, U46619 or AVP. Increase in 
perfusion pressure in placentas. 
 
(Myatt et al., 1992) 
(McCarthy et al., 1994), 
(Hull et al., 1994), 
(Amarnani et al., 1999), 
(Wareing, 2002), 
 (Sweeney et al., 2008). 
Relaxation in U46619-
constricted MA from pregnant 
sheep; human MA from term 
pregnant women pre-constricted 
with AVP, NE, U46619, 60 
mM KPSS. 
(Anwar et al., 1999), 
(Sweeney et al., 2008), 
(Wareing et al., 2004). 
Histamine 
 
 
Relaxation in perfused human 
placentas and CPA constricted with 
sub-maximal concentrations of 
U46619, but not in maximally 
U46619- or KPSS-constricted CPA. 
 
(Myatt et al., 1992), 
(McCarthy et al., 1994), 
(Hull et al., 1994), 
(Amarnani et al., 1999), 
(Mills et al., 2007b). 
Relaxation in UA from non-
pregnant post-menopausal 
women constricted with 30 mM 
KPSS. 
(Spitaler et al., 2002) 
Substance P Minimal relaxation in human CPA. (Hull et al., 1994) 
Relaxation in PE-constricted 
MA from pre-eclamptic and 
term pregnant women. 
(Wimalasundera et al., 
2005) 
UA: uterine arteries (animal), MA: myometrial arteries (human), CPA: chorionic plate placental arteries (human), U46619: thromboxane A2 mimetic, 5-HT: 
serotonin, PGF2: prostaglandin F2, PE: phenylephrine, NE: norepinephrine, ET-1: endothelin-1, VP: vasopressin, NA: noradrenaline, AVP: arginine vasopressin.
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Table 1.2: Effect of endothelium-independent vasodilators on placental and maternal vasculatures. 
 
                 Placental Vasculature                                                 Myometrial Vasculature 
SNAP: S-nitroso-N-acetyl-DL-penicillamine, SNP: sodium nitroprusside, SNG: S-nitroso-N-glutathione, GTN: glyceryl trinitrate. 
Vasodilators Comments References Comments References 
SNAP 
(NO donor) 
 
Relaxation in U46619-constricted 
human CPA and perfused placentas 
constricted with PGF2. 
(Myatt et al., 1991), (Hull et 
al., 1994),  
(Zhang et al., 2001). 
  
SNP  
(NO donor) 
 
Concentration-dependent relaxation 
in sub-maximally U46619-
constricted human CPA at low 
(7%) and high (20%) O2. 
Relaxation in perfused human 
placentas constricted with PGF2.  
(Zhang et al., 2001), (Mills et 
al., 2007a), (McCarthy et al., 
1994), (Mills et al., 2009), 
(Mills et al., 2005) 
Dose-dependent relaxation in UA 
from pregnant rats pre-constricted 
with PE. Relaxation in MA from 
pregnant and non-pregnant 
women. 
(Lu et al., 2008), 
(McCarthy et al., 1993), 
(McCarthy et al., 1994) 
SNG 
(NO donor) 
 
Relaxation in (sub-) maximally 
U46619-constricted human CPA 
and in perfused human placentas 
constricted with PGF2. 
 
(Zhang et al., 2001)   
GTN 
(NO donor) 
Relaxation in (sub-) maximally 
U46619-constricted human CPA 
and in perfused human placentas 
constricted with PGF2, U46619 and 
ET-1. 
 
(Myatt et al., 1991), (Myatt 
et al., 1992), (Zhang et al., 
2001). 
  
YC-1 
(sGC activator) 
Increase in placental perfusion 
pressure. (Bainbridge et al., 2002)   
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Table 1.2 (continued): Effect of endothelium-independent vasodilators on placental and maternal vasculatures. 
 
                  Placental Vasculature                                                Myometrial Vasculature 
NIF: Nifedipine, VER: Verapamil, NIT: nitrendipine, NKB: neurkinin B. 
Vasodilators Comments References Comments References 
NaNO2 
(NO donor) 
Relaxation in human U46619-
constricted CPA. Relaxation in 
perfused human placentas 
constricted with PGF2. 
(Zhang et al., 2001)   
NIF 
(Ca2+ channel 
blocker) 
 
Concentration-dependent relaxation 
in human CPA constricted with 40 
mM, 124mM KPSS or 5-HT. 
(Potency: NIF > VER). 
 
(Lindow et al., 1988), 
(Reviriego and Marin, 1989) 
(Marin et al., 1990), (Blea et 
al., 1997), (Kook et al., 
1996). 
Small relaxation in 124 mM 
KPSS-constricted human non-
pregnant MA, but not in VP- or 
NA-constricted MA. 
(Maigaard et al., 1985) 
VER 
(L-type Ca2+ channel 
blocker) 
 
Relaxation in human CPA (and 
umbilical) artery. (Potency: VER < 
NIF). 
 
(Belfort et al., 1994), (Kook 
et al., 1996) 
Relaxation in ovine UA. 
Inhibition of ANG II-induced 
prostacyclin increases in uterine 
arteries from pregnant ewes. 
(Magness and Rosenfeld, 
1993), (Belfort et al., 1994) 
NIT 
(Ca2+ channel 
blocker) 
Almost full relaxation in 124 mM 
KPSS-constricted CPA from 
pregnant women. 
(Maigaard et al., 1986) 
 
Almost complete abolishment of 
124 mM KPSS-constricted MA 
from pregnant women. 
 
(Maigaard et al., 1986) 
NKB 
 
Decreased fetal-side arterial 
pressure in human perfused 
placenta pre-constricted with 
U46619. 
 
(Brownbill et al., 2003) 
No effect on BK-induced 
relaxations in AVP-constricted 
human MA. 
(Wareing et al., 2003a) 
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Whilst functional studies observing contractile and relaxatory responses of placental 
and myometrial SM have been carried out, studies pertaining to Ca2+-sensitisation and –
desensitisation in these arteries are very limited. Agonist-induced sensitisation of 
contractile filaments to calcium has been described in placental and myometrial SMC, 
albeit at only one concentration of sub-maximally, activating Ca2+ (Wareing et al., 
2005b). Expression of ROKI! has been reported in term human placental, myometrial 
and omental arteries and linked to thromboxane-induced Ca2+-sensitisation (Wareing et 
al., 2005b). Similarly, it was shown that Ca2+-sensitisation was effected at a single sub-
maximal concentration of Ca2+ by another G protein-coupled agonist (S1P) and ROK 
involvement suggested (Hemmings et al., 2006). While Ca2+-sensitisation has been 
demonstrated in myometrial and placental arteries, albeit at only one chosen level of 
sub-maximal activating Ca2+, the phenomenon of Ca2+-desensitisation has not yet been 
reported in these tissues.  Several studies in a variety of animal SM tissues (vascular and 
non-vascular) have reported the phenomenon of Ca2+-desensitisation, primarily via 
cyclic nucleotide (cAMP/cGMP) pathways.  One may therefore speculate that 
desensitisation to activating Ca2+ may also occur in human myometrial and placental 
VSM.  
 
Developing our understanding of these processes in healthy human vascular tissues and 
exploring whether the mediators involved are consistent with those reported in animal 
tissues will contribute significantly to our knowledge of the molecular mechanisms 
regulating arterial tone of myometrial and placental vessels during pregnancy. The 
findings may also have wider applications to human blood vessels in general.  
 
1.6. Aims of the present study 
 
To this end, this work sought to answer three biological queries: 
(i) whether myometrial and placental arteries develop Ca2+-sensitisation over a 
wider range of concentrations, 
(ii) whether the phenomenon of Ca2+-desensitisation occurs in these artery types 
and whether it may be mediated by cGMP-dependent pathways, 
(iii) whether myometrial and placental arteries display differing sensitivities in 
their contractile and/or relaxatory responses, 
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2. Chapter 2 
Materials and Methods  
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2.1. Chemicals and Solutions 
2.1.1. General chemicals 
 
The following chemicals were obtained as powder, prepared as 10-2 M stock solutions 
in double-deionised water (ddH2O) and stored at -20 °C in the freezer after their 
preparation, unless stated otherwise. They were used to assess contractile and relaxatory 
capacities of the human myometrial (MA) and placental (PA) arteries. 
U46619 and YC-1 were purchased from Calbiochem. U46619 was made up by drying 
the ethanol (in which it was dissolved) by passing a flow of N2 gas over the solution and 
then resuspending in a solution of 1:1.85 100 % ethanol: 1 mg/L Na2CO3 (Hemmings et 
al., 2006). YC-1 was prepared in Dimethyl Sulfoxide (DMSO). 
8-bromo-cGMP was purchased from Biomol.  
Spinghosine-1-phosphate (S1P) was purchased from Enzo Life Sciences and made up as 
a 2.64 ! 10-3 M stock by dissolving it in 1.5 mL of methanol at 80-100 °C for 45 
minutes and aliquoted equally into glass vials. For each experiment, the methanol was 
dried off with N2 gas and the S1P was re-suspended in the appropriate volume of 0.01 
M NaOH (Hemmings et al., 2006). 
Bradykinin (BK), histamine (His), sodium nitroprusside (SNP) and endothelin-1 (ET-1) 
were all purchased from Sigma-Aldrich. SNP was made up fresh for every experiment. 
ET-1 was prepared to a stock concentration of 10-4 M. 
A23187 was purchased from EMD Biosciences.  
 
2.1.2. General and controlled calcium (stock) solutions 
2.1.2.1. Solution chemicals 
 
The following chemicals were used to make up general solutions (Section 2.1.2.2) and 
controlled calcium stock solutions (Section 2.1.2.3). 
Glucose, EDTA, EGTA and CaCl2 were purchased from BDH Laboratories, NaCl, KCl, 
NaHCO3 and KH2PO4 from Fisher Scientific and MgSO4, MOPS, Magnesium Oxide 
(MgO), Methanesulphonic Acid (Ms), PIPES, Na2CP, Na2ATP and DMSO were 
purchased from Sigma-Aldrich. 
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2.1.2.2. General Solutions 
 
Three solutions were used most regularly and prepared twice a week (Table 2.1). Tissue 
collection buffer (TCB) was used for the processing of human samples (see Section 2.1). 
Physiological salt solution (PSS) and high-potassium salt solution (60 mM KPSS) were 
used at the beginning of each experiment (see Section 2.4). All three solutions were 
prepared to a pH of 7.4 and CaCl2 was added last in a physiological pH to avoid 
precipitation of Ca2+. The pH of TCB was adjusted using 1 M KOH. PSS and 60 mM 
KPSS were prepared by gassing the solution with 5 % CO2 in air to lower the pH to 7.4. 
Solutions were stored at 4 °C in the fridge. pH measurements were carried out using a 
pH electrode and pH meter. 
 
Table 2.1: Composition of general solutions.  
Chemicals 
Tissue Collection 
Buffer (TCB) 
Physiological Salt 
Solution (PSS) 
High-potassium 
physiological salt 
solution (KPSS) 
NaCl 154 119 63.7 
KCl 5.4 4.7 60 
MgSO4 1.2 2.4 2.4 
MOPS 10 - - 
NaHCO3 - 25 25 
KH2PO4 - 1.17 1.17 
Glucose 5.5 6.05 6.05 
EDTA - 0.0684 0.0684 
CaCl2 1.6 1.6 1.6 
The concentrations of chemicals are presented in mM.  
 
 
2.1.2.3. Controlled calcium stock solutions 
 
The following solutions were prepared as stock solutions for the controlled calcium 
solutions G1, G10 and CaG (Table 2.2), which were used in the permeabilisation 
experiments (Section 2.1). 
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0.1M K2EGTA was made up as a 200 mL solution by using 7.60 g KOH and 2.26 g 
EGTA in ddH2O, whilst heating at 50 - 100 °C.  
0.1M CaEGTA was prepared as 100 mL solution using 3.80 g EGTA, 1.01 g CaCO3 
and 1.09 g KOH in ddH2O.  
0.1M Magnesium methanesulfonic acid (MgMs2) was made up as a 200 mL solution 
using 0.80 g Magnesium oxide (MgO) and 2.60 mL Methanesulfonic acid (Ms) in 
ddH2O.  
Finally, 1M KMs was prepared using 11.22 g KOH and 12.98 mL Ms in ddH2O and pH 
was adjusted to 7 using 1 M KOH.  
 
 
Table 2.2: Compositions of the controlled calcium solutions G1, G10 and CaG. 
Chemicals 
Relaxing solution 
G1 
Calcium-free 
solution G10 
Calcium-activating 
solution CaG 
PIPES 30 30 30 
Na2CP 10 10 10 
Na2ATP 5.16 5.16 5.16 
MgMS2 7.31 7.92 7.25 
KMs 43.1 46.6 47.1 
K2EGTA 1 10 - 
CaEGTA - - 10 
The concentrations of each chemical are given in mM. 
 
 
G1, G10 and CaG were prepared in ddH2O to a pH of 7.1 with 1M KOH. The three 
solutions were prepared once a week and their pH was checked before each experiment.  
 
2.1.2.4. Ca2+-containing solutions for experiments with !-toxin-permeabilised 
arteries 
 
Ca2+-containing or pCa solutions were prepared by adding accurate set volumes of G10 
and CaG, as indicated in the pCa table below (Table 2.3) (Horiuti, 1988).  
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Table 2.3: The G10 and CaG compositions of a range of pCa solutions. 
pCa solutions CaG G10 
9 0.03607 9.96393 
8 0.34935 9.65065 
7.5 1.02715 8.97285 
7 2.65792 7.34208 
6.7 4.19403 5.80597 
6.3 6.44778 3.55222 
5.5 9.20459 0.79541 
4.5 9.99378 0.00622 
The volumes of CaG and G10 are in mL (Horiuti, 1988). 
 
 
  46 
2.2. Human Tissue processing 
2.2.1. Placental and myometrial biopsies  
 
Placental and myometrial biopsies were obtained from healthy women with 
uncomplicated pregnancies either after vaginal delivery or following elective Caesarean 
section at 37-41 weeks’ gestation. The study was approved by the Newcastle and North 
Tyneside 2 Research Ethics Committee (08/H0907/96 (myometrial biopsies, Appendix 
A, Section A.1) and 09/H0908/11 ((placental biopsies) Appendix A, Section A.2). All 
women were given an information sheet about the study (Appendix B, Sections B.1 
(myometrial) and B.2 (placental)). Any questions about the study were answered by a 
research midwife. Those wishing to participate gave written informed consent in 
compliance with the Helsinki Declaration. 
 
During this study, several problems were encountered with the supply of myometrial 
tissue from pregnant women. Figure 2.1 illustrates the number of consented samples 
compared to number collected. The discrepancy between the number of consenting 
women and the number of biopsies obtained, primarily related to the surgeon failing to 
take the biopsy. In some cases this was because of haemorrhage but in others no 
explanation was available. In addition, some samples were obtained from women 
delivered of a small-for-gestational age infant (birth weight for gestational age less than 
the 10th centile), which were not used for functional experimentation. Confirmation of 
FGR was determined by post-delivery calculation of the individualised birth ratio 
(IBR), which takes into account maternal factors including height, weight, parity and 
ethnicity (Wilcox et al., 1993). These represented another 4 % of all myometrial 
biopsies and 4 % of placental ones. 
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Figure 2.1: Histogram of human myometrial consents July 2009 – July 2011. Black: 
consented samples, Blue: collected biopsies, and Purple: biopsies from fetal growth restricted 
(FGR) pregnancies.  
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During the first six months of the project, several quality control measures were 
developed to ensure consistency in arterial profiles throughout the experiments. These 
measures were determined from personal experience as well as guidance from the 
literature. Section 2.4 gives a detailed overview of these. Figure 2.2 illustrates the 
number of collected samples compared to the number of samples used in the in vitro 
myography studies. The demographic data of the women who contributed samples to 
the myographic experiments are shown in Table 2.4.  
 
 
 
 
Figure 2.2: Summary of myometrial biopsies obtained and used for in vitro functional 
studies. Blue: Collected biopsies Red: Biopsies used in functional studies.  
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Table 2.4: Demographic details of the participants used in this study. 
Characteristics Myometrial Biopsies Placental Biopsies 
Number of patients 62 75 
Age 31 ± 9.9 30 ± 4.4 
Body Mass Index at 
booking 
27 ± 3.7 27 ± 2.5 
Smoker  12 % 10 % 
Parity 1.2 ± 0.9 1.2 ± 1.1 
Gravidity 2.6 ± 1.2 2.4 ± 1.1 
Gestational age (weeks) 39 ± 0.8 39 ± 0.9 
Birthweight (g) 3478 ± 23.6 3440 ± 21.7 
Birthweight centile 62 ± 7.4 61 ± 6.2 
Sex (%) Female : 47 % 
Male : 53 % 
Female : 41 % 
Male : 59 % 
Figures are presented as mean ± SEM. 
 
 
2.2.2. Tissue microdissections 
 
Whole placentas were collected in cylindrical hospital buckets from rooms adjacent to 
the hospital theatres within minutes of vaginal delivery or completion of the Caesarean 
section. Placental arteries were dissected (as described below) within 30 - 60 minutes of 
delivery. This study used placental arteries dissected from eight placentas following 
vaginal delivery alongside placental arteries obtained from placentas following 
Caesarean sections, as a study by Mills et al (2007) reported that the mode of delivery 
(vaginal versus Caesarean section) did not alter arterial vascular contractility (Mills et 
al., 2007a).  
The chorionic plate arteries were identified on the surface of the whole placenta (Figure 
2.3, left) by following the branches from the umbilical artery. Arterial branches, which 
are thicker-walled than veins and uppermost on the chorionic surface, were followed to 
the edge of the placenta. A biopsy of around 4 ! 3 ! 1 cm and containing small 
chorionic plate arteries was then cut from the whole placenta and placed in cold tissue 
collection buffer (TCB) in a dissecting dish containing a 2 cm thick layer of Sylgaard 
gel to hold fixing pins. Chorionic plate arteries (< 500 "m diameter) were carefully 
dissected free from surrounding tissue using 11 cm long Dumont number 5 stainless 
steel forceps and straight 10 cm Spring stainless steel dissecting scissors (both World 
Precision Instruments (WPI)) under a stereomicroscope (Leica, at 2 ! magnification). 
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Dissected arteries were placed in a small petri glass dish filled with cold TCB, cleaned 
free of connective tissue using the same dissecting instruments and cut into 1-2 mm 
lengths for subsequent mounting onto the small-vessel wire myograph (see Section 
2.3.1). Thereafter, arteries were kept on ice for immediate experimental use. When 
samples were obtained late in the afternoon, arteries were kept in cold TCB overnight 
for use in the morning, which did not alter vascular function.  A bank of placental 
arteries was also created by freezing fresh cleaned arteries in liquid nitrogen and storing 
them at – 80 °C for later use in Western Blotting (see Chapter 4). 
 
 
 
Figure 2.3: Photograph of a placenta following delivery by elective Caesarean section. 
Left: whole placenta. Right: magnified area of the edge of the placenta where a biopsy 
containing a third order placental artery branch (arrow) was taken. 
 
 
Human myometrial biopsies were collected and transported to the laboratory similarly 
to whole placentas. Figure 2.4 illustrates a myometrial biopsy taken from the upper lip 
of the lower segment uterine incision at Caesarean section. The biopsy (~ 1.5 ! 1 ! 1 
cm) was pinned down in a dissecting dish containing Sylgaard gel in TCB. Myometrial 
arteries (< 500 "m) were identified on the biopsy surface as white thick walled vessels. 
Arteries were distinguished from veins on the basis of their thicker walls and their 
failure to collapse when emptied of blood. They were isolated from the surrounding 
tissue using straight 8 cm long McPherson-Vannas stainless steel dissecting scissors and 
11 cm long Dumont number 5 stainless steel forceps (both WPI). They were then placed 
in a petri glass dish with TCB and cleaned from surrounding myometrial and connective 
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tissue using the same instruments. Similarly to the placental arteries, the myometrial 
vessels were then cut into 1-2 mm lengths. When samples were obtained late in the 
afternoon, arteries were kept in cold TCB overnight for their use in the morning; 
otherwise they were used for an experiment immediately after cleaning.  A bank of 
available myometrial arteries was also created by freezing arteries in liquid nitrogen and 
storing them at – 80 °C for later use for Western Blotting (see Chapter 4). 
 
 
 
Figure 2.4: Photograph of a myometrial biopsy. The arrow indicates a myometrial artery 
prior to dissection from surrounding myometrial tissue. 
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2.3. The myograph system 
2.3.1. The mounting procedure 
 
Placental chorionic plate or myometrial arteries were mounted onto a Multi Wire 
Myograph System Model 610M manufactured by Danish Myo Technology in Aarhus N, 
Denmark. Each one of the four baths (Figure 2.5) composing the myograph system 
contains two jaws, one attached to a micrometer to allow stretching of the vessel, the 
other connected to a strain gauge for recording isometric tension development onto a 
computer using the MyoDaq software (version 2.2). 
 
 
 
 
Figure 2.5: Photograph of a myograph bath. 1: Jaw connected to the micrometre. 2: Jaw 
connected to the tension transducer. 
 
 
Figure 2.6 shows a zoomed-in photograph of the myograph bath and mounted vessel 
(Figure 2.6A) and a schematic drawing of a mounted vessel (Figure 2.6B). During the 
mounting procedure, the vessels were immersed in 6 mL PSS. To mount a vessel, two 
40 !m wires were gently introduced along the lumen. The first wire was hooked onto 
the top left-side screw and stabilised between the two jaws pressed against each other. 
The vessel was then shimmied up the wire into the space between the jaws. The jaws 
were then moved apart slightly. The bottom end of the wire was then pulled tightly 
against the jaw and screwed onto the lower left-side screw and the top end was pulled 
equally tightly and screwed onto the upper left-side screw. A second wire was then 
introduced along the vessel lumen ensuring that the end of the wire did not traumatise 
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the vessel wall. The jaws were positioned back together and the bottom end of this wire 
was pulled tightly against the second jaw and screwed onto the top right-side screw. 
Finally, the top end was also pulled and screwed to the lower right-side screw. Both 
wires were then positioned side-by-side in a parallel manner. The exact length of the 
arteries was then measured under the microscope using the calibrated eyepiece graticule. 
 
 
 
 
Figure 2.6: Representations of a mounted vessel onto myograph jaws. A: Photograph of the 
myograph bath with a mounted artery. B: Schematic drawing of a vessel mounted on the 
myograph jaws. The vessel, (red arrow) is positioned in the space between the jaws and the 
wires (grey), tightly secured on four screws, are parallel to each other. 
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2.3.2. The normalisation procedure 
2.3.2.1. Theory 
 
Normalisation is the procedure, carried out on each artery, to set it to a width intended 
to simulate its anticipated physiological intra-luminal pressure in vivo (Mulvany and 
Halpern, 1977). This procedure determined the internal circumference (ICset pressure), 
which an artery would have had when relaxed. The starting width of each artery was 
noted and the vessel stretched in a step-wise manner (see Figure 2.7), the change in 
width and tension were continually monitored by the micrometer and strain gauge 
respectively, and the effective pressure (kPa) was calculated at each step: 
Effective pressure = (wall tension(mN/mm)/(IC(!m)/2")) 
wall tension (mN) = tensionplateau–tensionbaseline and IC = internal circumference of the 
artery in µm (= total stretch + diameters of the two wires). 
An exponential curve was then fitted to the internal circumference versus effective 
pressure plot (Davis and Gore, 1989). Using the Laplace equation, the point on the 
exponential curve which corresponded to the set transmural pressure was determined 
and denoted ICset pressure. The Laplace equation is derived from a formula developed 
independently by Thomas Young (Young, 1805) and Pierre-Simon Laplace (Laplace, 
1806); it defines the relationship between pressure, tension and radius of a solid sphere. 
In this context it is assumed that an artery behaves as such,  
P = (T # K) / r 
r = radius in meters, T = tension in Newton, K = a constant to be derived from the wall 
length and P = pressure in Pascals.  
Finally, the internal circumference was set to 0.9 of ICset pressure (see Section 2.3.3), 
which has been shown to yield the maximal active wall tension in rat mesenteric arteries 
(Mulvany and Halpern, 1977, Mulvany and Nyborg, 1980, Mulvany and Warshaw, 
1979, Davis and Gore, 1989). 
The normalised lumen diameter was then calculated: 
Diameter = (0.9 of ICset pressure) / ". 
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2.3.2.2. Practice 
 
The MyoDaq software includes an algorithm that allows calculation of 0.9 of ICset pressure. 
The vessel length was entered in the software program. Figure 2.7 shows a raw tracing 
of an artery undergoing the normalisation procedure. Initially, each artery was set to the 
‘zero’ position. This was the position at which the artery had the smallest diameter, i.e. 
it had not yet developed any tension. This position was obtained by adjusting the jaws 
slowly until the wires touched without pushing against each other. The zero stretch and 
tension were entered into the software program. The artery was then stretched in a step-
wise manner, leaving enough time after every stretch for the vessel to reach a steady- 
state tension, as illustrated in Figure 2.7 (1 to 6), with total stretch and tension entered at 
each step. The software program calculated the internal circumference at each step and 
stretching was stopped when the effective pressure exceeded the set pressure. The 
program then fitted the internal circumference versus effective pressure data to an 
exponential curve and used the Laplace relation to determine ICset pressure and calculate 
0.9 of ICset pressure and the diameter of the vessel. 
 
 
 
Figure 2.7: Schematic diagram of the normalisation procedure on a human myometrial 
artery. (0): starting point, ie. ‘zero’ tension. (1), (2), (3), (4), (5) and (6): positions at which the 
vessel was stretched progressively. (F): position at which, after having exceeded the desired ‘set 
pressure’ (see below), the stretch was adjusted (reduced) to 0.9 of the internal circumference 
anticipated at the desired simulated physiological ‘set pressure’. The vessel was then left to 
equilibrate. x axis: time in minutes. y axis: tension in mN/mm. 
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2.3.3. Normalisation of the myometrial and placental arteries 
 
The myometrial and placental circulations are exposed to differing intraluminal blood 
pressures. The blood pressure in the myometrial vasculature is considered to be close to 
that in the systemic circulation, (80 - 100 mmHg or 13.3 kPa), whilst the placental 
vasculature is thought to be exposed to lower pressures (28 - 40 mmHg or 5.13 kPa) 
(Griffin et al., 1983, McCarthy et al., 1994, Kleiner-Assaf et al., 1999, Struijk et al., 
2008). Pressures can be presented either in Pascals (1000 Pascals = 1 kPa) or mmHg. 
From a pressure in Pa, the conversion factor to mmHg is 0.0075 (Pellicer, 2000). Thus, 
throughout this study, MA were stretched in order to reach an internal circumference 
equivalent to 0.9 of IC13.3kPa and PA were normalised to an internal circumference of 0.9 
of IC5.13kPa (Wareing et al., 2002, Hudson et al., 2007).  
 
2.4. Quality assessment of human arteries 
 
In this study, the mean ± SEM diameter of MA was 314 ± 4.17 microns (n = 62), whilst 
that of PA was 297 ± 7.35 microns (n = 75). Normalisation and subsequent 
experimentations were carried out whilst gassing with 5 % CO2 in air (oxygen content 
of 18 – 21 % - BOC Special Gases, British Oxygen Company, UK). Chapter 5 clarifies 
this choice of oxygenation for both MA and PA. Permeabilisation experiments (see 
Section 2.5) were carried out at 26 °C, whilst intact experiments were carried out in 
37 °C.  
All experiments were started as follows: 
Following normalisation, human arteries (MA or PA) were left to equilibrate in PSS for 
20 to 30 minutes. Addition of 60 mM of KPSS was intended to induce sustained 
constrictions in both artery types. High K+ depolarizes the vascular smooth muscle cell 
membrane and opens voltage-dependent Ca2+ channels, resulting in an influx of 
extracellular Ca2+ and an activation of contractile machinery (Somlyo and Somlyo, 
2003). Figure 2.8 shows the extent of constriction induced by 60 mM KPSS in human 
MA and PA at 37 °C. PA constricted less than MA (MA: 8.2 ± 0.5 kPa, 54 arteries 
versus PA: 5.9 ± 0.2 kPa, 96 arteries, P < 0.05, unpaired t-test). 
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Figure 2.8: Constrictions to 60 mM KPSS in human myometrial (MA) and placental 
arteries (PA). y axis: Force production in kPa. * Statistical difference relative to PA (P < 0.05, 
unpaired t-test). 
 
 
Arteries, which constricted with less than 3 kPa, were deemed of poor quality and were 
therefore discarded. They represented 5 % of MA and 6 % of PA of all experiments.  
Once constriction to 60 mM KPSS had reached a plateau, arterial endothelial function 
was assessed with the addition of BK (1 µM). MA relaxed to BK (by 36 ± 2.7 %, n = 54 
at 37 °C). As MA are known to have a prominent agonist-mediated endothelial-
dependent relaxatory capacity, any vessels, which relaxed less than 30 % to BK (1 µM), 
were deemed of poor endothelial quality and discarded. These represented 6 % of all 
MA. The relaxations observed in this study were similar to those reported in the 
literature (Hudson et al., 2007, Sweeney et al., 2008). In contrast, pre-constricted PA 
did not relax substantially to this agonist (relaxation of 6.2 ± 1.1 %, n = 92 at 37 °C). 
Similar findings had previously been observed in PA pre-constricted to maximal 
concentrations of the thromboxane agonist U46619 (1 µM) (Sweeney et al., 2008) and 
support the notion that PA are resistant to agonist-mediated endothelial-dependent 
relaxation.  
Following exposure to BK, arteries were washed out with PSS and left to equilibrate for 
10 minutes. Arteries were then either permeabilised (see Section 2.5) or left intact. 
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2.5. The permeabilisation procedure 
 
The permeabilisation procedure was the method of choice to assess possible Ca2+-
sensitisation or –desensitisation phenomena in human arteries, as it enabled tight control 
of intracellular Ca2+ concentrations ([Ca2+]i). The procedure involved generation of 
small pores in the cell membrane using !-toxin, secreted naturally occurring toxin 
produced by the bacterium Staphylococcus aureus, and purchased under license from 
List Biological Laboratories (see Appendix D). !-toxin allowed only proteins and 
molecules of 1 - 4 kDa to escape from the cell (Fussle et al., 1981, Bhakdi et al., 1984, 
Lind et al., 1987). Thus, proteins essential to cellular contractile and relaxatory 
mechanisms were assumed to remain within the cell and functional. Membrane G 
protein-coupled receptors were also assumed to retain their function following 
permeabilisation (Bhakdi et al., 1984, Kitazawa et al., 1989). 
 
2.5.1. Preparation of Staphylococcus aureus !-toxin stock aliquots 
 
To permeabilise each artery, 300 units (U)/ml of !-toxin were used. Other groups had 
used 500 – 2000 U/ml (Hudson et al., 2007, Hemmings et al., 2006, Wareing et al., 
2005b), but after running test experiments with 400 and 300 U/ml, I observed that 300 
U/ml were enough to carry out successful permeabilisation.  
 
Each stock vial of !-toxin came as 0.25 mg powder. Each vial had a specific activity in 
units per mg, which could change depending on the lot number. The procedure was as 
follows: 
1) The number of active units present in the 0.25 mg vial was calculated.  
2) Each !-toxin vial was then dissolved in 500 µl sterile double deionised water 
(ddH2O) 
3) The volume required to obtain 300 units of !-toxin in an aliquot was then calculated 
and aliquots of this volume were prepared. 
4) The aliquots were stored at – 20 °C until use for experiments. 
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The !-toxin was prepared wearing a facemask and protective eyewear, in a fume hood. 
All the equipment used to prepare the aliquots, including pipettes and pipette tip boxes, 
were thoroughly cleaned in diluted bleach to remove all toxicity. 
 
2.5.2. Preparation of the !-toxin permeabilisation cocktail  
 
In each permeabilisation experiment, 25 µl !-toxin permeabilisation cocktail was added 
directly onto each artery. For each experiment, four arteries were used, therefore 100 µl 
!-toxin cocktail was needed. The cocktail contained 300 U/ml of !-toxin (in variable 
volumes according to the lot number), 10 µM (1 µl of stock) ionophore A23187, which 
rendered the intracellular stores permeable to Ca2+, and variable volumes (µl) of a pCa 
solution, to ensure the cocktail had a final pCa of 6.7. To determine the necessary pCa 
solution, the following steps were followed: 
1) The volume of Ca2+-activating solution, CaG, needed to make up pCa 6.7 was 
determined. 
2) The dilution factor necessary to obtain a final pCa of 6.7 was determined.  
3) The volume of CaG, which makes up pCa 6.7, was multiplied by the dilution factor. 
This provided the volume of CaG making up the unknown pCa solution. 
4) The now known CaG volume was then searched in the pCa table (Table 2.3) and the 
corresponding pCa solution determined. 
5) The pCa solution for the cocktail was prepared using G10 and CaG solutions in the 
compositions indicated in the pCa table. 
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2.5.3. The permeabilisation protocol 
 
The raw tracing shown in Figure 2.9 illustrates the permeabilisation procedure. 
Following normalisation and assessment of contractile viability (Section 2.4), each 
intact artery was exposed to a mock intracellular relaxing solution (G1, Table 2.2). G1 
solution contains a high concentration of K+, which acts to open the membrane voltage-
gated Ca2+ channels, allowing influx of Ca2+ and resulting in contraction of the artery. 
The chelator EGTA present in G1 likely mops up any residual extracellular Ca2+ ions in 
the bath (from the previous PSS solution), resulting in arterial relaxation back to 
baseline. G1-induced constrictions were similar in MA and PA (MA: 5.6 ± 0.1 kPa, 151 
arteries and PA: 4.7 ± 0.2 kPa, 189 arteries).  
 
 
Figure 2.9: Raw tracing of the permeabilisation procedure in a human myometrial artery. 
The small increases, shown by the white arrows, represent changes in solutions and occur due to 
mechanical movements of the myograph transducer. Red arrow illustrates a relaxation resulting 
from EGTA mopping up Ca2+ ions. y axis: tension in mN/mm. x axis indicates time in 
hours:minutes:seconds. 
 
 
Following removal of the relaxing solution from the bath, vessels devoid of all Ca2+ 
ions were ready for permeabilisation and each artery was incubated with a 25 !l droplet 
of "-toxin cocktail. Incubation was carried out for 30 minutes or until the pCa 6.7-
induced constriction had reached plateau.  
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Following permeabilisation, arteries were bathed in the relaxing solution G1, followed 
by exposure to a specified low-calcium solution (pCa 9, Table 2.3). Subsequent 
exposure to the activating solution pCa 4.5 (Table 2.3) was intended to induce 
substantial constriction of the artery, as this pCa solution contains maximal [Ca2+]. To 
maximize chances of consistent results, arteries, which constricted to pCa 4.5 with less 
than 3 kPa, were deemed unsuitable for further experimentation and discarded (1 % 
placental arteries and 1 % myometrial arteries). Experimental experience indicated that 
arteries, which constricted with less than 3 kPa to pCa 4.5, became erratic. Raw tracings 
on the monitor were very noisy rather than smooth-lined, which would be representative 
of controlled tone of vessels.  A further wash with pCa 9 relaxed the arteries back to 
baseline and experimental protocols were then started. Specific experimental protocols 
will be detailed in the materials and methods section of the relevant results chapter. 
 
2.6. Immuno-blotting 
 
The following experiments were kindly carried out in liaison with Julie Taggart. The 
final western blots presented in this thesis illustrating expression levels of proteins 
PKGI, telokin, MLCK, MYPT1 and CPI-17 were carried out by Julie Taggart. 
Homogenisations of frozen samples (myometrial and placental arteries, myometrial 
tissues, rat brain and rat aorta) used for the assessment of the protein expression were 
carried out in modified RIPA buffer (50 mM Tris HCl, 150 mM NaCl, 1% NP-40, 0.5% 
Na-deoxycholate, 1 mM EGTA pH 7.4) with 2 % (vol/vol) protease inhibitor and 0.5 % 
(vol/vol) phosphatase inhibitor (Sigma Chemicals, St. Louis, MO, USA) at 5 µl buffer 
per mg of tissue. Homogenates were centrifuged at 10,000 ! g at 4 °C for 10 minutes 
and supernatants were collected. Protein concentrations were determined using Bio-Rad 
DC Protein Assay reagents (Bio-Rad Laboratories, Hercules, CA). Table 2.5 illustrates 
the conditions of immune-blots carried out for each protein. Human myometrial tissue 
from pregnant women was used as positive control for HSP20, MLCK, MYPT1 and 
CPI-17, whilst rat aorta and rat brain were the controls of choice for PKGI" and telokin, 
respectively. All protein samples were separated by SDS-PAGE at 80 mA for 90 
minutes. Electro-blotting was carried out onto 0.2 #M polyvinylidene difluoride 
(PVDF) membranes (Biorad Laboratories, Hercules, CA) with transfer voltage and time 
described in Table 2.5 for each protein. Membranes in preparation for immuno-blotting 
for PKGI" were blocked in 5 % Bovine Albumin Serum (BSA, Sigma-Aldrich) 
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overnight at 4 °C. All other membranes were blocked in 5 % milk in TBS-Tween (TBS-
T: 100 mM Tris Base, 66 mM NaCl, 0.1 % Tween 20 (0.1 % w/v), pH 7.5) overnight at 
4 °C. Following exposure to primary and secondary antibodies, membranes were 
washed 3 ! 5 minutes in TBS-T. All secondary antibodies were conjugated with 
horseradish peroxidase. Membranes were stained with enhanced chemiluminescence 
(ECL) substrate (GE Healthcare, Buckinghamshire, UK) and visualised on photographic 
film (Thermo Scientific, IL, USA). Actin was used as a loading control by assessing 
membranes stained by incubating them with Ponceau Red (Sigma-Aldrich) for 30 mins 
at RT. Stained membranes and films were scanned using the UMAX Powerlook III 
Scanner and Softmax Pro Software.  
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Table 2.5: Summary of immuno-blotting conditions for PKGI! and PKG-interacting myofilament-associated proteins. 
Antibody 
Protein 
Concentration 
(µg) 
PC Percentage Acrylamide Gel Electro-Blotting  Primary Antibody Secondary Antibody 
 PKGI! 20 Rat Aorta 10 % 90 V for 90 mins 
Goat IgG, 1:400 (sc-10335, 
Santa Cruz, CA), 5% BSA, 
o/n 4 °C 
 
Rabbit anti-goat, 1:5,000 
(Dako), 5% BSA, 1 hr RT 
HSP20 5 
Human 
Myometrium 
(pregnant) 
15 % 100 V for 45 mins 
Rabbit IgG, 1:7,500 
(ab13491, Abcam), 1% milk, 
o/n 4 °C 
 
Goat anti-rabbit, 1:5,000 
(Dako), 1% milk, 1 hr RT 
Telokin 10 Rat Brain Pre-cast 4 – 15 % 100 V for 45 mins 
Rabbit IgG, 1:2,000 
(ab76092, Abcam), 1% milk, 
1 hr RT 
Goat anti-rabbit, 1:5,000 
(Dako), 1% milk, 1 hr RT 
MLCK 7.5 
Human 
Myometrium 
(pregnant) 
 
8 % 90 V for 110 mins 
Rabbit IgG, 1:10,000 
(ab76092, Abcam), 1% milk, 
1 hr RT 
Goat anti-rabbit, 1:5,000 
(Dako), 1% milk, 1 hr RT 
MYPT1 20 
Human 
Myometrium 
(pregnant) 
Pre-cast 4 – 15 % 90 V for 110 mins 
Rabbit IgG, 1:200 (sc-25618, 
clone H-130, Santa Cruz, 
CA), 1% milk, o/n 4 °C 
  
Goat anti-rabbit, 1:5,000 
(Dako), 1% milk, 1 hr RT 
CPI-17 10 
Human 
Myometrium 
(pregnant) 
12 % 100 V for 45 mins 
Rabbit IgG, 1:500 (c-7905-
50, US Biochemical), 1% 
milk, o/n 4 °C 
Donkey anti-rabbit, 1:250 
(ThermoScientific), 1% 
milk, 1 hr RT 
Pre-cast gels were obtained from Bio-Rad Laboratories, Hercules, CA, BSA: Bovine Albumin Serum, mins: minutes, o/n: overnight, hr: hour, RT: room temperature, 
PC: positive control. 
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2.7. Analysis and Statistics 
2.7.1. Analysis 
2.7.1.1. Functional Studies 
 
Vessel tone was measured in units of mN/mm, which were subsequently converted into 
active effective pressure (kPa) taking into account the diameter of the vessel.  
Active effective pressure = (wall tension(mN/mm)/(diameter(!m)/2000)) 
where wall tension = tensionplateau–tensionbaseline  
Raw tracings illustrating changes in tension are presented in kPa, except for Figures 2.7 
and 2.9, which were presented in mN/mm in this Chapter. 
Arterial relaxation to BK, His, SNP, YC-1 or 8-bromo-cGMP (8-br-cGMP) was 
measured as a percentage of constriction to 60 mM KPSS, contractile agonists or pCa 
solutions. 
 
2.7.1.2. Immuno-blotting 
 
Identification of the optical density of bands representing proteins in MA and PA 
allowed for quantification of protein expression. Optical densities from the western blot 
scans were determined using Intelligent Quantifier Software (BioImage Systems Inc.). 
Protein expression was quantified by normalising the optical density of each band in 
MA and PA to the optical density of the positive control following the subtraction of 
background. All resulting data sets were also normalised to the scans’ background noise. 
 
2.7.2. Statistics 
 
n represents the number of patients. Throughout this study, statistical analyses were 
carried out using unpaired t-tests, one-way ANOVAs or two-way ANOVAs as 
appropriate. Values were quoted as mean ± standard error of the mean. Statistical 
analysis was carried out using the software GraphPad Prism, version 4.0. Statistical 
significance was taken at P < 0.05.  
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3. Chapter 3 
Ca2+-sensitisation in human myometrial and placental arteries in the 
presence of G protein-coupled agonists 
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3.1. Introduction 
 
Successful fetal growth and pregnancy outcome are dependent upon adequate blood 
flow in the uteroplacental circulations. In turn, this requires a balance of contractile and 
relaxatory factors within the maternal uterine and feto-placental circulations. Aberrant 
expression of several contractile agonists has been linked to pregnancy complications 
which display raised vascular resistance such as pre-eclampsia and hypertension in 
pregnancy (Wetzka et al., 1997, Faxen et al., 2000, Yamamoto et al., 2010). It is 
important, therefore, to develop our understanding of the regulation of blood vessel tone 
in placental and uterine circulations and to elucidate the mechanisms, which may 
regulate placental arteries (PA) differently from myometrial arteries (MA). As 
mentioned previously, it is reasonable to propose that maternal uterine and fetal 
placental vasculatures may experience different regulatory influences. Ca2+ activation of 
the contractile filaments of SM is the primary mechanism of contractile regulation in 
blood vessels.  In addition, this pathway is often targeted by physiological agents 
effecting endothelial-dependent vasodilatory influences, which are known to differ 
between MA and PA (Chapter 5, Sweeney et al., 2008).  Therefore, it is important to 
establish whether these arteries differ in their sensitivities to Ca2+-dependent force 
production. 
 
Studies have implicated the contractile agonist thromboxane, whose mimetic is U46619, 
in pregnancy complications. It has been shown that the ratio of 
prostacyclin:thromboxane production rate was decreased in the human placenta and 
placental bed from pre-eclamptic pregnancies compared to those from normal 
pregnancies, thus favouring the vasoconstrictive thromboxane (Wetzka et al., 1997) and, 
thereby, offering one mechanism for localised elevation in blood pressure associated 
with this condition. Similarly, S1P, a potent angiogenic factor, expressed in mammalian 
uteri and other tissues, has been shown to play an important role in the 
endometrial/placental angiogenesis during pregnancy in ewes (Dunlap et al., 2010, Hla, 
2004, Mizugishi et al., 2007, Skaznik-Wikiel et al., 2006, Su et al., 2008). Insufficient 
endometrial/placental vascularisation can compromise pregnancy and lead to 
pathological conditions such as preeclampsia (Dunlap et al., 2010). These findings 
stress the importance of adequate control of S1P and thromboxane production/activity 
during pregnancy, highlighting the need to further understand their involvement in 
vascular tone regulation in arteries from the human placenta and myometrium. In 
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addition to these two agonists, a third vasoconstrictor, endothelin-1 (ET-1), has been 
associated with cardiovascular diseases and is considered to be one of the most potent 
naturally occurring peptidic agonists (Inoue et al., 1989). Overexpression of ET-1 has 
been reported in systemic hypertensive disorders and pregnancy related complications, 
such as preeclampsia (Tanfin et al., 2011, Agapitov and Haynes, 2002, Wang et al., 
2008, Faxen et al., 2000). Additionally, ET-1 mRNA levels were found to be 
significantly higher in the placenta compared to myometrium from women with healthy 
pregnancies (Faxen et al., 2000). These findings highlight the importance of 
understanding the signalling mechanisms regulating vascular tone in these two human 
organs. 
 
Previous studies have reported that both PA and MA constricted to sub-maximal 
concentrations of Ca2+ (pCa 6.7) when their membranes had been rendered permeable to 
small solutes by toxin permeabilisation. Such constrictions were further enhanced with 
the addition of the G protein-coupled agonists U46619 in both artery types and by S1P 
in chorionic plate PA (Wareing et al., 2005b, Hemmings et al., 2006). This indicated 
that enhancement of Ca2+-dependent force production at one particular supra-basal and 
sub-maximal [Ca2+]i occurred in both artery types. However, neither of these studies 
carried out rigorous comparisons of the Ca2+-dependency of constriction, nor agonist-
mediated Ca2+-sensitisation of force, between PA and MA. There are currently no 
studies reporting Ca2+-sensitisation induced by ET-1 in human arteries and knowledge 
on the contractile effects of this vasoconstrictor is also limited in arteries from the 
reproductive organs in humans (Cooper et al., 2005). 
 
Consequently, in this study, I aimed to establish novel information regarding the role of 
these three physiologically important G protein-coupled agonists in regulating tone in 
human arteries from the placenta and myometrium. In particular, to assess (i) Ca2+-
dependent responses over a range of [Ca2+]i (pCa 9 – 4.5), (ii) whether Ca2+-
sensitisations mediated by U46619, ET-1 and S1P occurred in PA and MA and (iii) 
whether responses differed between the two artery types. To do so, I utilised the 
experimental model of !-toxin permeabilisation, which allowed for tight experimental 
control of [Ca2+]i.  
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3.2. Materials and Methods 
3.2.1. Experimental protocol 
 
As described previously, permeabilisation experiments were carried out at 26 °C. 
Isolated human MA and PA, isometrically mounted on wire myographs, were 
constricted to 60 mM KPSS, permeabilised with !-toxin and constricted to pCa 4.5 
(Section 2.5.3).  
 
Contractile responses were then assessed to increasing Ca2+ concentrations (pCa 9, 8, 
7.5, 7, 6.7, 6.3, 6, 5.5 and 4.5). Each individual artery was exposed to a pCa curve in 
one of the five following conditions: 
1. pCa alone (Time Control or TC) 
2. pCa + 10-6 M U46619 
3. pCa + 10-8 M ET-1 
4. pCa + 0.1 % BSA (TC + BSA) 
5. pCa + 10-5 M S1P 
For each tissue type (MA and PA), two experiments were run to accommodate the five 
experimental conditions. One myograph could only accommodate four vessels. 
Therefore, in one experiment, conditions 1, 2 and 3 were assessed and in a second 
experiment, conditions 4 and 5 were assessed from the same tissue. 
 
These functional experiments lasted 9 -10 hours following normalisation of the vessels. 
 
3.2.2. Analysis and Statistics 
3.2.2.1. Analysis 
 
Assessment of the constrictive responses of each artery type was carried out as an 
analysis of the change in tension (extrapolated as active effective pressure) of the TC 
compared to the contractile changes in the presence of the G protein-coupled agonist. 
Additionally, for each experimental condition, the level of tension production to every 
pCa (plus or minus agonist) was calculated as a percentage of the maximal tension 
development observed during that pCa dose-response protocol. This enabled a visual 
representation of possible changes in Ca2+-sensitivity of contraction between conditions. 
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The log EC50, which was the pCa value at which half (50%) of the maximal constriction 
was reached, was determined from the raw data obtained from each artery type exposed 
to every condition. Each raw data set was fitted onto a sigmoidal curve with nonlinear 
regression using the following equation 
Y = min + (max – min) / (1 + 10 ^ (Log EC50 – X) * Hill Slope) 
where min and max represent minimal and maximal raw values of tension development 
and Hill Slope represents the slope factor or steepness of the slope. 
All the data sets presented in this chapter fitted onto sigmoidal curves with r2 > 0.90. 
Log EC50 values were compared between experimental conditions (in the presence or 
absence of G protein-coupled agonists) and between artery types. 
 
3.2.2.2. Statistics 
 
Contractile responses to 60 mM KPSS and pCa 4.5 were compared between MA and 
PA using unpaired t-test. 
 
Tension development pCa curves were compared between experimental conditions for 
each artery type using two-way ANOVA, including a Bonferroni post-hoc test for 
detailed breakdown of the analysis. Paired comparisons between TCcondition and 
condition were made as follows: 
• TCU46619 versus U46619 
• TCET-1 versus ET-1 
• TCALL versus TCS1P + BSA 
• TCS1P + BSA versus S1P 
Tension development pCa curves were also compared between artery types for every 
experimental condition using two-way ANOVA, including a Bonferroni post-hoc test 
for detailed breakdown of the analysis. Comparisons were made as follows: 
• With TC: PA versus MA  
• With U46619: PA versus MA 
• With ET-1: PA versus MA 
• With S1P: PA versus MA 
Log EC50 values were compared between experimental conditions using paired 
Student’s t-test as follows: 
• EC50 (TC) versus EC50 (U46619) 
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• EC50 (TC) versus EC50 (ET-1) 
• EC50 (TC) versus EC50 (TC + BSA) 
• EC50 (TC) versus EC50 (S1P) 
Log EC50 values were also compared between artery types using unpaired Student’s t-
test as follows: 
• With TC: EC50 (PA) versus EC50 (MA) 
• With U44619: EC50 (PA) versus EC50 (MA) 
• With ET-1: EC50 (PA) versus EC50 (MA) 
• With S1P: EC50 (PA) versus EC50 (MA) 
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3.3. High K+- and Ca2+-induced force production of human myometrial and 
placental arteries 
 
Figure 3.1 shows the original tracings of an individual myometrial artery (A) and an 
individual placental artery (B) exposed to 60 mM KPSS pre-permeabilisation and pCa 
4.5 post-permeabilisation. In this example, 60 mM KPSS and pCa 4.5 induced increases 
in tension both artery types. In MA, the KPSS-induced constriction was 8.2 kPa and 
similar to the pCa 4.5-induced constriction, which was 7.8 kPa. In PA, KPSS-induced 
constriction was 4.6 kPa, whilst that induced by pCa 4.5 was almost double the previous 
constriction, at 8.1 kPa.  
 72 
 
 
 
Figure 3.1: Original raw tracings of responses in (A) a myometrial and (B) a placental artery to 60 mM KPSS pre-permeabilisation and to pCa 4.5 post-
permeabilisation.  
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Figure 3.2 illustrates the contractile responses to high K+ (60 mM KPSS) pre-
permeabilisation and high Ca2+ (pCa 4.5) post-permeabilisation in human MA and PA. 
60 mM KPSS-induced constrictions were greater in MA compared to PA (MA: 8.63 ± 
0.31 kPa, n = 49 versus PA: 5.75 ± 0.14 kPa, n = 51). Constrictions to pCa 4.5 were 
similar to 60 mM KPSS-induced constrictions in MA, however in PA, they were 1.67 ± 
0.06-fold higher than those induced by KPSS. Consequently, mean constrictions to pCa 
4.5 in PA exceeded those in MA (MA: 7.42 ± 0.22 kPa, n = 49 versus PA: 8.63 ± 0.24 
kPa, n = 51). 
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Figure 3.2: Summary data of contractile responses to 60 mM KPSS (A) and pCa 4.5 (B) in 
myometrial and placental arteries. Constrictions to 60 mM KPSS were assessed in intact 
arteries and constrictions to pCa 4.5 determined in permeabilised MA and PA. y axis: Force 
production in kPa. x axis: Red squares represent myometrial arteries (MA). Blue circles 
represent placental arteries (PA). * Statistical difference relative to PA. 
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3.4. Ca2+-induced force production of human myometrial and placental arteries 
over increasing Ca2+ concentrations 
 
Figure 3.3 shows an original tracing of the increasing force development in one 
individual permeabilised MA (Figure 3.3A) and one individual PA (Figure 3.3B) during 
assessment of responses to increasing Ca2+ concentrations or pCa (9 – 4.5). In these 
examples, tension development started at pCa 7 in MA, whilst in PA, the force 
production started at a lower pCa (pCa 6.7 i.e. at a higher [Ca2+]). The magnitude of 
these constrictions appear similar over their respective ranges of [Ca2+]i (i.e. pCa 7 to 
4.5 in MA and pCa 6.7 to 4.5 in PA). 
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Figure 3.3: Original raw tracings of responses in (A) a myometrial and (B) a placental 
permeabilised artery to increasing Ca2+ concentrations. 
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Figure 3.4A illustrates the group mean ± SEM comparisons of maximal constriction 
(kPa) pCa curves in MA versus PA. There was no difference in the maximal forces 
developed between these two artery types (n = 8). Figure 3.4B displays the comparison 
of the tension developed in MA or PA at each pCa when expressed as a percentage of 
the maximal force produced in each individual artery. The curve representing MA data 
sets is shifted to the left with a greater percentage constriction between pCa 7 and pCa 6 
compared to PA. This indicates an increase in sensitivity to [Ca2+]i in MA compared to 
PA; a suggestion which is supported by the lower EC50 compared to PA (log EC50 (MA) = 
-6.64 ± 0.07 and log EC50 (PA) = -6.26 ± 0.05). These results therefore illustrate that, 
whilst maximal constrictions were similar between MA and PA, the former artery type 
displayed a higher sensitivity to the same sub-maximal [Ca2+]i.  
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Figure 3.4: Summary data of contraction responses to increasing Ca2+ concentrations in 
myometrial (MA) and placental (PA) arteries. A: Mean maximal force productions (kPa) at 
each pCa (9 – 4.5) in MA and PA. B: The force developed at each pCa is expressed as a 
percentage of the maximal force developed in that individual artery type and the mean data 
shown for both MA and PA. 
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3.5. Agonist-induced enhancement of Ca2+-dependent constriction in human 
myometrial and placental arteries 
3.5.1. Assessment of agonist effects on Ca2+-dependent constriction of human 
myometrial arteries 
 
Figure 3.5 shows original tracings of the increasing force development in four 
individual permeabilised myometrial arteries during assessment of Ca2+-sensitisation 
induced by three different G protein-coupled agonists. The first artery was exposed to 
pCa alone and small tension development started at pCa 7 (Figure 3.5A). The second 
artery was exposed to the same increasing pCa in the presence of 10-6 M U46619 
(Figure 3.5B). Finally, the third and fourth arteries were exposed to the same increasing 
[Ca2+]i in the presence of 10-8 M ET-1 and 10-5 M S1P (Figures 3.5C and 3.5D, 
respectively). Arteries exposed to any of the three agonists seem to develop greater 
tension over the same range of pCa, with a particular increase at pCa 7 (Figures 3.5A, 
3.5B and 3.5C).  
 
In MA, all TC data sets paired to U46619 were also paired to ET-1. However, it was 
important to confirm that there were no differences between the two TC data sets that 
were utilised (ie. TC for comparison to U46619 or ET-1 and TC + BSA for comparison 
to S1P as BSA was used as a carrier molecule for S1P). In the presence of BSA, the 
forces produced over the range of pCa were not different from those obtained in the 
presence of pCa alone (data not shown). In addition, their respective EC50 values were 
not different (log EC50 (TC) = -6.64 ± 0.07 vs. log EC50 (TC+BSA) = -6.62 ± 0.06). Thus, 
BSA had no constrictive nor Ca2+-sensitising effect on MA. Consequently, only one 
original raw tracing representing TC was shown in Figure 3.5. 
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Figure 3.5: Original raw tracings of agonist effects on Ca2+-dependent force of four individual permeabilised myometrial arteries. A: pCa curve showing 
arterial responses in a first artery to increasing [Ca2+]i (pCa 9 - 4.5). B, C and D: pCa curves showing arterial responses to increasing [Ca2+]i (pCa 9 - 4.5) in a 
second, third and fourth artery, in the presence of 10-6 M U46619, 10-8 M ET-1 or 10-5 M S1P, respectively.  
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Figure 3.6 shows the group comparisons of maximal constriction (kPa) of pCa curves in 
the three experimental conditions in human MA. In the presence of all three agonists, 
U46619, ET-1 and S1P, the forces produced over the range of pCa were greater than 
those observed in the TC (n = 8 Figure 3.6A, n = 5 Figure 3.6B and n = 4 Figure 3.6C, 
respectively). In arteries exposed to U46619 and ET-1, constrictions were greater than 
TC from pCa 7 onwards (pCa 7 – 4.5), whilst in the presence of S1P, significance was 
obtained particularly at pCa 6.3.  
 
Figure 3.7 presents the mean forces developed at each pCa expressed as a percentage of 
the maximal force developed in each experimental condition. The curves representing 
U46619, ET-1 and S1P data sets are shifted to the left compared to the TC (Figures 
3.7A, 3.7B and 3.7C, respectively), which indicates an increase in the sensitivity to Ca2+ 
in MA, induced by these agonists. This is supported by the lower EC50 values for the 
U46619 data sets (log EC50 (TC) = -6.64 ± 0.07 and log EC50 (U46619) = -7.05 ± 0.05), the 
ET-1 data sets (log EC50 (TC) = -6.64 ± 0.07 and log EC50 (ET-1) = -6.93 ± 0.15) and the 
S1P data sets (log EC50 (TC) = -6.64 ± 0.07 and log EC50 (S1P) = -6.78 ± 0.05).  
 
Thus, taken together, these results indicate that agonists mediated the enhancement of 
Ca2+-dependent force, and a sensitisation to the activating Ca2+, in permeabilised human 
myometrial arteries. 
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Figure 3.6: Summary force data in the presence of the G protein-coupled agonists, 
U46619, ET-1 and S1P, in permeabilised myometrial arteries. A, B and C: Mean (± SEM) 
maximal force productions (kPa) at each pCa in the presence of the G protein-coupled agonists 
U46619, endothelin-1 (ET-1) or sphingosine-1-phophate (S1P), respectively. TC: time control, 
ie. increasing Ca2+ concentrations in the absence of a G protein-coupled agonist. * Statistical 
difference relative to TC. ! Statistical difference relative to TC at the specific pCa.  
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Figure 3.7: Normalised force data in the presence of the G protein-coupled agonists, 
U46619, ET-1 and S1P, in permeabilised myometrial arteries. A, B and C: Mean (± SEM) 
force developed at each pCa expressed as a percentage of the maximal force developed in each 
individual group over a range of nine pCa (9 – 4.5), in the presence of U46619, ET-1 or S1P, 
respectively.  
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3.5.2. Assessment of agonist effects on Ca2+-dependent constriction of human 
placental arteries 
 
Similarly to the experiments carried out in human MA, agonist-mediated Ca2+-
sensitisation was assessed in human PA in the same conditions. Figure 3.8 shows 
original tracings of the increasing force development in four individual permeabilised 
PA during the assessment of agonist effects on pCa-induced contractions. The first 
artery was exposed to increasing pCa amounts alone (time control, TC) and contraction 
started in pCa 6.7 (Figure 3.8A). The second artery was exposed to the same increasing 
pCa in the presence of 10-6 M U46619 (Figure 3.8B). Finally, the third and fourth 
arteries were exposed to the same increasing pCa with 10-8 M ET-1 or 10-5 M S1P 
(Figures 3.8C and 3.8D, respectively). In the presence of U46619, the force produced 
was greater over the same range of pCa (Figure 3.8B). ET-1 and S1P also seem to have 
induced greater tension development than pCa alone, although it appears, to a lesser 
extent than with U46616 (Figures 3.8C and 3.8D). In the presence of U46619, ET-1 and 
S1P, constrictions started at a lower [Ca2+]i (pCa 7) compared to the TC. 
 
In this set of results, the U46619 and ET-1 data sets were all paired to the TC data sets. 
However, I wished to verify that these TC (pCa alone) were not different from the TC + 
BSA data sets, which were paired to the pCa curves ran in the presence of S1P. No 
statistical comparison could be carried out between the two TC (TC and TC + BSA) due 
to the small n number for the TC + BSA data sets (n = 2). However, the mean EC50 
values between these two conditions seemed similar (log EC50 (TC) = -6.26 vs. log EC50 
(TC+BSA) = -6.28), indicating that BSA may not have affected the magnitude of 
constrictions nor sensitivities to Ca2+ in PA. As a result, only one original raw tracing 
representing the TC was shown in Figure 3.8.  
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Figure 3.8: Original raw tracings of agonist effects on Ca2+-dependent force of four individual permeabilised placental arteries. A: pCa curve showing 
arterial responses in a first artery to increasing [Ca2+]i (pCa 9 - 4.5). B, C and D: pCa curves showing arterial responses to increasing [Ca2+]i (pCa 9 - 4.5) in a 
second, third and fourth artery, in the presence of 10-6 M U46619, 10-8 M ET-1 or 10-5 M S1P, respectively. 
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Figure 3.9 shows the group comparisons of maximal constrictions (kPa) of pCa curves 
in the three experimental conditions in human PA. In the presence of U46619, the 
tension development was greater than that observed in TC (pCa alone) (n = 8, Figure 
3.9A). Similarly, ET-1 induced greater constrictions compared to TC (n = 9, Figure 
3.9B). Note that for the TC - S1P (Figure 3.9C), statistical comparison could not be 
carried out as there are only n = 2, however these preliminary data seem to indicate that 
S1P induces greater constriction over the range of pCa when compared to TC. 
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Figure 3.9: Summary of force production (kPa) in the presence of the G protein-coupled 
agonists, U46619, ET-1 and S1P, in permeabilised placental arteries. A, B and C: Mean (± 
SEM) maximal force productions (kPa) at each pCa in the presence of the G protein-coupled 
agonists U46619, endothelin-1 (ET-1) or sphingosine-1-phophate (S1P), respectively. TC: time 
control, ie. increasing Ca2+ concentrations in the absence of a G protein-coupled agonist. * 
Statistical difference relative to TC. ! Statistical difference relative to TC at the specific pCa. 
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Figure 3.10 displays the mean forces developed at each pCa expressed as a percentage 
of maximal force developed in each experimental condition. The curves representing 
U46619, ET-1 and S1P data sets are shifted to the left, which is indicative of an increase 
in sensitivity to Ca2+ induced by these agonists (Figures 3.10A, 3.10B and 3.10C, 
respectively). This notion is supported by lower EC50 values for the U46619 data (log 
EC50 (TC) = -6.26 ± 0.05 and log EC50 (U46619) = -6.97 ± 0.06) and the ET-1 data sets (log 
EC50 (TC) = -6.26 ± 0.05 and log EC50 (ET-1) = -6.63 ± 0.1). Statistical analysis was not 
carried out on the data sets for S1P, as the n number (n = 2) was too small. However, 
the average logEC50 is lower in the presence of S1P compared to the TC condition (log 
EC50 (TC) = -6.26 and log EC50 (S1P) = -6.64).  
 
Consequently, these results illustrate that agonists mediated the enhancement of Ca2+-
dependent force, and a sensitisation to that activating Ca2+, in permeabilised human 
placental arteries. 
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Figure 3.10: Normalised force data in the presence of the G protein-coupled agonists, 
U46619, ET-1 and S1P, in permeabilised placental arteries. A, B and C: Mean (± SEM) 
force developed at each pCa expressed as a percentage of the maximal force developed in each 
individual group over a range of pCa (9 – 4.5), in the presence of U46619, ET-1 or S1P, 
respectively.  
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3.6. Comparison of Ca2+-dependent contractions between myometrial and 
placental arteries 
 
Having established that the enhancement of Ca2+-dependent force production, and Ca2+-
sensitisation, in both human MA and PA arteries are effected by a variety of G protein-
coupled agonists, a comparison of the data between these artery types was subsequently 
investigated. As presented in Section 3.4, MA and PA constricted with a similar 
magnitude to a range of activating [Ca2+]i (Figure 3.4A). However, MA displayed a 
greater sensitivity to the same [Ca2+]i as compared to PA. This was illustrated by the 
shift to the left of the MA pCa-force curve relative to PA and by their different EC50 
values (Figure 3.4B). It was of interest, therefore, to extend such assessment by 
comparing the responses to the same range of pCa in the presence of three G protein-
coupled agonists, U46619, ET-1 and S1P, between these two artery types. 
 
Figure 3.11 illustrates the comparisons of maximal constriction (kPa) of pCa curves in 
the four experimental conditions (TC, U46619, ET-1 and S1P) in human permeabilised 
MA and PA. The maximal force developed over the range of pCa alone (9 – 4.5) is 
similar in the two artery types (Figures 3.11A and 3.4A). Likewise, the forces produced 
with U46619 over the same range of pCa were not different between MA and PA 
(Figure 3.11B). However, as illustrated in Figure 3.11C, MA constricted more to the 
same range of pCa compared to PA in the presence of ET-1.  Statistical analysis was not 
carried out to compare the contractile effect of S1P between these two arteries due to 
the small n number of S1P data sets in PA. Nonetheless it appears that MA constricted 
considerably more than PA, particularly over pCa 6.7 to 3.5 (Figure 3.11D). 
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Figure 3.11: Comparison of force production in the presence and absence of the three G protein-coupled agonists in permeabilised myometrial (MA) and 
placental (PA) arteries. A: Mean (± SEM) maximal force productions (kPa) at each pCa in MA versus PA (Time Control). B, C and D: Mean maximal force 
productions (kPa) at each pCa between MA and PA in the presence of the G protein-coupled agonists U46619, endothelin-1 (ET-1) or sphingosine-1-phophate 
(S1P), respectively. * Statistical difference relative to TC.  
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Figure 3.12 shows the mean tension developed at each pCa expressed as a percentage of 
the maximal force produced in each experimental condition in MA versus PA. As 
mentioned previously, the curve representing MA data is shifted to the left and force 
production started at a higher pCa (pCa 7) compared to PA data, indicating a greater 
sensitivity to Ca2+ in MA (Figures 3.12A and 3.4B). This was supported by the lower 
EC50 in MA compared to PA. Conversely, as illustrated in Figure 3.12B, there seem to 
be no differences between the curves representing MA and PA data sets in the presence 
of U46619 over the range of pCa, indicating that these two artery types display a similar 
sensitivity to Ca2+ in the presence of this agonist. This notion was maintained by the 
similar EC50 values in these two artery types (log EC50 (PA) = -6.97 ± 0.06 and log EC50 
(MA)= -7.05 ± 0.05). In the presence of ET-1, the curve representing MA data is shifted 
to the left compared to that representing PA data, possibly illustrating a greater 
sensitivity to Ca2+ in MA compared to PA in the presence of this agonist (Figure 3.12C). 
Surprisingly, the EC50 values did not support this notion, as no difference was detected 
between EC50 values from these two artery types (log EC50 (PA) = -6.63 ± 0.10 and log 
EC50 (MA)= -6.93 ± 0.15). Finally, in the presence of S1P, the curves representing MA 
and PA data sets seem to differ, but only at pCa 6.3 and 6 (Figure 3.12D). This may be 
due to the small n number for PA.  
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Figure 3.12: Comparison of normalised force data in the presence of three G protein-coupled agonists in permeabilised myometrial (MA) and placental 
(PA) arteries. A: Mean (± SEM) force developed at each pCa expressed as a percentage of the maximal force developed in PA versus MA. This data has been 
displayed before in Fig 3.2B.  B, C and D: Mean force developed at each pCa expressed as a percentage of the maximal force developed between PA and MA 
arteries in the presence of U46619, ET-1 or S1P, respectively.  
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3.7. Discussion 
 
The intention of this study was to establish whether agonist-mediated enhancement of 
Ca2+-dependent constrictions occurred in human myometrial (MA) and placental (PA) 
arteries and whether there were any differences between the two artery types. Vessels 
were permeabilised with !-toxin, which facilitated discreet control of the activating 
Ca2+ concentrations acting on the myofilaments while retaining the G protein-coupled 
mechanisms. The key findings were that the sensitivity of MA and PA to activating 
Ca2+ differed, G protein-coupled agonists enhanced the Ca2+-dependent force 
production in both MA and PA and that this was also associated in each case with 
increased Ca2+-sensitisation of force.  
 
To date, there are few reports of Ca2+-dependent force production in !-toxin 
permeabilised human MA and PA (Wareing et al., 2005b, Hemmings et al., 2006). In 
both studies, sub-maximal constrictions produced by pCa 6.7 were further enhanced by 
exposure to either U46619 or S1P. However, there have been no reports of the 
development of force and sensitisation over incremental Ca2+ concentrations in these 
human arteries in the presence or absence of agonists.  
 
Methods previously used to achieve selective permeabilisation (i.e. permeabilisation of 
the cell’s plasma membrane only), have included the use of glycerol, which was the first 
detergent used for such purposes in skeletal (striated) and vascular (smooth) muscles 
(Filo et al., 1965), the application of high voltage discharges to bovine adrenal 
medullary chromaffin cells (Baker and Knight, 1981) and rat pancreatic islet cells 
(Stutchfield and Howell, 1984) and the use of non-ionic detergents such as digitonin, 
saponin or "-escin (a saponine derivative) on human cavernosa cells, guinea pig taenia 
ceci SM fibres or SM cells, respectively (Endo et al., 1982, Muraki et al., 1992, Krall et 
al., 1988). A permeabilising agent should create permanent ‘leaks’ but digitonin and 
saponin fail to achieve stable permeabilisation of erythrocytes with pores apparently 
resealing (Duncan and Schlegel, 1975). Additionally, permeabilisation using these 
detergents, although cheap and apparently technically simple, was unreliable due to the 
narrow range of concentrations, incubation time and temperature over which the desired 
selective effect could be obtained (Dunn and Holz, 1983, Baker et al., 1985). These 
different permeabilising agents also all induced leakage of intracellular key contractile 
proteins to the extracellular environment, which meant that, in (vascular) smooth 
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muscle preparations, the medium required supplementation with CaM to activate 
MLCK and to try and minimise the decrease in constrictions observed with successive 
contraction-relaxation cycles (Endo et al., 1982, Filo et al., 1965, Muraki et al., 1992). 
Moreover, with the exception of !-escin, permeabilisation with these agents did not 
retain the G protein-coupled receptor function, which for the purposes of this study was 
essential (Endo et al., 1982, Muraki et al., 1992). 
 
The benefits of Staphylococcal "-toxin as a membrane permeabilising agent were 
initially established in 1985 (Ahnert-Hilger et al., 1985). Staphylococcal "-toxin pores 
are comprised of homogenous ring-structured hexamers forming pores of apparently 
uniform size with a functional diameter of around 1.5 nm regardless of the dose of toxin 
applied (Fussle et al., 1981, Bhakdi and Tranum-Jensen, 1991). It is therefore highly 
unlikely that the "-toxin molecules (Mr = 34,000) would permeate such pores and gain 
access to the cell interior with secondary effects on intracellular membranes or protein 
function (Bhakdi and Tranum-Jensen, 1991). The small size of the "-toxin pores also 
allows retention of intracellular molecules of ~ 4 kDa whilst maintaining G protein 
coupled receptor-mediated signalling integrity (Bhakdi et al., 1984, Bhakdi and 
Tranum-Jensen, 1984, Kitazawa et al., 1989). Kitazawa et al. (1989) showed that 
constrictions in "-toxin-permeabilised guinea pig SM strips were induced by activation 
of G protein-coupled "-adrenergic and muscarinic receptors by their respective agonists, 
phenylephrine and carbachol. Additionally, these constrictions were dependent on GTP, 
as addition of GDP!S inhibited them; this indicated that functionality of G protein-
coupled receptors was retained following "-toxin permeabilisation (Kitazawa et al., 
1989). Thus, this toxin was the permeabilising agent of choice for this study.  
 
In the current study, addition of high K+ (60 mM KPSS) induced greater constrictions in 
intact MA compared to PA. This difference was, however, not apparent in 
permeabilised arteries exposed to pCa 4.5. Thus, one possibility for the lower 
constrictions observed with KPSS in intact PA compared to MA may be differences in 
the sensitivity of myofilaments to the activating Ca2+.  It is commonly accepted that an 
increase in [Ca2+]i induces constriction of VSMC via binding of Ca2+ to calmodulin, 
activation of MLCK and phosphorylation of the regulatory MLC20 (Somlyo, 1985, 
Somlyo and Himpens, 1989). Conversely, the activity of myosin light chain 
phosphatase (MLCP), and a decrease in [Ca2+]i reducing MLCK activity, leads to 
MLC20 dephosphorylation and relaxation of VSMC (Hartshorne et al., 1998). Thus, the 
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ratio of kinase to phosphatase activities determines the contractile/relaxatory state of a 
VSMC. In this study, human MA and PA both displayed concentration-dependent 
increases in force production over a range of pCa and although, no differences in 
maximal force production were observed between MA and PA constricted with 
incremental [Ca2+] (pCa 9 - 4.5), MA contracted at lower [Ca2+]i (pCa 7) compared to 
PA (pCa 6.7), suggesting a higher sensitivity of the regulatory contractile mechanism to 
Ca2+ in arteries from the myometrium compared to those from the placenta.  
 
Work in different SM types offer possible explanations for this difference in 
sensitivities between PA and MA. It has been suggested, for example, that differences 
in Ca2+ sensitivity may occur between two SM ‘types’ (phasic versus tonic) and these 
may be due, at least in part, to differences in the MCLK/MLCP activity ratios between 
different SM types (Somlyo and Himpens, 1989). Thus, the observed differences in 
sensitivity between PA and MA may be due to differing MLCK/MLCP activity ratios 
within their respective VSMC. Studies have also shown that Ca2+ sensitivity of MLCK 
may be regulated by phosphorylation at its Ser-512 by protein kinase A (PKA), which 
leads to a reduction in the affinity of MLCK to Ca2+/CaM by around 10 fold (Conti and 
Adelstein, 1981). Increased levels of PKA in PA would therefore induce a reduction in 
sensitivity to Ca2+ compared to MA, as was observed in this study. Levels of PKA have 
not yet been assessed in the two artery types. It has also been suggested that the 
inhibitory phosphorylation of MLCK is a result of an autoinhibitory mechanism 
mediated by Ca2+-dependent phosphorylation of MLCK by the calmodulin kinase II 
(CaMKII) (Tansey et al., 1994, Miller et al., 1983). Higher levels of activated CaMKII 
in PA could thus result in MLCK inhibition and lowered sensitivity to Ca2+. Finally, it is 
thought that SMC contain two isoforms of MLCK, long and small. The long MLCK has 
a higher binding affinity for actin filaments compared to the short MLCK, stimulating 
greater actinomyosin filaments interaction (Blue EK et al., 2002, Smith et al., 2002). 
Therefore, MA may have a different ratio of long MLCK/short MLCK than PA, 
explaining the greater Ca2+-sensitivity in MA. Assessment of expression levels of short 
MLCK was carried out in MA and PA and no differences in expression were observed 
between the two artery types (see Chapter 4). Thus, further assessment of the long 
MLCK expression and post-translational modifications may be useful for future studies 
in order to elucidate if there was any role for MLCK in the difference of sensitisation to 
Ca2+ between the two artery types. 
 97 
Only a handful of studies have assessed agonist-induced Ca2+-sensitisation in human 
MA and PA and then at just one supra-basal [Ca2+]i level (Hemmings et al., 2006, 
Hemmings, 2006, Wareing et al., 2005b). In the present study, human MA and PA 
developed a sensitisation to Ca2+ in the presence of three G protein-coupled agonists, 
U46619, ET-1 and S1P. It is commonly accepted that Ca2+-sensitisation occurs via 
activation of heterotrimeric G proteins (G!q or/and G!12/13), stimulation of the small 
GTPase RhoA and subsequent activation of RhoA-associated kinase (ROK) (Gong et al., 
1996, Sward et al., 2000). This sequence of events is entirely dependent upon presence 
of GTP, as activation of RhoA occurs by catalysis of the GDP–RhoA complex to GTP–
RhoA and subsequent translocation of the complex to the G protein-coupled receptors 
on the plasma membrane (Fujihara et al., 1997, Gong et al., 1997). GTP was therefore 
added to each experiment with G protein-coupled agonists, as it is a small molecule, 
which may have escaped the cell during the permeabilisation procedure.  
 
As discussed in the Introduction (Chapter 1, Section 1.4.2.2), the involvement of the 
RhoA/ROK pathway in Ca2+-sensitisation has been reported previously. Wareing et al. 
(2005) have shown that inhibition of ROKI/II by Y27632 abolished Ca2+-sensitisation 
in both permeabilised MA and PA. Similarly, S1P-induced Ca2+-sensitisation in these 
two artery types was shown to be dependent upon activation of the RhoA/ROK pathway, 
as addition of Y27632 also inhibited the phenomenon (Hudson et al., 2007, Hemmings 
et al., 2006). This ROK-dependent mechanism was also reported in animal models 
showing that ROK stimulation, by RhoA, contributed to Ca2+-sensitisation (Somlyo and 
Somlyo, 2000, Sward et al., 2000). In this study, the sensitisation to Ca2+, observed in 
the presence of U46619 and S1P, was therefore likely mediated via stimulation of ROK 
following activation of RhoA. No prior studies have assessed the Ca2+-sensitising 
effects of ET-1 in human arteries, however it is known that ET-1 induces 
vasoconstriction via activation of the G protein-coupled ETA/B receptors (Kublickiene et 
al., 2000). This could have therefore subsequently activated the RhoA/ROK pathway 
via G!q and/or G!12/13 and induce Ca2+-sensitisation.  
 
Inhibition of MLCP by thiophosphorylation of the targeting subunit, MYPT1, at Thr-
696 by ROK has been shown in many SM preparations to induce sensitisation of the 
myofilaments to Ca2+ (Kitazawa et al., 1991a, Kitazawa et al., 1989, Sward et al., 2000, 
Ito et al., 2003, Kimura et al., 1996). Moreover, the small 17 kDa peptide, CPI-17, has 
also been shown to induce MLCP inhibition following its activation by phosphorylation 
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by both ROK and PKC (Koyama et al., 2000, Eto et al., 1995). Given the likely role of 
ROK in Ca2+-sensitisation in this study’s human arteries, this phenomenon may result at 
least in part from inhibition of MLCP.  
 
The difference in sensitivity observed in the presence of Ca2+ alone between the two 
artery types did not persist in the presence of the G protein-coupled agonists U46619. 
There are a number of possible explanations for these findings. The structure of a vessel 
wall is an important factor in determining its mechanical performance. Studies have 
shown that in contrast to human MA, PA lack a distinct IEL, the barrier separating the 
vascular EC and SMC layers (Sweeney et al., 2006b). The physiological significance of 
this is not known. One may speculate, however, that the absence of the IEL may 
facilitate permeation of blood-borne circulating factors, such as contractile agonists, 
reaching the SMC quicker and affecting contractility of these arteries. This may have 
increased the ability of PA to sensitise to Ca2+ in the presence of U46619, allowing PA 
to ‘catch up’ with the sensitising abilities of MA. In this case, therefore, the sensitisation 
to Ca2+ was greater in PA than MA. However, it is unclear why similar observations 
were not made in the presence of ET-1. Conversely, compared to MA, PA have been 
shown to have a thicker medial layer with the SMC separated by considerable amounts 
of ECM (Sweeney et al., 2006b). The force development may therefore be reduced in 
PA compared to MA in the presence of ET-1. Finally, there is good evidence to suggest 
that the umbilical and placental vessels are not innervated, as immunohistological and 
neurohistochemical studies have shown the absence of adrenergic and cholinergic 
nerves. Contraction of these vessels can therefore not be elicited via neurotransmitters, 
such as noradrenaline and norepinephrine (Reilly and Russell, 1977, Fox and Khong, 
1990). As a compensatory mechanism, PA may have evolved to give other circulating 
factors, such as U46619, and their signalling pathways a more prominent role. This may 
have explained the similar responses in MA and PA to U46619, but not the observed 
difference in contractile responses in the presence of ET-1.  
 
Another explanation for these observations may be that the expression levels of key 
contractile proteins involved in Ca2+-sensitisation, such as RhoA/ROK or CPI-17 differ 
between MA and PA. Upon addition of U46619, higher levels of (activated) 
RhoA/ROK may induce greater Ca2+-sensitisation in PA compared to MA via inhibition 
of MLCP. Similarly, increased CPI-17 expression and phosphorylation thereof may 
induce greater phosphatase inhibition in PA compared to MA, thus allowing greater 
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sensitivity to Ca2+ in the former artery type. However, as will be described in the 
following chapter (Chapter 4), levels of CPI-17 did not differ between MA and PA. The 
differences in sensitisation capacity with U46619 may more likely be due to differences 
in activity of the signalling proteins involved. It is yet unclear, why ET-1 did not induce 
similar responses between MA and PA. This discrepancy in constriction and 
sensitisation to thromboxane A2 and ET-1 illustrates a paucity in our knowledge of the 
pathways activated by these contractile factors in human arteries, highlighting a need 
for further investigation of the specific signalling mechanisms activated by these 
agonists. 
 
This study has highlighted several novel findings in human myometrial and placental 
arteries. First, the pattern of Ca2+-sensitivity of the myofilaments and agonist-dependent 
modulation of Ca2+-sensitisation in both artery types.  Second, that placental arteries 
display a lower sensitivity to Ca2+ alone as compared to myometrial arteries. Third, that 
this difference in Ca2+-sensitivity does not persist in the presence of the thromboxane A2 
agonist. It was important to establish these phenomena as a prelude to subsequently 
investigating the actions of vasorelaxants on myofilament activation in each artery type. 
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4. Chapter 4 
Ca2+-desensitisation in human myometrial and placental arteries 
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4.1. Introduction 
 
Vascular smooth muscle (VSM) tone is primarily controlled by a balance between the 
levels of myosin light chain kinase (MLCK) and myosin light chain phosphatase 
(MLCP) activity and the ensuing phosphorylation state of the myosin light chains 
(MLC20) (Somlyo and Somlyo, 1994). There are several signalling mechanisms 
modulating Ca2+ availability and Ca2+ sensitivity of the contractile apparatus, which also 
regulate the contractile and relaxatory responses of VSM to receptor agonists.  
 
Studies in human placental and uterine vessels have shown that U46619-, ET-1- and 
S1P-induced contractile responses increased in the presence of nitric oxide synthase 
(NOS) inhibitors, such as L-NNA or L-NAME, highlighting these agonists’ role in 
regulating vascular tone (Myatt et al., 1992, Fried and Liu, 1994, Hemmings et al., 2006, 
Hudson et al., 2007, Kublickiene et al., 2000). The importance of these G protein-
coupled receptor proteins was further emphasised following reports of increased 
expression of these peptides in both placental and myometrial vasculatures in 
pathological pregnancies, which were characterised by raised vascular resistance 
(Wetzka et al., 1997, Faxen et al., 2000, Agapitov and Haynes, 2002, Hla, 2004, Wang 
et al., 2008, Dunlap et al., 2010). Concurrently, the development of endothelial 
dysfunction is thought to exacerbate the observed increase in resistance. Studies 
reported impaired endothelial-dependent relaxations in the vasculatures from women 
with pre-eclampsia, gestational diabetes, hypertension and fetal growth restriction, even 
though increased levels of the NO and/or aberrant (hyper-) activity of NOS were 
observed (McCarthy et al., 1993, Knock and Poston, 1996, Knock et al., 1997, VanWijk 
et al., 2000, Wareing et al., 2005a, Wareing et al., 2006d, Myers et al., 2006).  
 
The potent vasodilator action of the cGMP/PKG pathway has been ascribed to a 
decrease in [Ca2+]i through the activation of multiple Ca2+ lowering mechanisms 
(Lincoln and Cornwell, 1993) and/or to a decrease in Ca2+ sensitivity of myofilaments, 
referred to as Ca2+-desensitisation (Wu et al., 1996, Gong et al., 1996, Wooldridge et al., 
2004, Lee et al., 1997).  
 
This phenomenon has been fairly well established in animal tissues (vascular and non-
vascular) and reported in human bronchial tissues (Yoshii et al., 1999).  However, no 
studies have thus far presented this phenomenon in human arteries from the 
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myometrium and placenta. Nishimura and van Breemen (1989) first showed that 
desensitisation to Ca2+ could be mediated by cGMP. They studied rat mesenteric 
arteries, permeabilised with Staphylococcal !-toxin with [Ca2+]i held constant by Ca2+ 
EGTA buffer (Nishimura and van Breemen, 1989). A similar role for cGMP was also 
reported in Triton X-100 skinned smooth muscle (SM) fibres from guinea-pig taenia 
coli and rat mesenteric arteries (Pfitzer et al., 1984, Pfitzer et al., 1986). Relaxations of 
the !-toxin-permeabilised rabbit ileum SM, which occurred at constant [Ca2+]i, were 
shown to result from activation of PKG isoform I (PKGI) by 8-br-cGMP. This also 
correlated with an increase in MLCP activity inducing increased MLC20 
dephosphorylation (Wu et al., 1996). Further studies in intact swine carotid arteries and 
VSMC reported that stimulation of the cGMP/PKG axis induced an increase in MLCP 
activity, possibly via leucine-zipper interactions between PKGI and the targeting 
subunit of MLCP, MYPT1 (Surks et al., 1999, Etter et al., 2001, Bolz et al., 2003, 
Bonnevier et al., 2004, Khatri et al., 2001, Lu et al., 2008). These studies therefore 
inferred that Ca2+-desensitisation occurred via activation of PKG and subsequent 
increase in MLCP activity to induce SM relaxation at constant [Ca2+]i. It is noteworthy, 
however, that the NO-cGMP/PKG axis has been suggested to induce relaxation via 
interaction with other proteins including HSP20 (Rembold et al., 2000), telokin (Wu et 
al., 1998) or CPI-17 (Bonnevier and Arner, 2004). There are no studies identifying 
expression of these proteins in arteries from the human placenta and/or uterus. 
 
Thus far, assessment of the desensitisation mechanisms in permeabilised SM in the 
literature has been performed at individual concentrations of activating Ca2+ alone, such 
as pCa 6.0, 6.1, 6.2, 6.3, 6.5, 6.7 or pCa 4.5 in animal tissues (vascular and non-
vascular) (Lee et al., 1997, Bonnevier and Arner, 2004, Choudhury et al., 2004, Wu et 
al., 1996, Wu et al., 1998, Shcherbakova et al., 2010), but not in tissues that were pre-
sensitised to [Ca2+] using G protein-coupled receptor agonists.  
 
Thus this body of work sought to determine:  
(i) whether the phenomenon of Ca2+-desensitisation occurred in human 
myometrial and placental arteries constricted to [Ca2+] alone or to [Ca2+] in 
the presence of G-protein coupled receptor agonists U46619, ET-1 or S1P, 
(ii) if the extent of cGMP-induced relaxations differed between these two artery 
types, 
(iii) whether Ca2+-desensitisation was mediated via the cGMP/PKG/MLCP axis, 
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(iv) if PKGI!, HSP20, telokin, MYPT1 or CPI-17 are expressed in MA and PA 
and if expression levels of these proteins differed between the two artery 
types. 
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4.2. Materials and methods 
4.2.1. Experimental protocol 
4.2.1.1. Functional Experiments 
 
Protocol 1: !-toxin-permeabilised human MA and PA were constricted with pCa 4.5 
then exposed to pCa 9. Arteries were bathed in a sub-maximal Ca2+ solution (pCa 6.7 + 
2 µM GTP) followed by addition of 1 "M U46619 to each artery. Finally, 8-br-cGMP 
was added to three individual arteries (10 "M, 1 "M or 0.1 "M) and the fourth artery 
was used as a time-matched control. The effect of 8-br-cGMP was monitored for 30 - 
35 minutes until plateau. 
 
Protocol 2: !-toxin-permeabilised human MA and PA were exposed to pCa 4.5, then 
pCa 9. Arteries were then bathed in pCa 6.7 + 2 µM GTP with the addition of either of 
two G protein-coupled agonists, 10-8 M ET-1 or 10-5 M S1P in two individual arteries. 
S1P was added with 0.1 % BSA. 10 "M 8-br-cGMP was subsequently added to one 
artery from each condition and the second artery was used as a time-matched control. 
The time control for S1P also contained 0.1 % BSA. The effect of 8-br-cGMP was 
monitored for 30 - 35 minutes until plateau. 
 
Protocol 3: !-toxin-permeabilised MA and PA were exposed to the high-calcium 
solution (pCa 4.5) and left until plateau was reached at 15 minutes. 10 "M 8-bromo-
cGMP (8-br-cGMP) was subsequently added and its effect was monitored until plateau 
at 30 - 35 minutes. 
 
Protocol 4: !-toxin-permeabilised human MA and PA were incubated with a 30 "l 
droplet of either pCa 9 (lowest [Ca2+]) or 1 "M calyculin A, a protein phosphatase PP1 
and PP2A inhibitor. Incubations were carried out for 90 - 100 minutes (time to plateau). 
Next, arteries were exposed to pCa 4.5 until plateau. Finally, 10 "M 8-br-cGMP was 
added to the bath and the effect monitored for at 30 - 35 minutes. 
 
These functional experiments lasted 5 - 6 hours following normalisation of the vessels. 
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4.2.1.2. Immuno Blotting 
 
Expression levels of six proteins were assessed MA and PA: PKGI!, HSP20, telokin, 
MLCK, MYPT1, CPI-17. For detailed methodology, see Chapter 2, Section 2.6 and 
Table 2.5. 
 
4.2.2. Statistics 
 
The effect of 8-br-cGMP was compared between MA and PA for each separate 
experimental protocol using two-way ANOVA followed by Bonferroni post-hoc test. 
 
Constrictions induced by pCa 6.7 were compared to total constrictions (pCa 6.7 + 2 µM 
GTP + agonist) for each experimental condition (U46619, ET-1 and S1P), using paired 
Student t-test. 
 
Unpaired t-tests were used to compare:  
- Total constrictions between experimental conditions (U46619, ET-1 and S1P) 
for each artery type (MA and PA), 
- Constrictions induced by pCa 6.7 and total constrictions between MA and PA 
for each experimental condition (U46619, ET-1 and S1P), 
- T1/2 (time to half maximal relaxation) between MA and PA for each protocol. 
 
Protein expression levels of MA and PA were compared between the two artery types 
using unpaired t-test.  
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4.3. Ca2+-desensitisation in arteries pre-sensitised with G-protein-coupled agonists 
 
Initial assessment of Ca2+-desensitisation was carried out using the non-hydrolysable 
cGMP mimetic, 8-br-cGMP, in arteries pre-sensitised with G-protein-coupled receptor 
agonist U44619.  
 
4.3.1. Assessment of Ca2+-desensitisation in U46619-induced Ca2+-sensitised human 
myometrial and placental arteries 
 
Figure 4.1 shows the response to 10 µM 8-br-cGMP of an individual permeabilised MA 
pre-sensitised with U46619. Figure 4.1A illustrates a first MA exposed to pCa 6.7, 
which induced a sub-maximal contraction to 36 % of the previous pCa 4.5 constriction. 
Subsequent addition of 1 µM U46619 led to a further pronounced tonic contraction at 
the same [Ca2+] to 61 % of the pCa 4.5 constriction. This indicated Ca2+-sensitisation. 
Figure 4.1B illustrates a second MA constricted with pCa 6.7. The sub-maxmial 
constriction elicited reached 22 % of the previous pCa 4.5 constriction. Subsequent 
sensitisation to Ca2+ was induced by 1 µM U46619 and the constriction elicited was 
117 % of the pCa 4.5 constriction. Subsequent addition of 10 !M 8-br-cGMP induced a 
sustained relaxation of 69 % of total contraction. Figure 4.1A illustrates the time-
matched MA, which showed no decrease. 
 
Figure 4.2 shows the effect of 10 µM 8-br-cGMP on an individual permeabilised PA 
pre-sensitised with the thromboxane mimetic, U46619. Figure 4.2A illustrates a PA 
exposed to pCa 6.7, which induced a sub-maximal contraction to 31 % of the previous 
pCa 4.5 contraction. Subsequent addition of 1 µM U46619 led to further development 
of force at the same [Ca2+] to 55 % of the pCa 4.5 constriction. This indicated Ca2+-
sensitisation of force. Figure 4.2B illustrates a second PA constricted with pCa 6.7, 
which induced 23 % of the pCa 4.5 constriction. 1 µM U46619 sensitised the artery to 
Ca2+, which reached 69 % of pCa 4.5. Subsequent addition of 10 !M 8-br-cGMP 
induced a relaxation of 37 % from total contraction. The time-matched PA, on the other 
hand, maintained the constriction throughout (Figure 4.2A).  
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Figure 4.1: Effect of 10 µM 8-bromo-cGMP in two individual permeabilised myometrial arteries pre-sensitised with U46619. A: First artery exposed to 
pCa4.5, pCa 9, sub-maximal Ca2+ solution pCa 6.7 + 1 !M U46619. B: Second artery exposed to pCa 4.5, pCa 9, sub-maximal Ca2+ solution pCa 6.7 + 1 !M 
U46619 and 10 !M 8-bromo-cGMP. 
 
    
Figure 4.2: Effect of 10 µM 8-bromo-cGMP in two individual permeabilised placental arteries pre-sensitised with U46619. A: First artery exposed to pCa4.5, 
pCa 9, sub-maximal Ca2+ solution pCa 6.7 + 1 !M U46619. B: Second artery exposed to pCa 4.5, pCa 9, sub-maximal Ca2+ solution pCa 6.7 + 1 !M U46619 and 10 
!M 8-bromo-cGMP. 
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Figure 4.3 shows the group mean ± SEM relaxation responses over 30 minutes to 10 
!M 8-br-cGMP in MA and PA. Total constrictions to pCa6.7/U46619 did not differ 
between the two artery types (MA: 7.52 ± 0.81 kPa, n = 8 versus PA: 7.45 ± 1.05 kPa, n 
= 6). Both artery types relaxed in the presence of the cGMP mimetic compared to their 
respective time controls (TC) (MAcGMP:  69.5 ± 5.12 % versus MATC: 6.65 ± 1.71 %, n 
= 8 and PAcGMP: 49.3 ± 6.04 % versus PATC: 8.95 ± 2.79 %, n = 6). The mean maximal 
relaxation to 10 !M 8-br-cGMP in MA was greater than that in PA. Additionally, the 
rate of relaxation in MA was greater than that in PA, as highlighted by the time at which 
half the maximal relaxation (t1/2) was reached. MA reached its t1/2 at 4.67 ± 0.43 minutes, 
whilst PA reached it at 10.2 ± 1.02 minutes.  
 
Thus, Ca2+-desensitisation occurred in human MA and PA, which were constricted and 
sensitised to Ca2+ via activation of the G protein-coupled pathway by the thromboxane 
mimetic, U46619. In addition, MA displayed a greater relaxatory capacity in the 
presence of the cGMP mimetic compared to PA. The difference in their time(s) to 
maximal relaxation may highlight a difference in sensitivity to cGMP between these 
two artery types. 
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Figure 4.3: Summary data of responses induced by 10 µM 8-bromo-cGMP in human 
myometrial and placental arteries pre-sensitised to the thromboxane mimetic, U46619. 
Responses to 10 µM 8-br-cGMP are expressed as percentages of the total constriction obtained 
with pCa 6.7 + 1 µM U46619 over a 30 minute time period. MA: Myometrial Arteries, PA: 
Placental Arteries, TC: Time Control. * Statistical difference relative to TC. ! Statistical 
difference relative to PA. 
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Next, it was of interest to assess whether there was a concentration-dependency of this 
possible difference between MA and PA. Therefore, given the prominent action already 
witnessed at 10 µM, the influence of 8-br-cGMP at lower concentrations (1 µM and 0.1 
µM) in arteries pre-sensitised to Ca2+ with U46619 was determined. 
 
Figures 4.4A and 4.4B illustrate the mean ± SEM responses to 1 µM and 0.1 µM 8-br-
cGMP, respectively, in human permeabilised MA and PA pre-sensitised to Ca2+ with 1 
µM U46619. Total constrictions (pCa 6.7 + 1 µM U46619) were similar in MA and PA 
(PA: 7.49 ± 1.55 kPa, n = 6 versus MA: 8.02 ± 1.01 kPa, n = 7). As illustrated in Figure 
4.4A, both artery types relaxed to 1 µM 8-br-cGMP relative to their time controls (TC) 
(MAcGMP: 62.6 ± 5.38 % versus MATC: 8.51 ± 2.25 %, n = 7 and PAcGMP: 48.9 ± 3.63 % 
versus PATC: 6.58 ± 2.03 %, n = 6). Moreover, the mean maximal relaxation was greater 
in MA compared to PA, as was the rate of relaxation. T1/2 in MA was 6.28 ± 0.95 
minutes compared to 11.2 ± 0.55 minutes in PA. 
 
Similarly, as illustrated in Figure 4.4B, 0.1 µM 8-br-cGMP relaxed both human MA and 
PA (MAcGMP: 48.3 ± 6.02 %, n = 7 versus MATC: 8.51 ± 2.25 % and PAcGMP: 33.1 ± 
4.82 %, n = 6 versus PATC: 6.58 ± 2.03 %) and the mean maximal relaxation was 
greater in MA compared to PA. In addition, the rate of relaxation was also greater as 
MA reached its t1/2 at 10.0 ± 1.21 minutes compared to 15.7 ± 0.44 minutes for PA. 
 
Table 4.1 summarises the relaxatory responses induced by 8-br-cGMP in the human 
MA and PA. The differences in mean maximal relaxations and t1/2 observed between 
MA and PA were consistent throughout the range of concentrations of 8-br-cGMP used. 
These results highlight that myofilament sensitivities to cGMP may be greater in human 
MA compared to PA. 
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Figure 4.4: Summary data of responses induced by 1 µM and 0.1 µM 8-bromo-cGMP 
responses in human myometrial and placental arteries pre-sensitised to the thromboxane 
mimetic, U46619. Responses to 1 µM 8-br-cGMP (A) and 0.1 µM 8-br-cGMP (B) are 
expressed as percentages of the total constriction obtained with pCa 6.7 + 1 µM U46619 over a 
30 minute time period. MA: Myometrial Arteries, PA: Placental Arteries, TC: Time Control. * 
Statistical difference relative to TC. ! Statistical difference relative to PA. 
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Table 4.1: Summary of maximal relaxations induced by 8-bromo-cGMP and time to reach 
half maximal relaxation in human permeabilised myometrial and placental arteries. 
                                      Myometrial Arteries                        Placental Arteries 
Concentration 
of 8-br-cGMP 
(µM) 
Maximal 
relaxation 
from 
constriction 
(%) 
T1/2 (minutes) 
Maximal 
relaxation 
from 
constriction 
(%) 
T1/2 (minutes) 
10 69.5 ± 5.12* 4.67 ± 0.43! 49.3 ± 6.04 10.2 ± 1.02 
1 62.6 ± 4.58* 6.28 ± 0.95!" 48.9 ± 3.63 11.2 ± 0.55 
0.1 48.3 ± 6.02*# 10.0 ± 1.21!# 33.1 ± 4.82# 15.7 ± 0.44# 
* Statistical difference relative to the maximal relaxation in human placental arteries.  
! Statistical difference relative to the t1/2 in human placental arteries. # Statistical difference 
relative to 10 µM and 1 µM 8-br-cGMP. " Statistical difference relative to 10 µM. 
 
 113 
4.3.2. Ca2+-desensitisation in human permeabilised myometrial and placental 
arteries pre-sensitised to Ca2+ with the G protein-coupled agonists, endothelin-1 
or sphingosine-1-phosphate 
 
Similarly to the assessment of Ca2+-sensitisation using a variety of G protein-coupled 
agonists as described in Chapter 3, it was important to rigorously establish whether the 
phenomenon of Ca2+-desensitisation in human permeabilised MA and PA also occurred 
when arteries were pre-sensitised with agonists other than U46619. To this effect, this 
set of experiments examined cGMP-induced Ca2+-desensitisation in human arteries 
sensitised to Ca2+ by the G protein-coupled agonists, ET-1 or S1P.  
 
Similarly to the previous experimental design using U46619 as the Ca2+-sensitising 
agent, permeabilised MA and PA were constricted with submaximal [Ca2+] (pCa 6.7), 
after which addition of 10-8 M ET-1 or 10-5 M S1P induced further development of force, 
thus illustrating a sensitisation to the activating Ca2+. Finally, addition of 10 µM 8-br-
cGMP induced relaxations in both ET-1-induced- and S1P-induced pre-sensitised PA 
and MA. A time-matched artery for each condition was used as a control.  
 
Figures 4.5 and 4.6 illustrate the mean ± SEM responses to 10 µM 8-br-cGMP in human 
permeabilised MA and PA following pre-sensitisation to Ca2+ by 10-8 M ET-1 or 10-5 M 
S1P, respectively. The time controls (TC) used in experiments with S1P contained 
0.1 % BSA (as described in Chapter 3). These were not different from the TC for ET-1-
sensitised MA and PA.  
 
As illustrated in Figure 4.5, MA and PA pre-sensitised with ET-1 relaxed to 8-br-cGMP 
compared to their TC (MAcGMP: 84.5 ± 5.60 % versus MATC: 14.6 ± 3.59 %, n = 7 and 
PAcGMP: 63.5 ± 6.89 % versus PATC: 7.19 ± 3.93 %, n = 6). Similarly, as demonstrated 
in Figure 4.6, the cGMP mimetic induced a relaxation in S1P-induced-sensitised MA 
and PA compared to their TC (MAcGMP: 108.1 ± 7.18 %, versus MATC: 10.2 ± 9.23 %, n 
= 4 and PAcGMP: 82.0 ± 1.70 % versus PATC: 9.69 ± 7.44 %, n = 4).  
 
The mean maximal relaxations to 8-br-cGMP were greater in MA compared to PA 
following ET-1-induced Ca2+-sensitisation. Importantly, the rate of relaxation was also 
greater in MA compared to PA. Indeed, t1/2 in MA was reached at 6.04 ± 0.77 minutes 
compared to 11.8 ± 1.73 minutes in PA. In S1P-sensitised arteries, 8-br-cGMP induced 
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a greater relaxation in MA compared to PA and their respective rates of relaxation also 
differed. The t1/2 in MA was reached at 3.57 ± 0.16 minutes, whilst that in PA was 
reached at 7.28 ± 0.87 minutes. 
 
These results indicated therefore, that PKG-mediated Ca2+-desensitisation occurs in 
human arteries when pre-sensitised to Ca2+ with a variety of agonists and that the 
desensitisation responses are greater in MA than PA.  
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Figure 4.5: Summary data of 8-bromo-cGMP-induced responses in human myometrial 
and placental arteries pre-sensitised to the G protein-coupled agonist endothelin-1. 
Responses to 10 µM 8-br-cGMP are expressed as percentages of the total constriction obtained 
with pCa 6.7 + 10-8M ET-1 over a 30 minute time period. MA: Myometrial Arteries, PA: 
Placental Arteries, TC: Time Control. * Statistical difference relative to TC. ! Statistical 
difference relative to PA. 
 
 
 
 
Figure 4.6: Summary data of 8-bromo-cGMP-induced responses in human myometrial 
and placental arteries pre-sensitised to the G protein-coupled agonist sphingosine-1-
phosphate. Responses to 10 µM 8-br-cGMP are expressed as percentages of the total 
constriction obtained with pCa 6.7 + 10-5M S1P over a 30 minute time period. MA: Myometrial 
Arteries, PA: Placental Arteries, TC: Time Control. * Statistical difference relative to TC. ! 
Statistical difference relative to PA. 
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Table 4.2 compares the constrictions induced by pCa 6.7 and the three G protein-
coupled agonists, U46619, ET-1 and S1P in human permeabilised MA and PA. All 
three agonists induced sensitisation to Ca2+, as evidenced by the increase in force 
production by U46619, ET-1 and S1P in both MA and PA.  
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Table 4.2: Constrictions induced by submaximal [Ca2+] and the G protein-coupled agonists, U46619, endothelin-1 and sphingosine-1-phosphate in human 
placental and myometrial arteries.  
Myometrial Arteries       Placental Arteries 
Agonist 
pCa 6.7-
induced 
constriction 
(kPa) 
Total 
Constriction 
(pCa 6.7 + 
agonist) 
pCa 6.7-
induced 
constriction 
relative to 
pCa 4.5 
constriction 
(%) 
Agonist-
sensitised 
constriction 
relative to 
pCa 4.5 
constriction 
(%) 
 
pCa 6.7-
induced 
constriction 
(kPa) 
 
Total 
Constriction 
(kPa) 
 
 
pCa 6.7-
induced 
constriction 
relative to 
pCa 4.5 
constriction 
(%) 
Agonist-
sensitised 
constriction 
relative to 
pCa 4.5 
constriction 
(%) 
 
U46619 
 
1.81 ± 0.78 
 
7.44 ± 1.05!  
 
35.3 ± 3.12 
 
73.8 ± 1.12 ! 
 
2.51 ± 0.33 
 
7.52 ± 0.81! 
 
32.3 ± 1.62 
 
57.8 ± 2.42 
 
ET-1 
 
1.75 ± 0.49 
 
5.06 ± 1.64!  
 
21.2 ± 3.67 
 
53.3 ± 8.37 
 
2.31 ± 0.43 
 
6.08 ± 0.61! 
 
24.1 ± 2.96 
 
56.4 ± 8.28 
 
S1P 
 
1.18 ± 0.22 
 
2.31 ± 0.34! *" 
 
21.7 ± 2.51 
 
24.1 ± 6.50*" 
 
1.65 ± 0.33 
 
3.11 ± 0.58! *" 
 
24.3 ± 3.63 
 
15.8 ± 4.73*" 
! Significant difference relative to the constriction induced by pCa 6.7 for each respective agonist and artery type. * Significant difference relative to U46619. " 
Significant difference relative to ET-1. ! Significant difference relative to placental arteries. 
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4.4. Assessment of protein kinase G-mediated Ca2+-desensitisation in human 
arteries pre-constricted with pCa 4.5 
 
It was of interest to establish whether the phenomenon of cGMP-induced Ca2+-
desensitisation also occurred in human arteries constricted with activating Ca2+ in the 
absence of agonist stimulation. Ca2+ alone, or Ca2+ in the presence of constrictor 
agonists, activate, in part, alternative intracellular pathways acting on the myofilaments. 
This, in turn, may influence the ability of PKG to counteract the constrictions. 
 
Figure 4.7 shows original tracings of two individual permeabilised human MA exposed 
to maximal [Ca2+] (pCa 4.5) alone (A) or to pCa 4.5 followed by 10 !M 8-br-cGMP (B). 
Figure 4.7A demonstrates that pCa 4.5 induced a sustained constriction over time. 
Figure 4.7B illustrates that 10 !M 8-br-cGMP induced a relaxatory response in the pre-
constricted MA. The relaxation reached plateau after 20 minutes and represented, in this 
artery, 69 % of the previously induced constriction. 
 
Figure 4.8 shows original raw tracings of two individual permeabilised human PA 
exposed to similar conditions. Figure 4.8A demonstrates that pCa 4.5 alone induced a 
sustained constriction over time. Figure 4.8B illustrates that addition of 8-br-cGMP 
induced a relaxation in the pCa 4.5 pre-constricted artery, which reached a plateau at 30 
minutes. In this artery, the relaxation was 20 % of the pCa 4.5-induced constriction.  
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Figure 4.7: Original raw tracings of the relaxatory effects of 10 µM 8-bromo-cGMP in two individual human myometrial arteries. A: Time-matched control 
exposed to pCa 4.5 shows a persistent contraction with only a slight drift downwards over time. B: A second artery, exposed to pCa 4.5, then to 10 !M 8-bromo-
cGMP, caused a large relaxation. 
 
         
Figure 4.8: Original raw tracings of the relaxatory effect of 10 µM 8-bromo-cGMP in two individual human placental arteries. A: Time-matched control 
exposed to pCa 4.5 shows a persistent contraction with only a slight drift downwards over time. B: Second artery, exposed to pCa 4.5, then to 10 !M 8-bromo-
cGMP, caused a small relaxation.  
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Figure 4.9 shows the group mean ± SEM relaxation responses over 30 minutes to 10 
!M 8-br-cGMP in MA and PA, expressed as a percentage of their previous pCa 4.5 
constrictions. Both MA and PA relaxed in the presence of the vasodilator compared to 
their respective time controls (TC) (MAcGMP: 49.2 ± 9.71 % versus MATC: 7.42 ± 
2.71 %, n = 7 and PAcGMP: 22.8 ± 6.6 % versus PATC: 4.81 ± 2.11 %, n = 6). Time-
matched responses in MA and PA were similar; therefore in the presented graph the 
data were pulled together in one time control data set. The mean maximal relaxation to 
8-br-cGMP in MA was greater than that in PA. Additionally, the rate of relaxation was 
faster in MA compared to PA, which was highlighted by a shorter t1/2 in MA compared 
to PA (MAt(1/2): 3.66 ± 0.19 minutes, n = 7 versus PAt(1/2): 8.75 ± 0.33 minutes, n = 6).  
 
As reported earlier, cGMP-induced mean maximal relaxations were greater in MA 
compared to PA, when arteries were pre-sensitised with the G protein-coupled agonists 
and when arteries were constricted to maximal [Ca2+]. Additionally, cGMP induced 
greater relaxations in MA sensitised with U46619 compared to arteries pre-constricted 
with pCa 4.5 (MApCa 4.5: 49.2 ± 9.71 %, n = 7 versus MAU46619: 67.5 ± 5.12 %, n = 8), 
ET-1 (MAET-1: 84.5 ± 5.60 %, n = 6) and with S1P (MAS1P: 108.1 ± 9.69 %, n = 4). 
Similarly, PA pre-constricted with pCa 4.5 relaxed less to 8-br-cGMP than arteries 
sensitised with U46619 (PApCa 4.5: 22.8 ± 6.68 %, n = 6 versus PA U46619: 49.3 ± 6.04 %, 
n = 6), ET-1 (PA ET-1: 63.5 ± 6.89 %, n = 7) or with S1P (PA S1P: 82.0 ± 1.70 %, n = 4).  
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Figure 4.9: Summary data of 10 µM 8-bromo-cGMP-induced responses in human 
myometrial and placental arteries. Responses to 8-br-cGMP are expressed as percentages of 
constrictions obtained with pCa 4.5 over 30 minutes. MA: Myometrial Arteries, PA: Placental 
Arteries, TC: Time Control. * Statistical difference relative to the time control (TC). ! 
Statistical difference relative to PA. 
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4.5. Potential role of myosin light chain phosphatase (MLCP) in PKG-mediated 
relaxation of Ca2+-constricted permeabilised arteries 
 
Having observed cGMP-activated-PKG-mediated Ca2+-desensitisation in human 
arteries from the myometrium and placenta, it was next of interest to establish whether 
this phenomenon was dependent upon an active MLCP by directly inhibiting the 
phosphatase using calyculin A (Suzuki and Itoh, 1993, Wareing et al., 2005b).  
 
Figure 4.10 illustrates the effect of 1 µM calyculin A on a permeabilised human MA 
(A) and PA (B). Exposure to pCa 4.5 preceding addition of the MLCP inhibitor induced 
similar constrictions in both artery types. Following relaxation back to baseline, at 
resting [Ca2+] (pCa 9), calyculin A induced an increase in force production in MA and 
PA. Subsequent exposure to pCa 4.5 did not further constrict either artery. Finally, 10 
!M 8-br-cGMP did not induce a relaxation in either artery type over 30 - 40 minutes. 
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Figure 4.10: Effect of the phosphatase inhibitor, calyculin A (1 µM), on PKG-mediated relaxation of two human arteries at resting [Ca2+]. Permeabilised 
MA (A) and PA (B) exposed to pCa 4.5, then pCa 9, followed by incubation with calyculin A (1 µM), a second exposure to pCa 4.5, and, finally, addition of 8-br-
cGMP (10 µM).  
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Constrictions induced by pCa 4.5 were similar in MA and PA (MA: 7.83 ± 1.98 kPa, n 
= 7 versus PA: 8.78 ± 2.31 kPa, n = 6) as were those induced by calyculin A (MA: 8.63 
± 0.68 kPa, n = 7 versus PA: 10.6 ± 2.31 kPa, n = 6). Calyculin A-induced constrictions 
were also similar to previous pCa 4.5 constrictions in both MA and PA. Figure 4.11 
shows the group mean ± SEM relaxation responses to 10 µM 8-br-cGMP in the 
presence of calyculin A in both MA and PA.  
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Figure 4.11: Summary data of 8-bromo-cGMP-induced responses in human myometrial 
and placental arteries in the presence of the phosphatase inhibitor, calyculin A. Responses 
to 8-br-cGMP are expressed as percentages of constrictions obtained with pCa 4.5 over a 30 
minute time period. MA: Myometrial Arteries, PA: Placental Arteries, Caly A: calyculin A. The 
data displayed in grey in this figure was that illustrated previously in Figure 4.9. 
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4.6. Expression of PKG and putative PKG-interacting myofilament-associated 
proteins of human myometrial and placental arteries 
 
PKG has been proposed to alter Ca2+-sensitivity of contraction by interacting with one, 
or more, of a variety of myofilament-associated proteins. The differences in 
responsiveness to 8-br-cGMP reported herein between MA and PA may reflect tissue-
specific expression profiles of such PKG effector proteins. Thus, it was of interest to 
explore this possibility by studying the expression of putative PKG-interacting proteins 
HSP20, telokin, MYPT1 and CPI-17, as well as PKGI!, the most abundant PKG 
isoform in SM (Francis et al., 2010).  
 
4.6.1. PKGI! protein levels in myometrial and placental arteries 
 
Figure 4.12 illustrates the expression patterns of PKGI! in six human MA and PA 
samples. Figure 4.12A shows that the expression of PKGI! was detected in human MA 
and PA and rat aorta (positive control, PC) at the expected molecular mass of around 75 
kDa. There are higher levels of PKGI! in the rat aorta compared to the MA and PA 
samples. Figure 4.12B shows equal loading throughout the membrane from patient to 
patient samples as assessed by actin staining.  There was no difference in the expression 
of PKGI! between MA and PA (MA: n = 11, PA: n = 12, Figure 4.13). 
 
 127 
 
 
 
 
 
 
Figure 4.12: PKGI! protein expression in human myometrial and placental arteries. A: 
Representative immunoblot of total PKGI! abundance in human myometrial arteries (MA, 20 
"g, n = 6) and placental arteries (PA, 20 "g, n = 6). PC: positive control, rat aorta, 20 "g. B: 
actin as a loading control. 
 
 
 
Figure 4.13: Quantified expression levels of PKGI! protein in human myometrial and 
placental arteries. Optical density of bands representing PKGI! in MA and PA was normalised 
to the optical density of PC. Relative O.D.: Relative Optical Density, MA: Myometrial Arteries, 
PA: Placental Arteries. 
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4.6.2. HSP20 protein levels in human myometrial and placental arteries 
 
Figure 4.14 illustrates the expression patterns of HSP20 in six human MA and PA 
samples. Figure 4.14A shows that expression of HSP20 was detected in both artery 
types and in the myometrium from a pregnant woman (PC), at the expected molecular 
mass of 20 kDa. A second band was also observed around 17 kDa. Higher protein levels 
were detected in the myometrial tissue sample compared to the arteries. A degree of 
inter-patient variability can also be observed in both MA and PA. There was no 
difference in the expression of HSP20 between the two artery types (n = 12, Figure 
4.15). 
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Figure 4.14: HSP20 protein expression in human myometrial and placental arteries. A: 
Representative immunoblot of total HSP20 abundance in human myometrial arteries (MA, 5 !g, 
n = 6) and placental arteries (PA, 5 !g, n = 6). PC: positive control, human myometrium 
(pregnant patient), 5 !g. B: actin as a loading control. 
 
 
 
Figure 4.15: Quantified expression levels of HSP20 protein in human myometrial and 
placental arteries. Optical density of bands representing HSP20 in MA and PA was normalised 
to the optical density of PC. Relative O.D.: Relative Optical Density, MA: Myometrial Arteries, 
PA: Placental Arteries. 
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4.6.3. Telokin protein levels in human myometrial and placental arteries 
 
Figure 4.16 illustrates the expression patterns of telokin in 4 - 6 human MA and PA 
samples. Figure 4.16A shows that expression of telokin was detected in both artery 
types and in rat brain (PC) at the expected molecular mass of around 17 kDa. A second 
band of lower intensity was also observed around 16 kDa. Considerable inter-patient 
variability in the expression of telokin was observed for both MA and PA. There was no 
difference in the expression of telokin between ten samples of MA and PA (Figure 4.17). 
 
Telokin expression is under the control of an intronic promoter of the MLCK gene such 
that the amino acid composition of telokin is identical to a C-terminal portion of MLCK 
(Gallagher et al., 1991, Herring and Smith, 1996). Indeed, telokin expression was 
probed in these experiments by use of an anti-MLCK antibody whose epitope was 
shared with telokin.  Thus, it was of curiosity to ascertain if MLCK expression probed 
by the same antibody displayed a similar patient-to-patient variability as telokin. Figure 
4.18A shows the results of MLCK expression of six human MA and PA samples with a 
band at the anticipated molecular mass of approximately 130 kDa. There was less 
patient-to-patient variation in MLCK expression than telokin. No difference was 
observed for MLCK expression between twelve human MA and PA samples (Figure 
4.19). 
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Figure 4.16: Telokin protein expression in human myometrial and placental arteries. A: 
Representative immunoblot of total telokin abundance in human myometrial arteries (MA, 10 
!g, n = 6) and placental arteries (PA, 10 !g, n = 4). PC: positive control, rat brain, 10 !g. B: 
actin as a loading control. 
 
 
 
Figure 4.17: Quantified expression levels of telokin protein in human myometrial and 
placental arteries. Optical density of bands representing telokin in MA and PA was normalised 
to the optical density of PC. Relative O.D.: Relative Optical Density, MA: Myometrial Arteries, 
PA: Placental Arteries. 
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Figure 4.18: MLCK protein expression in human myometrial and placental arteries. A: 
Representative immunoblot of total MLCK abundance in human myometrial arteries (MA, 7.5 
!g, n = 6) and placental arteries (PA, 7.5 !g, n = 6). PC: positive control, human myometrium 
(pregnant patient), 7.5 !g. B: actin as a loading control. 
 
 
 
Figure 4.19: Quantified expression levels of MLCK protein human myometrial and 
placental arteries. Optical density of bands representing MLCK in MA and PA was normalised 
to the optical density of PC. Relative O.D.: Relative Optical Density, MA: Myometrial Arteries, 
PA: Placental Arteries. 
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4.6.4. MYPT1 protein levels in human myometrial and placental arteries 
 
Figure 4.20 illustrates the expression patterns of the MLCP targeting subunit, MYPT1, 
in six human MA and PA samples. Figure 4.20A shows that expression of MYPT1 was 
detected in both artery types and in human myometrium (pregnant patient serving as the 
PC) at the expected molecular mass of around 115 kDa. There was no difference in the 
expression of this protein between MA and PA samples (n = 12, Figure 4.21). 
 
 
 
 
Figure 4.20: MYPT1 protein expression in human myometrial and placental arteries. A: 
Representative immunoblot of total MYPT1 abundance in human myometrial arteries (MA, 20 
!g, n = 6) and placental arteries (PA, 20 !g, n = 6). PC: positive control, human myometrium 
(pregnant patient), 20 !g. B: actin as a loading control. 
 
 
 
Figure 4.21: Quantified levels of MYPT1 protein in human myometrial and placental 
arteries. Optical density of bands representing MYPT1 in MA and PA was normalised to the 
optical density of PC. Relative O.D.: Relative Optical Density, MA: Myometrial Arteries, PA: 
Placental Arteries. 
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4.6.5. CPI-17 protein levels in human myometrial and placental arteries 
 
Figure 4.22 illustrates the expression patterns of CPI-17 in six human MA and PA 
samples. Expression of CPI-17 was detected in both artery types and in rat brain (PC) 
was observed at the expected molecular mass of around 17 kDa. A second band of 
lower intensity was also observed around 16 kDa. Like for telokin, there is considerable 
patient-to-patient variation but, overall, there is no difference in the expression of this 
protein between MA and PA samples (n = 12, Figure 4.23). 
 
 
 
 
Figure 4.22: CPI-17 protein expression in human myometrial and placental arteries. A: 
Representative immunoblot of CPI-17 abundance in human myometrial arteries (MA, 10 !g, n 
= 6) and placental arteries (PA, 10 !g, n = 6). PC: positive control, rat brain, 20 !g. B: actin as a 
loading control. 
 
 
 
Figure 4.23: Quantified levels of CPI-17 protein in human myometrial and placental 
arteries. Optical density of bands representing CPI-17 in MA and PA was normalised to the 
optical density of PC. Relative O.D.: Relative Optical Density, MA: Myometrial Arteries, PA: 
Placental Arteries. 
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4.7. Discussion 
 
This work sought to establish whether the phenomenon of cGMP-dependent Ca2+-
desensitisation occurred in human MA and PA. The main findings were: first, that both 
artery types exhibited decreases in Ca2+-sensitivity in the presence of 8-br-cGMP in 
arteries constricted to either Ca2+ alone or sensitised to Ca2+ with a G protein-coupled 
receptor agonist. Second, that permeabilised MA displayed a greater relaxatory capacity 
to cGMP/PKG compared to PA. Third, that the mechanism of Ca2+-desensitisation may 
be dependent upon an active MLCP. Fourth, that both MA and PA express 
myofilament-associated proteins thought to be involved in the cGMP/PKG relaxatory 
pathway and regulation of vascular tone but that no differences in expression levels for 
any of the proteins were demonstrated between the two artery types. 
 
Both MA and PA sensitised to sub-maximal activating Ca2+ in the presence of the G 
protein-coupled agonists U46619, ET-1 and S1P. Constrictions induced by U46619 and 
ET-1 at pCa 6.7 in this set of experiments were similar to those observed at pCa 6.7 in 
arteries exposed to incremental [Ca2+] (Chapter 3) in both MA and PA. Both U46619 
and ET-1 induced greater sensitisations than S1P in the two artery types. Additionally, 
the sensitisations induced by S1P were lower than those in arteries exposed to 
incremental [Ca2+]. The sensitisation capacity of S1P has been documented in MA and 
PA and was reported as being rather variable, in that it did not occur to the same degree 
or in each experiment (Hemmings et al., 2006, Hudson et al., 2007). This may illustrate 
a degree of variability in vessel responses to this agonist. In addition, although the 
present study found a consistent U46619-induced Ca2+-sensitisation in MA and PA, 
previous reports have shown greater sensitisations induced by this agonist in the two 
artery types. Wareing et al. (2005b) reports sensitisations of 131 ± 19 % and 54 ± 15 % 
of contraction to pCa 4.5 solution in !-toxin permeabilised from MA and PA from 
pregnant women, respectively (Wareing et al., 2005b). The present results were 
consistent with respect to PA (57.8 ± 2.42 % from pCa 4.5 constriction). However, MA 
responded to a lesser extent compared to these reports (73.8 ± 1.12 % from pCa 4.5 
constriction), which may indicate a degree of variability in MA to U46619 also.  
 
Agonist-mediated Ca2+-sensitisation likely occurred, at least in part, from inhibition of 
MLCP. Several studies point to agonist-mediated Ca2+-sensitisation involving ROK-
induced phosphorylation of the MLCP targeting subunit MYPT1 at Thr-696 (Kitazawa 
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et al., 1991, Kitazawa et al., 1989, Sward et al., 2000, Ito et al., 2003, Kimura et al., 
1996, Somlyo and Somlyo, 2000, Hudson et al., 2007, Hemmings et al., 2006, Wareing 
et al., 2005b). The likely involvement of this pathway in Ca2+-sensitisation of MA or 
PA is supported by previous data showing that U46619- or S1P-induced Ca2+-
sensitisations were reduced upon addition of the ROK inhibitor, Y27632 (Hemmings et 
al., 2006, Hudson et al., 2007, Wareing et al., 2005b).  
 
The present study is the first report of Ca2+-desensitisation occurring in human arteries 
from the myometrium and placenta. Assessment of this phenomenon was carried out 
using the same permeabilisation technique as described and discussed in Chapter 3. 
Ca2+-desensitisation occurred in a dose-responsive manner across a concentration range 
(0.1 - 10!M) spanning estimates of physiological concentrations of cGMP (Francis et 
al., 2010). Basal concentrations of cGMP in VSMC are reported to be around 0.1 µM, 
with a 3 - 6 fold increase during active SM relaxation (Francis et al., 2010). The range 
of 8-br-cGMP concentrations used in this study were close to physiological and supra-
physiological concentrations, assuming that all 8-br-GMP used was active and bearing 
in mind that the activity of 8-br-GMP may be slightly lower than native cGMP. The 10 
µM used is actually one of the lower concentrations reported in the literature, where the 
range of concentrations more frequently used was 50 – 300 µM (Bonnevier and Arner, 
2004, Khromov et al., 2006, Nakamura et al., 2007, Wu et al., 1996, Wu et al., 1998, 
Russo et al., 2008). A few animal studies have used lower concentrations between 0.5 – 
10 µM 8-br-cGMP (Choudhury et al., 2004, Lee et al., 1997, Khatri et al., 2001, Pfitzer 
et al., 1986). In these studies, tissue-specific responses to 8-br-cGMP were also 
compared to assess possible differences in sensitivities between tissue types; Khatri et 
al. (2001) showed that 0.1 – 100 µM 8-br-GMP induced maximal (100 %) relaxation in 
permeabilised chicken aortic SM strips, but did not induce any responses in chicken 
gizzard SM. Choudhury et al. (2004) reported greater relaxations to 5 µM 8-br-cGMP in 
permeabilised rabbit tonic femoral arteries (30 %) compared to permeabilised phasic 
ileum SM (60 %) at pCa 6.3, highlighting a difference in sensitivities to the same 
concentrations of 8-br-cGMP between phasic and tonic SM. Differing levels of tonic 
versus phasic SM in MA and PA may also have influenced in the relaxatory capacities 
in the two artery types. In this study, MA and PA did not relax substantially more to 10 
µM, compared to 1 µM 8-br-cGMP, but did relax faster. This may indicate a relaxatory 
threshold in these arteries, which might have developed to protect against acute changes 
within the fetal environment. In addition, this study found differences in mean maximal 
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relaxation to cGMP and in the times to half maximal relaxations over the three 
concentrations of 8-br-cGMP between the two artery types, suggesting different 
sensitivities to cGMP in MA compared to PA.  
 
The decrease in Ca2+ sensitivity induced by 8-br-cGMP in both Ca2+-constricted and 
Ca2+-sensitised MA and PA likely occurred via activation of PKG. It is thought that 
relaxation in SMC may be induced via the NO-activated cGMP/PKG pathway 
(Waldman and Murad, 1987, Nishimura and van Breemen, 1989, Nakamura et al., 2007, 
Murad, 1994). Pfeifer et al. (1998) carried out an elegant study, which showed that 
intact aortic rings isolated from the PKGI-null mice had ablated 8-br-cGMP-induced 
relaxation compared to the PKGI control mice. Similarly, intact ileum strips from 
PKGI-deficient mice did not relax to 100 µM 8-br-cGMP, whilst those from WT mice 
did (Bonnevier et al., 2004).  
 
PKGI has been proposed to potentially affect a variety of intracellular signalling 
proteins. Indeed, variations in the expression of several PKG-interacting proteins have 
been proposed to underlie SM tissue-specific sensitivities to NO/cGMP/PKG. These 
proteins include: (i) HSP20, whose phosphorylation state induced by both PKA and 
PKG on Ser-16 has been associated with active relaxation of permeabilised bovine 
carotid SM (Beall et al., 1997, Beall et al., 1999, Rembold et al., 2000); (ii) telokin, 
whose phosphorylation by PKG at Ser-13 has been shown to be increased by 8-br-
cGMP and induce Ca2+-desensitisation (Wu et al., 1998); (iii) MYPT1 LZ positive 
isoform of MLCP, which has been found to interact with the LZ domain of PKGI! 
(Surks et al., 1999, Khatri et al., 2001); (iv) CPI-17, whose increased dephosphorylation 
at residue Thr-38 following addition of 8-br-cGMP induced relaxation of mice femoral 
arteries and ileal SM (Bonnevier and Arner, 2004). Given the reported differences in 
response to 8-br-cGMP in permeabilised MA and PA it was possible that alterations in 
the expression of one or more of these proteins may be a contributory factor.  However, 
levels of PKGI!, HSP20, telokin or CPI-17 protein were similar between MA and PA. 
There was considerable patient-to-patient variation between samples, particularly for 
telokin and CPI-17 expression. Levels of total MYPT1 protein were also similar for MA 
and PA.  However, the antibody used to probe MYPT1 would not distinguish between 
LZ -positive and -negative isovariants of MYPT1.  Thus, future experiments studying 
mRNA encoding each isovariant could be performed to ascertain if there is a variation 
in MYPT1 isoform ratio, rather than MYPT1 total protein, between MA and PA.  It is 
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also possible that the activities of these proteins differ between the two artery types, 
rather than their expression levels, and future studies may assess this. Of note is the fact 
that protein expressions were assessed in full arterial samples, which included EC, IEL, 
SMC, ECM, rather than isolated SMC. Accurate quantification of the expression of 
PKGI and its putative interacting proteins was limited. Further studies may therefore 
use isolated SMC from fresh arterial samples for assessment of the aforementioned 
proteins.  
 
MLCP is a known key regulator of vascular tone. The potential role of MLCP in Ca2+-
desensitisation was illustrated in this study with the broad class phosphatase inhibitor 
calyculin A, which prevented relaxant actions of 8-br-cGMP in both artery types. 
Calyculin A was first identified as a PP1 and PP2A inhibitor in SM fibers in 1989 
(Ishihara et al., 1989) and shortly after was also found to induce contraction under Ca2+-
free conditions (Hartshorne et al., 1989). It exhibits a greater affinity for PP2A 
compared to PP1 similarly to the phosphatase inhibitor, MCLR (Takai et al., 1995). 
MCLR was reported to possess a higher affinity for PP2A and PP1 compared to 
calyculin A (Takai et al., 1995). Nonetheless, the efficiency of calyculin A in inhibiting 
MLCP has been shown in several studies, making it suitable for the present study. !-
escin- and ionomycin-treated skinned SM strips of the rabbit mesenteric artery 
constricted with maximal amplitudes, similar to those evoked by 10 µM [Ca2+], in Ca2+-
free solutions (containing either 20 mM EGTA or 4 mM EGTA) and the threshold 
concentration of calyculin A required for the increase in tension or MLC-
phosphorylation was 0.03 µM, with maximum effects obtained at 3 µM (Suzuki and 
Itoh, 1993). In addition, 1 µM calyculin A was shown to inhibit MLCP in "-toxin-
permeabilised rabbit trachea (Iizuka et al., 1999). Further, NO-induced Ca2+-
desensitisation was ablated in the presence of 0.12 µM calyculin A in rat aorta (Bolz et 
al., 2003) and in "-toxin-permeabilised human omental arteries from term pregnant 
women, 1 µM calyculin A induced substantial Ca2+-sensitisations at sub-maximal [Ca2+] 
(pCa 6.7), which were of similar magnitude to those induced by the thromboxane 
mimetic U46619 (Wareing et al., 2005b). These studies, therefore, demonstrated that 
even at sub-maximal activating Ca2+, calyculin A abolished MLCP activity. 
 
Accordingly, the 8-br-cGMP-induced relaxations were inhibited following pre-
incubation of MA and PA with calyculin A, inferring that MLCP was successfully 
inhibited. Measurements of MLC20 dephosphorylation would be valuable to support this 
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statement. Nevertheless, the present study indicated that Ca2+-desensitisation was, at 
least in part, dependent upon an active MLCP. Lee et al. also showed that 10 µM 8-br-
cGMP induced relaxations in sub-maximal activating Ca2+ solutions (pCa 6.7 or pCa 7), 
which were ablated following pre-incubations with either 10 µM MCLR or 1 µM 
calyculin A in both !-escin and "-toxin permeabilised rabbit femoral artery strips (Lee 
et al., 1997). Additional studies in "-toxin permeabilised rabbit ileum SM constricted 
with pCa 6.2 showed that 100 µM 8-br-cGMP induced relaxation and also increased the 
rate of MLC20 dephosphorylation, whilst MLCK activity was blocked with ML-9 (50 
µM) (Wu et al., 1996). Following stimulation of PKG by 8-br-cGMP, the observed 
increase in MLC20 dephosphorylation likely occurred after the increase in MLCP 
activity and binding of the phosphatase to myosin filaments (Somlyo and Somlyo, 
2003). Thus, Ca2+-desensitisation was induced by activation of PKG and subsequent 
increase of MCLP activity.  
 
Interestingly, this study showed that both MA and PA, which were pre-sensitised with 
U46619, ET-1 or S1P, relaxed to a greater extent than arteries pre-constricted with pCa 
4.5. This suggests that arteries sensitised in sub-maximal [Ca2+] can evoke greater 
desensitisation compared to arteries constricted with Ca2+ alone. MLCP, and 
particularly MYPT1, may be a key checkpoint in the two processes. In this study, 
agonist-induced pre-sensitisation in MA and PA likely occurred via activation of the 
RhoA/ROK pathway and ROK-induced phosphorylation at Thr-853 of MYPT1 and 
subsequent inhibition of MLCP (Kitazawa et al., 2009). Ca2+-desensitisation may then 
have occurred partly via inhibition of the RhoA/ROK pathway and partly via increase of 
MLCP activity by PKGI activation. In vitro studies in rabbit femoral SM strips have 
shown that PKGI phosphorylated RhoA at Ser-188 (Sauzeau et al., 2000a). This lifted 
phosphorylations at Thr-853 and at the predominantly endogenous Thr-696 of MYPT1, 
both of which are sites known to inhibit MLCP activity (Kitazawa et al., 2009, Sauzeau 
et al., 2000a, Gudi et al., 2002). Studies in permeabilised ileum SM also showed that 
PKGI could directly phosphorylate MYPT1 at Ser-695 and that this phosphorylation 
blocked the adjacent endogenous Thr-696 inhibitory phosphorylation, which then 
increased MLCP activity (Kitazawa et al., 2009, Wooldridge et al., 2004). In MA and 
PA constricted with Ca2+ alone, Ca2+-desensitisation likely occurred via PKGI-induced 
increase in MLCP activity. However, it is unlikely that inhibition of the RhoA/ROK 
pathway also played a role. RhoA is only active as a GTP/RhoA complex (Somlyo and 
Somlyo, 2003, Wang et al., 2002) and it is likely that endogenous GTP escaped the cell 
 140 
following permeabilisation. Therefore, in Ca2+-constricted arteries, PKGI probably 
phosphorylated Ser-695, increasing MLCP activity and inducing Ca2+-desensitisation. 
The reason for the difference in relaxations observed between pre-sensitised and pre-
constricted arteries is still unclear; however, MYPT1 seems to place a key role in the 
regulation of PKGI-mediated Ca2+-desensitisation.  
This study also showed that constrictions were induced by calyculin A in human 
permeabilised MA and PA at sub-basal [Ca2+] (pCa 9), which were of similar 
magnitude to those induced by maximal activating Ca2+ (pCa 4.5, 31.6 µM). The pCa 
4.5-induced constriction was likely elicited via the Ca2+/calmodulin (CaM)-activated 
MLCK, which is known to phosphorylate MLC20 at Ser-19 and Thr-18 (Somlyo and 
Somlyo, 1994). It is unlikely that the subsequent constriction following addition of 
calyculin A was induced by MLCK, rather it may have been induced by a kinase with 
lower Ca2+-sensitivity. Indeed, studies in rat caudal artery and chicken gizzard SM 
strips have shown that the activity of MLCK was dependent upon activating Ca2+ levels 
allowing formation of Ca2+-CaM complex (Weber et al., 1999). Addition of the protein 
phosphatase 1 (PP1) inhibitor (predominantly), microcystin-LR (MCLR), to Triton X-
100-skinned rat caudal arterial SM was found to elicit contractions at pCa 9 which 
correlated with the phosphorylation of MLC20 at Ser-19 and Thr-18 (Weber et al., 1999). 
This suggested that relatively Ca2+-insensitive kinase(s) induced development of these 
constrictions. Using chicken gizzard SM, such a MLC20 kinase was isolated and 
identified as the integrin-linked kinase (IKL) (Deng et al., 2001). A second kinase, 
zipper-interacting protein kinase (ZIPK), was also found to induce SM constriction in a 
Ca2+/CaM-independent manner. Both kinases were thought to induce constriction 
directly via both MCL20 and MYPT1 phosphorylations at Ser-19/Thr-18 and Thr-696, 
respectively (Murata-Hori et al., 1999, Niiro and Ikebe, 2001, Muranyi et al., 2002). In 
contrast, recent reports did not find a role for ZIPK in direct phosphorylation of MLC20 
(Wilson et al., 2005b). No studies have yet determined if these relatively Ca2+-
insensitive kinases, ILK and ZIPK, are present human PA and MA, nor their functional 
significance.  
 
In conclusion, the present report has shown for the first time that Ca2+-desensitisation 
occurs in human MA and PA constricted to maximal [Ca2+] and is likely mediated via 
cGMP-activated PKG and active MLCP. MA displayed greater sensitivities to cGMP 
compared to PA; such differences were not obviously explicable by alterations in the 
expression levels of a number of myofilament-associated, and putatively PKG-
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interacting, proteins. Differences in endothelial-dependent bradykinin-induced 
relaxations have also been shown in the two artery types (Sweeney et al., 2008). Thus, 
MA may possess a greater relaxatory capacity at both endothelial-dependent and –
independent levels of the NO/cGMP/PKG pathway compared to PA. The next chapter 
set out to determine whether intact MA displayed greater relaxations than PA when 
exposed to agents that directly elevate NO, or activate sGC, independent of endothelial 
agonists. 
 
 
 142 
5. Chapter 5 
Effect of endothelium-dependent and -independent vasodilators on 
intact human myometrial and placental arteries
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5.1. Introduction 
 
There is strong evidence that, generally speaking, the NO/cGMP/PKG axis plays an 
important role in the relaxation of the vasculature (Francis et al., 2010).  
Notwithstanding this generalisation, there is also an appreciation that the influence of 
this signalling axis may vary across the vascular tree.  Of particular interest to the 
studies highlighted in the previous chapter is the extent, and possible mechanisms 
therein, of such variations between the vasculatures of the human uterus and placenta. 
 
The pO2 in the myometrial vasculature is assumed to be close to that in the systemic 
circulation, namely around 100 mmHg, whilst that in the placental vasculature has been 
reported to range from 28 - 40 mmHg; these latter figures were determined by 
aspiration of intervillous blood through the chorionic plate at the time of cordocentesis 
(fetal blood sampling) (Soothill et al., 1986, Rodesch et al., 1992). A few studies have 
assessed the impact of O2 concentrations on the dilation of human placental chorionic 
plate arteries when exposed to various relaxatory agonists. However, consensus has not 
been reached as to whether endothelium-dependent and/or –independent relaxations are 
impaired when placental arteries are exposed to superfusates of O2 concentration 
assumed to be similar to that in the myometrial circulation in vivo (McCarthy et al., 
1994, Poston, 1996, Poston et al., 1995, Mills et al., 2009, Wareing et al., 2006a).  The 
most compelling work in this area has assessed in vitro placental artery function using 
superfusates bubbled with oxygen concentrations approaching those anticipated for pO2 
in vivo (Wareing et al., 2006a).  However, in order to adequately assess any variations 
in endothelium-dependent and –independent responses between myometrial and 
placental arteries, it seemed necessary to determine whether varied oxygen levels would 
impact on the relaxation capacities of chorionic plate placental arteries.  
 
Studies assessing the role of endothelial-dependent and –independent relaxation 
mechanisms in the human placental vasculature, as indicated in Chapter 1, Table 1.2, 
are conflicting.  In some, the addition of the endothelium-independent nitrovasodilator 
sodium nitroprusside (SNP, 10-5 M) induced relaxation and the eNOS inhibitor L-NNA 
led to an increase in basal tone (Poston et al., 1995, McCarthy et al., 1994, Learmont 
and Poston, 1996). With these studies, an important role for NO in the regulation of 
vascular tone of the placenta was indicated. Further studies on small chorionic plate 
placental arteries (~ 300 µm diameter) also showed substantial vasodilation to 
 144 
incremental concentrations of SNP (10-9 – 10-4 M), where relaxations reached 70 % of 
pre-constrictions to U46619 (Mills et al., 2007a). SNP, along with other endothelium-
independent vasodilators, such as SNAP or GTN, also induced relaxation in chorionic 
plate arterial segments of 1.5 – 2 mm diameter in a dose-dependent manner (1.3 ! 10-8 
M – 5.7 ! 10-2 M) (Zhang et al., 2001). Yet, a variety of endothelial-dependent agents 
usually elicited only modest relaxatory responses from placental arteries (McCarthy et 
al., 1994, Sweeney et al., 2008). 
 
The importance of NO in the human uterine vasculature has been shown in a variety of 
studies assessing vascular function in myometrial arteries from both healthy and/or pre-
eclamptic pregnant women. Reductions in relaxations to bradykinin were reported 
following incubation with L-NAME (and a prostaglandin inhibitor, indomethacin) in 
myometrial arteries from healthy pregnant women mounted on a small-vessel wire 
myograph (Luksha et al., 2010). Endothelium-dependent relaxations, assessed by 
addition of acetylcholine or bradykinin, were impaired in myometrial arteries from 
preeclamptic women compared to those from healthy pregnancies (Kenny et al., 2002).  
 
While the role of the NO-induced pathway has been assessed in both uterine and 
placental circulations, there are no studies comparing responses to a nitrovasodilator 
between myometrial and placental arteries under identical experimental conditions. In 
addition, studies in placental arteries which assessed responses induced by endothelium-
independent vasodilators did so with pre-constrictions to G protein-coupled receptor 
agonists, such as the thromboxane A2 mimetic (U46619) (McCarthy et al., 1994, Zhang 
et al., 2001, Mills et al., 2007a, Mills et al., 2007b, Mills et al., 2009), ET-1 (McCarthy 
et al., 1994), prostaglandins E2 and F2 (PGE2 and PGF2) (McCarthy et al., 1994), 
norepinephrine (NE) (McCarthy et al., 1993) or phenylephrine (PE) (Lu et al., 2008). 
Similarly, the effects of SNP concentrations were assessed in myometrial arteries pre-
constricted to U46619 (McCarthy et al., 1993). None of these studies reported the 
effects of nitrovasodilators in arteries pre-constricted via an alternative pathway, such as 
via opening of Ca2+-channels by high K+ depolarisation.  
 
There are currently no studies assessing the effects of a sGC activator in either human 
myometrial or placental arteries, although one study did report an increase in placental 
perfusion pressure, following carbon-monoxide exposure, by the sGC activator YC-1 
(Bainbridge et al., 2002).  
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I, therefore, wished to  
(i) first, determine whether oxygen concentrations similar to those assumed in 
the uterine circulation affect endothelial-dependent and -independent 
responses in pre-constricted placental arteries, 
(ii) second, assess responses to endothelial-dependent and -independent 
vasodilators in both pre-constricted myometrial and placental arteries, 
(iii) and compare these responses between the two artery types. 
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5.2. Materials and Methods 
5.2.1. Experimental Protocols 
5.2.1.1. Experimental design 1: assessing the effects of oxygen on the relaxation 
capacities on human placental arteries 
 
For each experiment, one set of four placental arteries (PA) was exposed to PSS 
bubbled with an [O2] similar to that assumed to be present in the myometrial circulation, 
ie. 100 mmHg. This was achieved by using a gas mixture with 20 % oxygen (5 % CO2 
in air - oxygen content of 18 - 21 % - BOC Special Gases, British Oxygen Company, 
UK). A second set of four PA from the same patient was exposed to PSS bubbled with 
an [O2] of ~38 mmHg, close to that assumed in vivo for the placental circulation, which 
was achieved using a gas mixture containing 7 % oxygen (5 % CO2/5 % O2 in nitrogen 
(N2) - oxygen content 6 - 8 % - BOC Special Gases, British Oxygen Company, UK). 
 
Following normalisation, both sets of PA were exposed to 60 mM KPSS and left to 
plateau 10 – 15 minutes. They were then exposed to the endothelium-dependent 
vasodilator, bradykinin (BK, 10-6 M) for 15 minutes until plateau. After washout with 
PSS and a second KPSS exposure (left to plateau 10 – 15 minutes), the endothelium-
dependent vasodilator histamine (His, 10-5 M) was added for 15 minutes until plateau 
and returned to PSS.  
Arteries were then again constricted with KPSS and left to plateau 10 – 15 minutes. For 
each set of four arteries, two PA were exposed to one of two endothelium-independent 
vasodilators, the nitric oxide donor sodium nitroprusside (SNP, 10-5 µM) or the soluble 
guanylate cylase activator YC-1 (3 ! 10-5 M) for 20 minutes or until plateau. YC-1 was 
used as it is a known potent sGC activator (Evgenov et al., 2006) and, as mentioned 
above, has been observed to exert vasoactive actions in perfused placental segments 
(Bainbridge et al., 2002). Therefore, it was the agent of choice in these studies.  The 
other two PA were used as paired vehicle controls for each vasodilator (ddH2O and 
DMSO, respectively).  
 
Following normalisation, these functional experiments lasted 3 hours. 
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5.2.1.2. Experimental design 2: assessing endothelium-dependent and –
independent responses in human myometrial and placental arteries 
 
MA and PA were exposed to a first 60 mM KPSS addition, followed by 10-6 M BK and, 
following wash-out with PSS, they were exposed to a second 60 mM KPSS, followed 
by 10-5 M His. Subsequently, the following protocols were carried out:  
 
Protocol 1: For both MA and PA, four arteries were constricted with 60 mM KPSS and 
left to plateau 10 – 15 minutes. Three arteries were exposed to one of nine 
concentrations of SNP (10-10 M, 10-9 M, 10-8 M, 3 ! 10-8 M, 10-7 M, 10-6 M or 10-5 M), 
whilst the fourth was used as vehicle control (ddH2O). Arteries exposed to SNP were 
left to plateau 15 – 20 minutes. This step was repeated three times, until all 
concentrations were assessed. Addition of a concentration of SNP was picked at random 
to add to each of three arteries and order of concentrations used was alternated for each 
experiment.  
 
Protocol 2: For both MA and PA, four arteries were constricted to 60 mM KPSS and 
left to plateau 10 - 15 minutes. Three arteries were exposed to one of six concentrations 
of YC-1 (10-7 M, 3 ! 10-7 M, 10-6 M, 3 ! 10-6 M, 10-5 M or 3 ! 10-5 M), whilst the 
fourth was used as vehicle control (DMSO). Arteries exposed to YC-1 were left to 
plateau 20 minutes. This was repeated twice, until all concentrations were assessed. 
Addition of a concentration of YC-1 was picked at random to add to one of three 
arteries and order of concentrations used was alternated for each experiment.  
 
Following normalisation, these functional experiments lasted 5 hours. 
 
5.2.2. Statistics 
5.2.2.1. Experimental design 1 
 
Responses to BK and His were expressed as percentages of the maximal constrictions to 
60 mM KPSS. Comparisons between maximal responses to BK or His at 20 % versus 
7 % O2 were carried out using Kruskal-Wallis one-way ANOVA test.  
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The change in tension with the addition of SNP or YC-1 was calculated as a percentage 
of the change in tension to KPSS. Changes in tension were calculated at 5 minutes 
intervals. The responses to SNP or YC-1 were compared at 20 % versus 7 % O2 using 
two-way ANOVA followed by Bonferroni post-hoc test.  
 
5.2.2.2. Experimental design 2 
 
Changes in tension to 60 mM KPSS were compared between MA and PA using 
unpaired t-test. Responses to BK and His were expressed as percentages of the maximal 
constrictions to 60 mM KPSS. The maximal effects of BK and His were compared 
between MA and PA using unpaired t-test.  
 
Responses to SNP and YC-1 were expressed as percentages of the maximal 
constrictions to 60 mM KPSS. The effect of 3 ! 10-8 M SNP was compared between 
MA and PA over 20 minutes using two-way ANOVA followed by Bonferroni post-hoc 
test. The effect of SNP was then compared between MA and PA over the range of 
concentrations used with two-way ANOVA followed by Bonferroni post-hoc test.  
 
The effect of 3 ! 10-6 M YC-1 was compared between MA and PA over 20 minutes 
using two-way ANOVA followed by Bonferroni post-hoc test.  
 
Half times to maximal relaxations were compared between MA and PA using unpaired 
t-test. 
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5.3. Assessing the effects of percentage oxygen saturation on endothelium-
dependent and –independent relaxations of placental arteries 
5.3.1. Endothelium-dependent relaxation in placental arteries exposed to 20 % and 
7 % oxygen 
 
Maximal relaxations induced by the endothelium-dependent vasodilator, BK (10-6 M), 
were not significantly different at 20 % O2 compared to 7 % (7.4 ± 1.8 % versus 8.3 ± 
2.4 %, respectively, n = 20). Similarly, there was no significant difference in the His-
induced maximal relaxations between 20 % and 7 % O2 levels (6.2 ± 2.9 % versus 7.7 ± 
1.4 %, respectively, n = 20).  
 
5.3.2. Endothelium-independent relaxations in placental arteries exposed to 20 % 
and 7 % oxygen 
 
Figure 5.1 illustrates the responses over time to 3 ! 10-5 M YC-1 (A) and 10-5 M SNP 
(B) as percentages of constriction to KPSS in PA exposed to 20 % and 7 % O2. Figure 
5.1A shows YC-1 induced relaxations in KPSS pre-constricted PA at either 20 % and 
7 % O2 relative to their respective vehicle controls (VC) (YC-120%: 91 ± 3.3 % 
relaxation versus VC20%: 2.7 ± 1.7 %, n = 5 and YC-17%: 86 ± 10 % relaxation versus 
VC7%: 3.1 ± 1.3 %, n = 5). The relaxations induced by YC-1 were greater at 20 % 
oxygen than at 7 % O2. Figure 5.1B shows that SNP-induced relaxations were invariant 
between 20 % and 7 % O2 (SNP20%: 65 ± 5.9 % versus VC20%: 3.5 ± 1.3 %, n = 5 and 
SNP7%: 65 ± 14 % versus VC7%: 3.4 ± 1.7 %, n = 5).  
 
 150 
 
 
 
 
Figure 5.1: Responses to 3 ! 10-5 M YC-1 (A) and 10-5 M SNP (B) in intact human 
placental arteries at 20 % and 7 % oxygen. A: Response to 3 ! 10-5 M YC-1 in PA expressed 
as a percentage of 60 mM KPSS-induced constriction. B: Response to 10-5 M SNP in PA 
expressed as a percentage of 60 mM KPSS-induced constriction. VC: Vehicle Control, SNP: 
Sodium Nitroprusside. * Statistical difference relative to VC, ° Statistical difference relative to 
7 % O2.  
 
 
Thus, these data indicate that oxygen levels similar to those present in the myometrial 
vasculature (around 20 %) do not impair the magnitude of endothelium-dependent or -
independent relaxations in human PA. Therefore, in the subsequent experiments on 
intact arteries carried out throughout this study, the oxygen levels of PSS were kept at 
20 % O2 for both artery types. 
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5.4. Effects of endothelial-dependent agonists on pre-constricted human 
myometrial and placental arteries 
 
Figure 5.2 shows original tracings of an intact human MA (A) and an intact human PA 
(B) exposed to 60mM KPSS followed by 10-6 M BK. Figure 5.2A demonstrates that 60 
mM KPSS induced a sustained constriction and that 10-6 M BK induced a relaxatory 
response in the pre-constricted MA. The relaxation reached plateau after 5 minutes and, 
in this experiment, reflected a 34 % reduction of the KPSS pre-constriction. Figure 5.2B 
shows that 60 mM KPSS induced a sustained constriction and that 10-6 M BK induced a 
minimal response in the pre-constricted PA, which represented a 6 % reduction of the 
KPSS pre-constriction. 
 
Figure 5.3 shows original tracings of an intact human MA (A) and an intact human PA 
(B) exposed to 60mM KPSS followed 10-5 M His. Figure 5.3A demonstrates that 60 
mM KPSS induced a sustained constriction and that 10-5 M His induced a relaxatory 
response in the pre-constricted MA, which reached a plateau after 5 minutes. In this 
experiment, His induced a relaxation of 76 % of the KPSS pre-constriction. Figure 5.3B 
shows that 60 mM KPSS induced a sustained constriction and that 10-5 M His induced a 
small response in the pre-constricted PA, which represented a 7 % reduction of the 
KPSS constriction. 
 
Overall constrictions induced by 60 mM KPSS were greater in MA compared to PA 
(MA: 12.7 ± 0.56 kPa, n = 12 versus PA: 6.15 ± 0.26 kPa, n = 12). Figure 5.4 illustrates 
the mean ± SEM responses to BK (A) and His (B) in human MA and PA. Figure 5.4A 
shows that maximal relaxations induced by 10-6 M BK in 60 mM KPSS-constricted 
arteries were greater in MA compared to PA (MA: relaxation of 33.9 ± 1.91 %, n = 12 
versus PA: relaxation of 6.91 ± 1.09 %, n = 12). Similarly, Figure 5.4B demonstrates 
that MA relaxed more to 10-5 M His compared to PA (MA: relaxation of 78.3 ± 1.90 %, 
n = 12 versus PA: relaxation of 8.30 ± 0.97 %, n = 12). His-induced relaxations were 
greater than those induced by BK. 
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Figure 5.2: Effect of 10-6 M bradykinin in an intact myometrial artery (A) and an intact placental artery (B) pre-constricted with 60 mM KPSS. MA (A) 
and PA (B) exposed to 60 mM KPSS, followed 10-6 M bradykinin. 
 
   
Figure 5.3: Effect of 10-5 M histamine in an intact myometrial artery (A) and an intact placental artery (B) pre-constricted with 60 mM KPSS. MA (A) and 
PA (B) exposed to 60 mM KPSS, followed 10-5 M histamine. 
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Figure 5.4: Summary data of maximal responses induced by bradykinin and histamine in human myometrial and placental arteries pre-constricted with 60 
mM KPSS. Maximal responses to 10-6 M bradykinin (A) and to 10-5 M histamine (B) are expressed as percentages of the constriction obtained with 60 mM KPSS. 
MA: Myometrial Arteries, PA: Placental Arteries. ! Statistical difference relative to MA. 
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5.5. Effects of YC-1 and SNP on pre-constricted human myometrial and placental 
arteries 
5.5.1. Assessment of YC-1 induced responses in KPSS-constricted myometrial and 
placental arteries 
 
Figure 5.5 shows original tracings of three individual intact human MA exposed to 60 
mM KPSS followed by DMSO (A), 60 mM KPSS followed by 10-6 M YC-1 (B) or 60 
mM KPSS followed by 3 ! 10-5 M YC-1 (C). Figure 5.5A demonstrates that KPSS 
induced a sustained constriction. Figures 5.5B and 5.5C illustrate that 10-6 M and 3 ! 
10-5 M YC-1, respectively, induced relaxatory responses in the pre-constricted MA, 
which, in these experiments, reached 32 % and 99 % of the KPSS pre-constrictions, 
respectively. The relaxations reached plateau at 16 minutes and 7 minutes, respectively.  
 
Figure 5.6 shows original tracings of three individual intact human PA exposed to 
similar conditions. Figure 5.6A demonstrates that 60 mM KPSS induced a constriction. 
Figures 5.6B and 5.6C illustrate that addition of both concentrations of YC-1 induced 
relaxations in the KPSS pre-constricted arteries. In this instance, 10-6 M YC-1 induced a 
relaxation of 9.5 % relative to the KPSS constriction, which reached plateau at 15 
minutes, whilst 3 ! 10-5 M YC-1 induced a relaxation of 97 %, which reached plateau at 
12 minutes. 
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Figure 5.5: Effect of YC-1 in three individual intact myometrial arteries constricted with 60 mM KPSS. A: First artery exposed to 60 mM KPSS. B: Second 
artery exposed to 60 mM KPSS, followed by 10-6 M YC-1. C: Third artery exposed to 60mM KPSS, followed by 3 ! 10-5 M YC-1. 
 
 
     
Figure 5.6: Effect of YC-1 in three individual intact placental arteries constricted with 60 mM KPSS. A: First artery exposed to 60 mM KPSS. B: Second 
artery exposed to 60 mM KPSS, followed by 10-6 M YC-1. C: Third artery exposed to 60mM KPSS, followed by 3 ! 10-5 M YC-1. 
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Figure 5.7 shows the group mean ± SEM responses to incrementing concentrations of 
YC-1 (10-7 M, 3 ! 10-7 M, 10-6 M, 3 ! 10-6 M, 10-5 M and 3 ! 10-5 M) in MA and PA. 
YC-1 induced greater relaxations in MA compared to PA, particularly at the sub-
maximal concentration 10-6 M (MA: relaxation of 32.7 ± 6.87 %, n = 5 versus PA: 6.41 
± 3.70 %, n = 6). Mean relaxations at maximal concentration of YC-1 (3 ! 10-5 M) were 
not different between MA and PA (MA: relaxation of 94.6 ± 5.35 %, n = 5 versus 93.6 
± 2.72 %, n = 6), however the rate of relaxation in MA was greater than that in PA, as 
highlighted by the time at which half the maximal relaxation (t1/2) was reached. MA 
reached its t1/2 at 3.77 ± 1.35 minutes, whilst PA reached it at 6.36 ± 0.21 minutes.  
 
Figure 5.8 shows the group mean ± SEM responses over 20 minutes to 10-6 M YC-1 in 
MA and PA. The respective vehicle controls (VC) were different between MA and PA 
(MAVC: increase of 1.71 ± 1.22 %, n = 5 versus PAVC: increase of 10.3 ± 1.67 %, n = 6). 
Both artery types relaxed in the presence of the sGC activator compared to their 
respective vehicle controls (VC) (MAYC-1: relaxation of 32.7 ± 6.87 %, n = 5 and PAYC-
1: relaxation of 6.41 ± 3.70 %, n = 6). Additionally, MA relaxed more to 10-6 M YC-1 
than PA. 
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Figure 5.7: Summary data of maximal responses induced by YC-1 in human myometrial 
and placental arteries pre-constricted with 60 mM KPSS. Maximal responses to 
incrementing concentrations of YC-1 (10-7 M, 3 ! 10-7 M, 10-6 M, 3 ! 10-6 M, 10-5 M and 3 ! 
10-5 M) are expressed as percentages of the constriction obtained with 60 mM KPSS. MA: 
Myometrial Arteries, PA: Placental Arteries. * Statistical difference between MA and PA 
responses to YC-1. " Statistical difference relative to MA at the specified concentration. 
 
 
 
 
Figure 5.8: Summary data of responses induced by 10-6 M YC-1 in human myometrial and 
placental arteries pre-constricted with 60 mM KPSS. Responses to 10-6 M YC-1 are 
expressed as percentages of the constriction obtained with 60 mM KPSS over a 20-minute time 
period. MA: Myometrial Arteries, PA: Placental Arteries, VC-MA: Vehicle Control for MA, 
VC-PA: Vehicle Control for PA. * Statistical difference relative to the respective VC. " 
Statistical difference relative to MA. 
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5.5.2. Assessment of SNP-induced responses in KPSS-constricted myometrial and 
placental arteries 
 
Figure 5.9 shows original tracings of three individual intact human MA exposed to 60 
mM KPSS followed by ddH2O (A), 60 mM KPSS followed by 3 ! 10-8 M SNP (B) or 
60 mM KPSS followed by 10-5 M SNP (C). Figure 5.9A demonstrates that KPSS 
induced a sustained constriction over time. Figures 5.9B and 5.9C illustrate that 3 ! 10-8 
M and 10-5 M SNP, respectively, induced relaxatory responses in the pre-constricted 
MA. In this experiment, the SNP-induced relaxations reached 14 % and 66 % of the 
KPSS constriction, which reached plateau at 9 minutes and 6 minutes, respectively. 
 
Figure 5.10 shows original tracings of three individual intact human PA exposed to 
similar conditions. Figure 5.10A shows that 60 mM KPSS induced a constriction. 
Figures 5.10B and 5.10C demonstrate that both concentrations of SNP induced 
relaxations in the KPSS pre-constricted arteries. In this instance, 3 ! 10-8 M SNP 
induced a relaxation of 52 % relative to the KPSS constriction, which reached plateau at 
18 minutes and 10-5 M SNP induced a relaxation of 72 %, which reached plateau at 7 
minutes.  
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Figure 5.9: Effect of sodium nitroprusside in three individual intact myometrial arteries constricted with 60 mM KPSS. A: First artery exposed to 60 mM 
KPSS. B: Second artery exposed to 60 mM KPSS, followed by 3 ! 10-8 M sodium nitroprusside (SNP). C: Third artery exposed to 60mM KPSS, followed by 10-5 M 
SNP. 
 
 
             
Figure 5.10: Effect of sodium nitroprusside in three individual intact placental arteries constricted with 60 mM KPSS. A: First artery exposed to 60 mM 
KPSS. B: Second artery exposed to 60 mM KPSS, followed by 3 ! 10-8 M sodium nitroprusside (SNP). C: Third artery exposed to 60mM KPSS, followed by 10-5 M 
SNP. 
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Figure 5.11 shows the group mean ± SEM responses to incrementing concentrations of 
SNP (10-10 M, 10-9 M, 10-8 M, 3 ! 10-8 M, 10-7 M, 10-6 M and 10-5 M) in MA and PA. 
There was no difference in the mean maximal relaxation at maximal concentration of 
SNP (10-5 M) between the artery types (MA: relaxation of 64.0 ± 4.46 %, n = 7 versus 
PA: relaxation of 73.6 ± 5.19 %, n = 6) and their rates of relaxation were similar, as 
highlighted by their t1/2. MA reached its t1/2 at 3.29 ± 1.25 minutes, whilst PA reached it 
at 3.52 ± 0.61 minutes. However, mean relaxations were greater in PA compared to MA 
at the following sub-maximal concentrations of SNP: 10-8 M (MA: relaxation of 3.99 ± 
2.23 %, n = 7 versus PA: 43.6 ± 10.0 %, n = 6), 3 ! 10-8 M (MA: relaxation of 14.5 ± 
3.31 %, n = 7 versus PA: 55.1 ± 7.14 %, n =6) and 10-7 M (MA: relaxation of 23.4 ± 
5.25 %, n = 7 versus PA: 63.6 ± 2.84 %, n = 6).  
 
Figure 5.12 shows the group mean ± SEM responses over a time-course of 20 minutes 
to a sub-maximal dose of 3 ! 10-8 M SNP in MA and PA. Constrictions to KPSS 
differed between MA and PA (MA: 10.7 ± 0.60 kPa, n = 7 versus PA: 6.35 ± 0.38 kPa, 
n = 6). Both artery types relaxed in the presence of the NO donor compared to their 
respective VC (MASNP: relaxation of 14.5 ± 3.31 % versus MAVC: no change at 0.01 ± 
0.22 %, n = 7 and PASNP: relaxation of 55.1 ± 7.14 % versus PAVC: increase of 15.1 ± 
6.06 %, n = 6). The mean maximal relaxation to 3 ! 10-8 M SNP in MA was lower than 
that in PA. 
 
These results may highlight a greater sensitivity to SNP in placental compared to 
myometrial arteries pre-constricted with high K+. 
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Figure 5.11: Summary data of responses induced by sodium nitroprusside in human 
myometrial and placental arteries pre-constricted with 60 mM KPSS. Responses to 
incrementing concentrations of SNP (10-10 M, 10-9 M, 10-8 M, 3 ! 10-8 M, 10-7 M, 10-6 M and 
10-5 M) are expressed as percentages of the constriction obtained with 60 mM KPSS. MA: 
Myometrial Arteries, PA: Placental Arteries. * Statistical difference between MA and PA 
responses to SNP. " Statistical difference relative to MA at the specified concentrations. 
 
 
 
 
Figure 5.12: Summary data of responses induced by 3 ! 10-8 M sodium nitroprusside in 
human myometrial and placental arteries pre-constricted with 60 mM KPSS. Responses to 
3 ! 10-8 M SNP are expressed as percentages of the constriction obtained with 60 mM KPSS 
over a 20 minute time period. MA: Myometrial Arteries, PA: Placental Arteries, VC-MA: 
Vehicle Control for MA, VC-PA: Vehicle Control for PA. SNP: sodium nitroprusside. * 
Statistical difference relative to the respective VC. " Statistical difference relative to SNP-MA. 
# Statistical difference relative to VC-MA. 
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5.6. Discussion 
 
This study sought to assess the effects of endothelial-dependent and –independent 
relaxatory agents on pre-constricted human MA and PA.  Bradykinin, or histamine, had 
considerable relaxatory influences on MA but limited effect on PA. The sGC activator, 
YC-1, and the NO donor SNP, induced significant relaxations in pre-constricted human 
MA and PA. YC-1 induced greater effects in MA than PA. These results again pointed 
to the possibility of greater relaxatory sensitivities over the sGC/PKG axis in MA 
compared to PA.  A surprising finding was that PA displayed greater relaxations at sub-
maximal concentrations of SNP compared to MA. This may indicate higher sensitivities 
to the NO donor in arteries from the placenta compared to those from the myometrium.  
 
Prior to the assessments of SNP- and YC-1-induced relaxations in human MA and PA, 
an initial evaluation of the effects of O2 was carried out in PA to determine whether 
similar O2 levels as those observed in the myometrial circulation (20 %) (Rodesch et al., 
1992) would alter vascular relaxation capacity of PA. This study showed that 
endothelium-dependent relaxations, as assessed by BK and His, were similar (and 
small) at 20 % and 7 % O2, as were endothelium-independent relaxations induced by the 
NO donor, SNP. YC-1-induced relaxations were, however, greater at higher (20 %) than 
lower (7 %) O2 levels. Smaller relaxations in PA at low versus high O2 may have falsely 
highlighted differences in relaxations between MA and PA. Previous studies had not 
reached a consensus as to the effects of O2 on PA vascular reactivity and were carried 
primarily in U46619-pre-constricted arteries. McCarthy et al (1994) reported that the 
sensitivity to SNP was reduced at high O2 (20 %) (McCarthy et al., 1994), whilst 
Wareing et al showed that responses to SNP were similar at higher (20 %) and lower 
(7 %) O2 levels and only altered relaxation capacity in hypoxic conditions (2 % O2) 
(Wareing et al., 2003b, Wareing et al., 2006b). Thus, the present results and prior 
studies supported the use of similar O2 levels in both PA and MA in the assessment of 
SNP- and YC-1-induced effects on the two artery types, as it would not likely highlight 
any differences, which may not have physiological relevance.  
 
In this study, the assessment of YC-1 and SNP-induced responses in arteries pre-
constricted via activation of Ca2+ channels, following addition of 60 mM K+, was a 
novel experimental design in human arteries. Most studies have carried out endothelial-
independent relaxatory studies on arteries pre-constricted via activation of G protein-
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coupled receptors with agonists such as U46619 (McCarthy et al., 1994, Mills et al., 
2007a), ET-1 (McCarthy et al., 1994), NE (McCarthy et al., 1993) or PE (Lu et al., 
2008). In this study, 60 mM K+ induced substantial constrictions in both MA and PA 
and these constrictions were greater in MA than PA. High K+ depolarises the VSMC 
membrane, activating voltage-gated Ca2+-channels, which allow an influx of Ca2+ in the 
cell (Himpens and Somlyo, 1988). Constriction of VSMC is then initiated via formation 
of the Ca2+-CaM complex, activation of MLCK and subsequent phosphorylation of 
MLC20 (Himpens and Somlyo, 1988, Somlyo and Himpens, 1989). Several explanations 
may account for the difference in contractile capacities observed between MA and PA. 
First, it has been suggested that SMC contain two isoforms of MLCK, long and small. 
The long MLCK is thought to display a higher binding affinity for actin filaments 
compared to the short MLCK (Blue EK et al., 2002, Smith et al., 2002). A higher level 
of long MLCK in MA may induce greater contractile capacities to high K+ in MA 
compared to PA. However, telokin and short (130 kDa) MLCK expression levels were 
found to be similar between MA and PA (Chapter 4), therefore long MLCK levels may 
also be similar between the two artery types.  A second explanation may lie in the vessel 
structure of MA and PA. It has been shown that PA contain a thicker medial layer with 
the SMC separated by considerably more amounts of ECM than MA (Sweeney et al., 
2006b). The development of force in PA may therefore be greatly reduced due to a 
lower number of SMC per selected area and thus less communication between SMC to 
propagate the contraction. Finally, differing expression levels of the voltage-gated Ca2+-
channels may also lead to differing contractile capabilities between the two artery types, 
although, to date, there are no reports comparing the expression levels of these channels 
between MA and PA. In addition to the lower K+-induced contractile capacity of PA 
versus MA, PA also presented a steady increase to high K+ over time and, contrary to 
MA, did not plateau. The reason for this response is yet to be determined. Such 
observations were not reported in the literature, however similar slow steady increases 
were shown in U46619-constricted PA (Mills et al., 2007b), which may reflect a more 
tonic SM phenotype of PA compared to MA (Sweeney et al., 2008). 
 
This study also extended previous suggestions that relaxatory capacities to endothelial-
dependent vasodilators differed between MA and PA, by comparing for the first time in 
the same controlled experimental circumstances, the effects of two different agents 
across each artery type. As detailed in Chapter 2, Section 2.4, endothelial function of 
arteries was routinely tested by the actions of BK on KPSS pre-constricted arteries.  The 
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relaxations of arteries to BK reported in the experimental sub-series of this chapter were 
similar to the responses observed overall in MA and PA presented in Chapter 2. MA 
displayed greater relaxations to both BK and His compared to PA, also consistent with 
former reports.  Sweeney et al (2008) showed that BK induced relaxations up to 94 % 
in U46619-constricted (10-6 M) MA, whilst relaxations in PA were small (10 %) 
(Sweeney et al., 2008). Additionally, Wareing et al (2004) reported BK-induced (10-10 – 
10-6 M) relaxations of up to 78 % and 69 % from arginine vasopressin (AVP)- and 
U46619-constricted MA, respectively (Wareing et al., 2004). The same group also 
highlighted the lack of significant responses to BK (10-10 – 10-6 M) of term PA pre-
constricted with either AVP (10-8 M), U46619 (10-6 M) or high K+ (Wareing, 2002).  
Moreover, incremental doses of His (10-8 - 10-6 M) induced small relaxations (up to 
17 %) in PA pre-constricted to sub-maximal, but not maximal, concentrations of 
U46619 (10-7 M) (Mills et al., 2007b). The same vasodilator also induced concentration-
dependent relaxations (10-10 – 10-5 M), which reached 70 %, in intact isolated small 
uterine arteries pre-constricted with 30 mM KCl (Spitaler et al., 2002). Thus, 
relaxations to BK and His observed in this study in MA and PA confirmed the 
difference in endothelial-dependent responses between the myometrial and placental 
circulations. 
The study also reported greater relaxations in MA compared to PA at the sGC/PKG 
level as shown with the addition of the sGC activator, YC-1, at sub-maximal 
concentrations (10-7 M, 3 ! 10-7 M, 10-6 M). This difference was not observed over the 
higher concentrations of YC-1 (3 ! 10-6 M, 10-5 M, 3 ! 10-5 M), although relaxations at 
maximal concentrations of YC-1 were faster in MA than PA. These results may 
highlight a greater sensitivity at the sGC level in MA compared to PA. The 
concentrations of YC-1 using in this study were similar or higher to those reported. 
Bainbridge et al (2002) used 10-4 M to show an increase in perfusion pressure in a 
placental cotyledon, whilst Seitz et al (1999) reported relaxations induced by 3 ! 10-5 M 
YC-1, albeit in KPSS-constricted rat aorta (Seitz et al., 1999).  
 
YC-1, a benzyl indazole cell-permeable derivative (Tulis et al., 2000) is known to 
activate sGC, increasing its activity by around 10 fold, independently of NO (Mulsch et 
al., 1997). The activating effects of YC-1 were thought to be highly dependent upon the 
presence of the reduced Fe2+ prosthetic heme moiety of sGC. Its removal was thought to 
abolish any NO- or heme-dependent activator-induced enzyme activation (Ignarro et al., 
1986, Foerster et al., 1996). However, YC-1 has also been suggested to activate sGC 
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independently of the heme moiety, with greater activation potential in the presence of 
the heme nonetheless (Martin, 2001).  YC-1 may have induced relaxations in MA and 
PA via: (i) PKG activation and modification of myofilament-associated events (cf. 
Chapter 1, Figure 1.8) and/or (ii) PKG-induced activation of large-conductance Ca2+-
activated K+-channels (BKCa) (cf. Chapter 1, Figure 1.7). Following activation of sGC 
by YC-1, production of cGMP and activation of PKG likely induced vasodilation in 
MA and PA (Waldman and Murad, 1987, Friebe and Koesling, 2003). The effect of 
YC-1 on PKG (and sGC) was shown in studies on human alveolar basal epithelial cells, 
which reported that addition of a PKG inhibitor, KT5823, and a sGC inhibitor, ODQ, 
reversed the stimulatory effect of YC-1 on the expression of the cyclooxygenase 
enzyme 2 (Chang et al., 2002). PA (300 – 700 µm) are known to express BKCa in both 
EC and VSMC (Sand et al., 2006). A role for PKG in the activation of BKCa channels 
was shown in studies in human coronary arterioles, which reported that inhibition of 
PKG (by Rp-8-Br-PET-cGMP), but not sGC (by ODQ), mimicked the inhibition of 
flow and H2O2-induced dilation observed following BKCa inhibition by iberiotoxin 
(Zhang et al., 2012). Meanwhile, a direct effect of YC-1 was shown on another K+ 
channel, namely the voltage-dependent K+ channel. A recent study in rabbit coronary 
SMC showed a YC-1-induced inhibition of these channels, which was not observed 
following pre-treatment with another sGC activator (Bay 41-2272), a sGC inhibitor 
(ODQ) or a PKG inhibitor (Rp-8-Br-PET-cGMP) (Park et al., 2010).  Thus, the putative 
actions of YC-1 on the contractile filaments and/or BK(Ca) channels are likely via direct 
activation of PKG. Measurements of PKG activation and/or cGMP elevation would be 
necessary to confirm these results. 
 
This study also assessed the role of NO in human MA and PA, using SNP. This was the 
nitrovasodilator of choice, as Zhang et al (2001) had shown that, in PA, SNP and GTN 
were equipotent and represented the two nitrovasodilators with the highest potency, 
compared to other vasodilators, such as SNAP, SNG or NaNO2 (Zhang, 2001). SNP is a 
“spontaneous” NO donor, which releases NO rapidly upon distribution in aqueous 
solvents and does not require enzymatic reduction or hydrolysis for this process (Verner, 
1974). Degradation of SNP also generates two other biologically active products 
besides NO, notably cyanide and free iron (Verner, 1974, Schroeder, 2006). The free 
cyanide radicals, which are released following reaction of the iron atom from the 
nitroprusside radical with free sulphydryl groups, are thought to then be linked to 
sulphydryl groups and form thiocyanate, which is less toxic (Verner, 1974). Rapid 
 166 
actions of SNP were observed in this study as relaxations reached a plateau within 5 – 
10 minutes in both MA and PA. This study has shown that SNP induced relaxations in 
human MA and PA over a range of concentrations (3 ! 10-8 – 10-5 M). Relaxations 
observed in pre-constricted MA and PA were similar to those reported in previous 
studies, in which the main contractile agent was U46619. McCarthy et al (1994) 
reported concentration-dependent relaxations to SNP (10-9 – 10-5 M), with maximal 
relaxations of 65 % in U46619-constricted arteries (McCarthy et al., 1994), while Zhang 
et al (2001) showed that PA, pre-constricted with submaximal concentrations of 
U46619 (3 ! 10-9 – 10-7 M), also displayed concentration-dependent relaxations (1.3 ! 
10-8 – 5.7 ! 10-5), which reached a maximum of 98 % (Zhang et al., 2001). Wareing et 
al (2006) further confirmed these findings when U46619-constricted PA were shown to 
relax up to 90 % to a range of SNP (10-10 – 10-4 M) (Wareing et al., 2006b). Finally, 
SNP-induced relaxations of U46619-constricted term MA were shown to reach 65 – 
70 % to a similar range of SNP as used in this study (10-10 – 10-5 M) (Andersen et al., 
2011).  
 
In this study, SNP-induced vasodilation likely occurred via two pathways working in 
synergy. The first involved activation of the NO/cGMP/PKG pathway. The release of 
NO is known to activate sGC (Friebe and Koesling, 2003) leading to the production of 
cGMP (Waldman and Murad, 1987), activation of PKG and VSMC relaxation (Warner 
et al., 1994). The second may involve direct activation of BKCa by NO and, as 
highlighted above, the downstream-activated PKG. The direct effect of NO on BKCa 
was shown following addition of a BKCa inhibitor, charybdoxin, which partly inhibited 
SNAP-induced relaxations and which were further inhibited following addition of ODQ 
(sGC inhibitor) (Sand et al., 2006). The exact mechanisms by which NO may directly 
activate BKCa are still unknown. Studies in human skin fibroblasts highlighted the 
stimulatory effect of PKG on BKCa via SNP following inhibition of these channels with 
the addition of a sGC inhibitor (ODQ) and PKG inhibitor (KT5823) (Lim et al., 2005).  
Voltage-dependent K+ channels may also play a role in hyperpolarising the membrane, 
as studies in rat mesenteric arteries have suggested that NO activates both sGC and 
voltage-dependent K+ channels (Irvine et al., 2003). Thus, SNP seems to influence both 
the SMC membrane potential, with its direct effect on K+ channels, and myofilaments 
with its stimulus on the sGC/PKG axis. 
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A surprising finding in this study was the observation that sub-maximal concentrations 
of SNP (10-8 M, 3 ! 10-8 M and 10-7 M) induced greater relaxations in PA compared to 
MA. Mean maximal relaxations at higher concentrations of SNP (10-6 M and 10-5 M) 
were not different between the two artery types. This may highlight a difference in 
sensitivity to SNP, rather than a difference in relaxatory capacity between MA and PA. 
The increased oxidative effect elicited by SNP may, at least partly, explain this 
observation. Onset of circulation during fetoplacental development is associated with an 
increase in oxygen concentration (Jauniaux et al., 2000) and in rates of ROS generation 
(Wisdom et al., 1991). A study on intact PA reported greater relaxations to SNP in the 
presence of ROS generating agonists (xanthine and xanthine oxidase) compared to 
controls (Mills, 2009), highlighting a sensitivity of PA to ROS. This sensitivity may not 
be present in MA, eliciting the observed difference in relaxations at sub-maximal 
concentrations of SNP.  A second explanation for the differences in responses to SNP 
and YC-1 between the two artery types considers the lower constrictions to high K+ in 
PA compared to MA. Membrane voltage change resulting from depolarisation to high 
K+ may be lower in PA than MA, resulting in less Ca2+ influx into the cell acting on the 
myofilaments in PA. The direct actions of SNP on K+ channels may therefore be 
effected on a less depolarised membrane, making it more susceptible to inhibition of 
these channels, thereby generating greater relaxations of PA compared to MA. 
Meanwhile, the main effects of YC-1 may be via PKG activation and its actions on 
myofilaments, resulting in greater relaxations in MA compared to PA. A third 
explanation may reside in differing expression levels and/or activities of K+ channels 
between MA and PA.  
 
In summary, this study has reported a surprising finding in the potential difference in 
sensitivity to the NO donor between MA and PA. However, upon activation of sGC 
with YC-1, MA displayed greater sensitivities than PA, in accordance with previous 
observations at the PKG level (Chapter 4).  It is unclear, why PA exhibited low 
endothelial-dependent relaxations and lower endothelial-independent sensitivities at the 
sGC and PKG levels compared to MA, yet presented enhanced sensitivities at the NO 
level. However, they may likely result from differing interactions between the actin-
myosin filaments and membrane channel stimulations, rather than differing expressions 
of proteins involved in the relaxatory pathway, since assessment of some of these 
proteins revealed no difference in expression between the two artery types (Chapter 4).  
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6 Chapter 6 
General Discussion 
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This study set out to answer three principal physiological queries: 
(i) Do human MA and PA display agonist-mediated Ca2+-sensitising responses 
over a range of [Ca2+]? 
(ii) Does the phenomenon of Ca2+-desensitisation occur in MA and PA and is it 
mediated via the cGMP/PKG pathway?  
(iii) Are there any differences in the contractile and/or relaxatory responses 
between the two artery types? 
 
A first contribution of this study reported that the phenomenon of Ca2+-sensitisation 
occurs over a range of [Ca2+] in human permeabilised arteries from the myometrium 
and placenta. Whilst constrictions to Ca2+ alone were shown to be similar between the 
two artery types, PA displayed lower sensitivities to Ca2+ than MA. SM force is 
predominantly determined by a balance between activities of MLCK and MLCP, with 
Ca2+ directly increasing the activity of MLCK (Fisher, 2010). The observed difference 
between MA and PA may originate from an innate difference in sensitivities to Ca2+ of 
the myofilaments. Table 6.1 illustrates differences in concentrations of solutes, 
vasoconstrictors and vasodilators present in the fetal (placental) and maternal 
circulations and thought to participate in regulating their tone. Of note is the fact that 
concentrations of several tone regulatory contractile and relaxatory agents have not been 
recorded in fetal circulations. This highlights a lack of knowledge of the building blocks 
involved in regulating vascular tone of the fetoplacental circulation. Concentrations of 
the physiologically important potassium, sodium, calcium and chloride have all been 
reported higher in the fetal compared to maternal vasculature (Delivoria-Papadopoulos 
et al., 1967, Faber and Thornburg, 1981, Mohammed et al., 1992, Bissonnette et al., 
1994), which may explain the observed differences in their contractile and/or relaxatory 
responses. Indeed, this difference in concentrations of Ca2+ may have rendered the 
maternal circulation more sensitive to lower [Ca2+] than the placental vasculature, 
leading to the greater contractile responses at sub-maximal Ca2+ observed in MA 
compared to PA. Similarly, greater [K+] and [Na+] in the fetal versus maternal 
circulation may also have impacted on the amplitude of high K+-induced constrictions 
in intact MA and PA. Opening of voltage-gated Ca2+ channels is the result of a change 
in membrane potential towards more positive values (depolarisation). Greater initial K+ 
levels in PA may regulate the membrane potential at rest to be more positive. Addition 
of high K+ may therefore result in less membrane voltage changes or depolarisation and 
less Ca2+ entering the cell to induce SMC constriction, which may explain the observed 
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lower high K+-induced constrictions in PA compared to MA. Indeed, constrictions 
induced by high Ca2+ (pCa4.5) reached similar magnitudes in both artery types; the 
differences between MA and PA may therefore reside at the membrane potential, rather 
than general contractile capacities. 
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Table 6.1: Concentrations of ions, vasodilators and vasoconstrictors in human maternal and fetal circulations. 
 
Solute 
Mean maternal concentration  
(± SEM) 
Mean fetal concentration  
(± SEM) 
References 
Calcium 2.1 ± 0.1 mmol/L water 2.6 ± 0.1 mmol/L water 
(Faber and Thornburg, 1981), (Delivoria-Papadopoulos et 
al., 1967), (Abramovich et al., 1987) 
Sodium 135.4 ± 2.4 mmol/L water 137.0 ± 2.8 mmol/L water (Faber and Thornburg, 1981), (Flexner et al., 1948) 
Potassium 4.3 ± 0.1 mmol/L water 4.8 ± 0.2 mmol/L water (Mohammed et al., 1992), (Canning and Boyd, 1984) 
Chloride 107 ± 2.0 mmol/L water 109 ± 2.3 mmol/L water (Faber and Thornburg, 1981), (Bissonnette et al., 1994) 
Thromboxane A2 0.76 nmol/L 
0.510 nmol/L (term gestation) 
0.286 nmol/L (peripheral 
plasma) 
(Mitchell and Robinson, 1978), (Sellers et al., 1981) 
Bradykinin 10 nmol/L  (Melmon et al., 1968) 
Prostaglandin F2! 19 nmol/L  (Craft et al., 1973) 
Prostaglandin E2 0.36 nmol/L  (MacKenzie et al., 1980) 
Endothelin-1 1.08 pmol/L 0.361 pmol/L (Bracero et al., 1995) 
Histamine  470.9 ± 109.8 nmol/L (Lorenz et al., 1972), (Kimera, 1999) 
Angiotensin II 0.49 nmol/L  (Broughton Pipkin and Smales, 1975) 
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Conversely to major ion concentrations, other central vasoactive agents were reported 
much lower in the fetal compared to the maternal circulation (Table 6.1), such as 
thromboxane A2 (TXA2) or ET-1, which may explain the results obtained in agonist-
mediated Ca2+-sensitisation. Following addition of the potent TXA2 mimetic, U46619, 
the sensitisation capacities in PA were raised, resulting in constrictions in this artery 
type to reach those in MA. The lower agonist levels in fetoplacental blood vessels may 
have led to an increase in sensitivity of this vasculature to contractile factors. The 
assessment of responses to vasconstrictive agonists in controlled Ca2+ conditions 
attempted to elucidate differences in sensitivities to both solute Ca2+ and agonist (TXA2, 
ET-1, S1P) in MA and PA. During pregnancy complications, such as preeclampsia and 
gestational hypertension, levels of the vasoconstrictors TXA2, ET-1 and angiontensin II 
have been shown to greatly increase (VanWijk et al., 2000, George and Granger, 2011). 
These are, in part, responsible for the increased peripheral vascular resistance and 
vasoconstriction observed in these disorders (Visser and Wallenburg, 1991). The 
increased sensitivity of PA myofilaments to Ca2+ in the presence of TXA2, as observed 
in the present study, may be exacerbated in the fetoplacental circulations of women with 
preeclampsia, intensifying existing differences between maternal and placental 
vasculature. 
 
 
The central contribution of this study underlined differences in the relaxatory patterns of 
MA and PA, which may highlight differing sensitivities to vasodilators involved in the 
regulation of myometrial and placental circulations.  
 
The first assessment highlighted the phenomenon of Ca2+-desensitisation. The 
vasodilator mimetic 8-br-cGMP induced relaxations in MA and PA via activation of 
PKG and desensitisation of the myofilaments to constant [Ca2+]. PKG induced greater 
relaxations in both constricted and sensitised MA compared to PA, however the 
difference in sensitivity between the two artery types was not due to differing levels of 
PKG, as expression of this protein was similar in MA and PA. It may be due to a 
redistribution of actin-interacting proteins in MA to enhance dissociation of actin 
filaments with myosin filaments and induce greater and faster relaxation. MA develop 
phasic-like responses, in that frequent oscillations rising in amplitude develop upon 
constriction with TXA2, whilst PA develop steady constrictions at the same agonist 
concentration (Sweeney et al., 2008), conferring PA a more slow tonic phenotype. 
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Surprisingly, pregnant (phasic) myometrial SM strips failed to relax upon addition of 8-
br-cGMP and PKG levels decreased throughout pregnancy, inferring that the pregnant 
human myometrium may be insensitive to cGMP/PKG (Cornwell et al., 2001). 
However, expression levels of two actin filament-associated proteins, caldesmon and 
calponin, were found to increase during pregnancy and increase cross-bridge 
dissociation of actin and myosin filaments to induce relaxation (Cornwell et al., 2001). 
Thus, should MA be predominantly phasic, the difference in responsiveness to cGMP 
between the myometrial and placental vasculature may result from a decrease in the 
accessibility of actin to myosin following redistribution of actin-interacting proteins.  
 
PKG is thought to interact with a variety of proteins, which have also been shown to 
interact with actin or myosin filaments in their phosphorylated state to induce relaxation. 
Ca2+-desensitisation may have been induced via the direct effects of PKG-interacting 
proteins on the myofilaments and via the increase in MLCP activity by PKG. Figure 6.1 
illustrates the possible signalling mechanisms involved in PKG-mediated 
desensitisation to Ca2+. 
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Figure 6.1: Potential mechanisms inducing PKG-mediated Ca2+-desensitisation in human myometrial and placental arteries. VSMC: vascular smooth muscle 
cell, GPCR: G-protein-coupled receptor, NO: nitric oxide, sGC: soluble guanylate cyclase, GTP: guanosine-5’-triphosphate, GDP: guanosine diphosphate, PKGI: 
protein kinase G isoform I, LZ: leucine zipper, HSP20: heat shock protein 20, VASP: vasodilator-stimulated phosphoprotein, MLCP: myosin light chain 
phosphatase, MLC20: myosin light chain 20. P-: phosphorylation site, deP-: dephosphorylation, Ca2+: calcium ion. Red arrow represents an increase in activity. Black 
arrows: stimulation. Black stop: inhibition. ?: uncertain mechanism. Grey lines: inhibited signalling. 
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The small heat shock protein 20 (HSP20) likely induced PKG-mediated Ca2+-
desensitisation in MA and PA via its interaction with actin filaments following its 
phosphorylation at Ser-16 by PKG. Phospho-HSP20 was associated with active 
relaxation of permeabilised bovine carotid SM, but not with MLC20 dephosphorylation 
(Beall et al., 1997, Beall et al., 1999, Rembold et al., 2000). Thus its effects were 
unlikely mediated via MLCP-induced actions on myosin filaments, rather by its direct 
association with actin filaments and a second heat shock protein, HSP27 (Tyson et al., 
2008a). Both HSP20 and HSP27 were found to co-localise with !-smooth muscle actin 
in the cytoplasm in human myometrium, although to differing degrees (MacIntyre et al., 
2008, Tyson et al., 2008a). HSP27 has also been shown to relocate from the cytoplasm 
of nonlabouring myometria to the actin cytoskeleton in labouring myometria 
(MacIntyre et al., 2008). While phospho-HSP27 would stabilise actin filaments for 
VSMC constriction, phospho-HSP20 may therefore induce relaxation through breaking 
the actin-myosin cross-bridge following alteration of the actin filaments via its 
association with HSP27 (and/or other proteins). Thus, Ca2+-desensitisation in MA and 
PA may have occurred both via phospho-HSP20 interaction with actin filaments 
inducing their dissociation from myosin filaments and via sequestration of HSP27 to the 
cytoplasm. This study has found that expression levels of HSP20 were similar in MA 
and PA. The difference in relaxation observed between MA and PA may therefore 
result from differences in the phosphorylated states of HSP20 affecting actino-myosin 
filament interactions. 
 
A second actin-binding protein, known as the small vasodilator-stimulated 
phosphoprotein (VASP), may also have been involved in inducing Ca2+-desensitisation 
in MA and PA, by inhibiting actin polymerisation (Reinhard et al., 2001, Kim et al., 
2010) and thus actin-myosin interactions following its activation and phosphorylation at 
Ser-239 by PKG (Smolenski et al., 1998, Schulz et al., 2002, Schafer et al., 2003).  
There are currently no studies reporting on levels of VASP or phospho-VASP in human 
MA and/or PA. The differences in relaxations between the two artery types may be due 
either to differing levels of VASP or, more likely, to greater levels of the phospho-
protein in MA compared to PA, which may result in greater actinomyosin filament 
dissociations in SMC from the myometrial versus placental circulation.  
 
PKG may also have desensitised the myofilaments of MA and PA to Ca2+ via inhibition 
of the RhoA/ROK pathway by PKGI-induced phosphorylation of ROK at Ser-188 
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(Sauzeau et al., 2000b, Gudi et al., 2002), which prevented inhibition of MLCP (Dong 
et al., 1998, Sward et al., 2003, Wang et al., 2002). Similarly, inhibition of the PKC- 
and ROK-activated CPI-17 by PKGI may also have induced Ca2+-desensitisation by 
accelerating dephosphorylation of CPI-17 at residue Thr-38 and releasing MLCP 
inhibition (Bonnevier and Arner, 2004). In addition, greater 8-br-cGMP-induced 
relaxations were reported in SM sensitised with GTP!S, ROK and PKC compared to 
unsensitised (sub-maximally Ca2+-constricted) SM (Bonnevier and Arner, 2004). 
Similar findings were also observed in the present study and may have resulted from 
higher levels of dephosphorylated CPI-17 in Ca2+-sensitised compared to Ca2+-
constricted arteries. The phosphorylated state of CPI-17 relies upon G protein-coupled-
receptor-dependent activation of PKC and ROK, which occurs in pre-sensitised arteries, 
but unlikely does so in unsensitised arteries. Greater dephosphorylated levels of CPI-17, 
releasing MLCP inhibition, may have stimulated increases in MLCP activity in Ca2+-
sensitised arteries to levels exceeding those observed in Ca2+-constricted vessels, where 
a balance between MLCK and MLCP activities may have still existed; thus inducing 
greater relaxations in sensitised arteries compared to Ca2+-constricted ones. MLCP-
induced increases in dephosphorylated MLC20 may highlight variations in the 
accessibility of actin to myosin in SMC from myometrial and placental circulations.  
CPI-17 protein levels have been reported to be lower in phasic (non-vascular) SM, 
which incidentally often presented lower sensitivities to NO and/or PKG, than those in 
arterial, more tonic SM (Woodsome et al., 2001, Fisher, 2010). One may have expected 
greater levels of CPI-17 in MA compared to PA to explain the increased relaxatory 
abilities of the former artery type, however, CPI-17 expression levels were found to be 
similar between MA and PA; the differences may therefore reside in the 
phosphorylated/dephosphorylated ratios of this protein. 
 
Another suggested mediator of cGMP-mediated Ca2+-desensitisation is telokin, whose 
phosphorylation at Ser-13 by PKG has been shown to induce relaxations in 
permeabilised rabbit ileal SM (Wu et al., 1998, Walker et al., 2001) and to enhance 
MYPT1/MLCP activity (Khromov et al., 2006); however only in conditions, in which 
the phosphatase was already inhibited (by phosphorylations at Ser-696/853, numbering 
of human isoform) (Khromov et al., 2012). Relaxations were greater and faster in MA 
than in PA and studies showed that predominantly fast phasic SM displayed higher 
telokin levels and greater relaxations compared to slow tonic SM (Choudhury et al., 
2004). However, the differences in relaxation between the two artery types, in this 
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instance, were not explained by differing expressions of telokin, as these were found to 
be similar in MA and PA. This, once more, underlines the subtle differences between 
the two circulations, which may not only be explained by differing protein levels. 
Assessment of phosphorylated telokin at Ser-13 may reveal greater levels in MA 
compared to PA, which would enhance MLCP affinity for myosin filaments in MA and 
displace their interaction with actin filaments via dephosphorylation of MLC20 
(Khromov et al., 2012).  
 
These protein expression studies highlighted that differences between the two 
circulations likely occur at the level of their SMC actin and myosin filament interactions. 
 
PKGI may also affect MLCP activity directly, partly via phosphorylating MYPT1 at 
Ser-695 (human isoform) (Nakamura et al., 1999, Wooldridge et al., 2004) and partly 
by interacting with its leucine-zipper (LZ) region at its C-terminus (Surks et al., 1999). 
Phosphorylation of Ser-695 by 8-br-cGMP was shown to prevent phosphorylation of 
the MLCP-inactivating Thr-696, which is immediately adjacent to Ser-695; thus 
preventing inhibition of MLCP (Wooldridge et al., 2004). However, phosphorylation at 
Thr-696 was also shown to decrease by only 50 % with 8-br-cGMP stimulation, whilst 
the tension of phenylephrine-pre-contracted rabbit femoral arteries and the MLC20 
phosphorylation fell to baseline (Nakamura et al., 2007), which indicated that Ser-695 
phosphorylation was not solely responsible for PKG-mediated Ca2+-desensitisation. The 
aforementioned PKG-interacting putative proteins and their effects on myofilaments 
and/or MLCP activity may have induced the remaining fall in tension observed. Such 
mechanisms may also have been in play in human MA and PA.  
 
Additional regulation of MLCP activity via LZ-LZ interaction with PKGI may also 
have played a role. Chicken gizzard and aorta SM expression of LZ-negative isoforms 
were shown to develop a resistance to cGMP as relaxation in response to 8-br-cGMP 
after Ca2+ activation of the myofilaments was abolished as was MLC20 
dephosphorylation (Khatri et al., 2001). Additionally, the LZ-negative isoform has been 
shown to predominate in fast-phasic VSM phenotypes (Huang et al., 2004, Payne, 
2004). Consistent with this consensus, small rat mesenteric arteries were found to 
express predominantly the LZ-negative isoform and to be less responsive to NO/cGMP 
signalling compared to large conductance vessels signalling (Feletou et al., 1989, Nagao 
et al., 1992, Sauzeau et al., 2000a).  It was proposed that MYPT1 isoforms may be 
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expressed in a tissue-specific manner throughout the vasculature (Payne, 2004) and that 
even in mature vasculatures, SMC retain their plasticity, such that they can undergo 
relatively rapid and reversible phenotypic changes in response to accommodate 
demands of the local environmental signals (Owens, 1995, Payne, 2004), such as those 
leading to remodelling and vasodilatory adaptations during pregnancy. Should MA 
contain mostly phasic SM, this artery type may have been expected to express 
predominantly LZ positive isoforms. However, the differences between two resistance 
artery types, such as MA and PA, may be more delicate than those observed between 
small (phasic) resistance arteries and large (tonic) conductance arteries. Assessing LZ-
positive and –negative MYPT1 isoforms may elucidate small differences between the 
two artery types, as assessment of MYPT1 expression levels, undifferentiating between 
LZ isoforms, were found to be similar in MA and PA.  
 
These subtle variations in LZ-positive isoform expression between MA and PA may 
result from differing O2 levels present in myometrial and placental circulations and may 
impact on MYPT1/PKG LZ-LZ interactions. Physiologically, it is thought that the 
placental circulation is exposed to lower O2 levels compared to the myometrial 
vasculature (Soothill et al., 1986, Rodesch et al., 1992) and recent studies reported that 
hypoxia reduced expression of LZ-positive MYPT1 in ovine fetal pulmonary arterial 
SMC and that interactions between LZ-positive MYPT1 and PKG were decreased, 
whilst those between LZ-positive MYPT1 and RhoA/ROKI were increased, resulting in 
increased phosphorylated MLC20 and contraction (Singh et al., 2011). In normoxic 
conditions, an increase in LZ-positive MYPT1 and PKG expressions was observed 
(Singh et al., 2011). The placental circulation may therefore display lower LZ-positive 
MYPT1 levels and, importantly, fewer LZ-positive MYPT1/PKGI interactions, 
resulting in smaller cGMP-induced Ca2+-dependent relaxations than in the myometrial 
circulation. Although O2 levels were kept similar for both artery types in the 
permeabilisation experiments, the disparity in MYPT1/PKG interactions between MA 
and PA may still have been highlighted, but may be even wider under physiological 
conditions.  
 
The second assessment highlighted that the greater relaxations observed in 
permeabilised MA compared to PA persisted over the sGC/PKG axis, in intact arteries; 
but, surprisingly, they were reversed at the NO level.  
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The sGC activator YC-1 likely acted via PKG, inducing subsequent increase in MLCP 
activity and stimulation of the BKCa for efflux of K+, hyperpolarisation and relaxation 
(Chang et al., 2002, Zhang et al., 2012). Following activation of PKG, the 
aforementioned PKG-interacting proteins likely intervened to induce relaxation in MA 
and PA, pre-constricted with high K+. HSP20 phosphorylation may have sequestrated 
HSP27 and destabilised actin-myosin interactions (Tyson et al., 2008a, MacIntyre et al., 
2008). Similarly, phosphorylation of VASP likely induced relaxation as studies in rat 
platelets reported increases in Ser-239 phosphorylated VASP (and cGMP levels) upon 
addition of YC-1 in vitro (Becker et al., 2000). Phospho-telokin also participated in 
relaxing high K+-constricted MA and PA by directly enhancing MLCP affinity for 
myosin filaments (Khromov et al., 2012). Finally, PKG acted upon MYPT1 activity via 
their LZ-LZ interactions and resulting increase in MLCP activity (Surks and 
Mendelsohn, 2003, Nakamura et al., 2007).  
 
Similarly, SNP induced relaxations via activation of PKG and its putative signalling 
pathways, as HSP20 phosphorylations at Ser-16 were found to increase in PKG-
expressing SMC upon treatment with SNP (Brophy et al., 2002) and increases in VASP 
Ser-239 phosphorylation following addition of SNP were shown to induce 
concentration-dependent relaxation of phenylephrine-constricted rat aorta (Schafer et al., 
2003). Phosphorylated telokin and LZ-LZ interactions of SNP-activated PKG and 
MYPT1 may have also contributed to induce MLCP-mediated vasodilation. 
Surprisingly, in these conditions, SNP-mediated relaxations were greater in PA 
compared to MA. A likely explanation for this observation may lie in the actions of 
SNP on the K+ channels and the sensitivity of PA to oxidative conditions, which may 
result from the lower O2 levels in the placental versus myometrial circulation (Rodesch 
et al., 1992). SNP-induced relaxations were greater in PA exposed to ROS generating 
agonists compared to controls (Mills et al., 2009). In addition, a recent study on rat 
retinal vessels inferred that ATP-sensitive K+ (KATP) channels were activated during 
exposure to ROS (Fukumoto et al., 2012). With PA presenting a particular sensitivity to 
ROS compared to MA, KATP channels along with other K+ channels (BKCa and voltage-
dependent) may also respond with greater sensitivity to oxidative stress in PA compared 
to MA, resulting in increased hyperpolarisation and greater relaxations in arteries from 
the placenta. These K+ channel sensitivities were also reduced in complicated 
pregnancy, such as fetal growth restriction, in which overall peripheral vascular 
resistance is also increased (Corcoran et al., 2008). SNP actions may have therefore 
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primarily affected membrane potentials, whilst YC-1 may have directed its effects 
towards the SMC’s actin-myosin filaments. Thus, regulation of myometrial vascular 
tone may result primarily from a sensitivity of the SM contractile apparatus to 
vasoactive and -dilatory agents, while regulation of the placental circulation may 
depend more on the membrane potential and channel activity states. 
 
The relaxatory patterns in MA and PA reported in the present study were assessed 
principally by functional experimentation and further evaluated by protein expression 
analyses. Additional studies to determine levels of the phospho-proteins directly 
involved in regulating the activity of MLCP and actin-myosin filament interactions may 
serve to further elucidate the tight balance required in the regulation of vascular tone in 
myometrial and placental circulations. However, it is noteworthy to mention that such 
studies would be carried out with great difficulty due to the very small amount of 
protein to be yielded from such small arteries, particularly when dealing with MA. For 
each functional experiment, four small 200 – 400 µm arteries of 1 – 2 mm length were 
mounted onto four myography baths. On average, a minimum of eight arterial lengths 
such as those was necessary to provide enough protein (5 µg) to load onto one lane of a 
western blot. From one myometrial biopsy and thus one patient, one could dissect 
enough arterial material to yield around 60 - 80 µg of protein. Antibody and protein 
concentration optimisations thus required the use of several myometrial samples. In 
addition, phospho-antibodies are notoriously unspecific and obtaining a reliable one 
recognising human sequences was proving rather difficult.  
 
This study may also have used a larger variety of compounds to confirm signalling 
pathways involved in the observed relaxations. Indeed, 8-br-cGMP is one cGMP 
mimetic and PKG activator that may be used; 8-pCPT-cGMP is another activator, 
which may have been used to assess Ca2+-desensitisation in the human arteries (El-
Awady et al., 2008). As the role of MLCP was established with the use of the 
phosphatase inhibitor calyculin A; a PKG inhibitor, such as KT5823 or Rp-8-Br-PET-
cGMP, may also have been used to confirm its role in the desensitisation phenomenon 
(Kang et al., 2012, Zhang et al., 2012). Similarly, the role of RhoA/ROK in Ca2+-
sensitisation may also have been directly confirmed using specific ROK inhibitors, such 
as fasudil or Y-27632 (Masumoto et al., 2001, Wareing et al., 2005b), although 
previous studies in human term MA and PA had already reported inhibition of TXA2-
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induced Ca2+-sensitisation following addition of Y-27632 (Wareing et al., 2005b). Thus, 
the involvement of the RhoA/ROK pathway was readily assumed in this study. 
 
Nonetheless, this study has highlighted novel scientific contributions in the differences 
in both constrictions and relaxations in isolated human arteries from the myometrium 
and the placental at term of healthy pregnancies. Whilst, putative signalling mechanisms 
may be similar in these two artery types, their sensitivities within these pathways 
showed great dissimilarities. Most importantly, it seems that the myometrial vasculature 
displays greater sensitivities across the sGC/PKG axis, which may result from 
differences in levels of MYPT1 isoforms and phosphorylated states of PKG-interacting 
proteins; thus directly affecting the activity of the central MLCP and actin-myosin 
filament interactions. The complex network of pathways involved may offer a plethora 
of possible leads for novel drug targets and further studies may highlight tissue-specific 
differences in the regulation of vascular tone of myometrial and placental circulations. 
This may not only allow development of more tissue-specific, and hopefully effective, 
therapeutics against pathophysiologies encountered during pregnancy, but may also 
extend for the treatment of other vascular disorders, such as asthma, functional bowel 
disease or cardiovascular disease. 
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A Appendix A: Ethical approval forms 
A.1 Myometrial ethical approval forms 
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A.2 Placental ethical approval forms 
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B Appendix B: Consent forms 
B.1 Myometrial consent forms 
 
 
 
 
CONSENT FORM 
 
Title of project: Novel regulation of human myometrial contractility by 
HDAC8 
 
Name of researchers:  Professor S. Robson, Dr N. Europe-Finner 
 
                                                 Please 
initial  box 
       
1. I confirm that I have read the information sheet dated 17th September 
 2008 for the above study and have had the opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to  
 withdraw, without giving any reason, without my medical care or legal  
 rights being affected. 
 
3. I understand that relevant sections of my medical notes and data collected 
during the study, may be looked at by individuals from regulatory  
authorities or from the NHS Trust, where it is relevant to my taking part in 
this research. I give permission to these individuals to have access to my  
records. 
 
4. I agree to take part in the above study. 
 
 
 
___________________                _________        _____________________ 
Name of patient                     Date                Signature 
 
 
 
___________________                _________        ____________________ 
Name of person taking consent      Date         Signature 
(if different from researcher) 
 
 
___________________                _________        _____________________ 
Researcher             Date         Signature 
 
 
 
 
1 for patient; 1 to be kept with medical notes 
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Novel regulation of human myometrial contractility by HDAC8 
Professor S. Robson, Dr N. Europe-Finner 
1. Introduction 
You are being invited to take part in a research study.  It is important for you to 
understand why the research is being done and what it will involve before you decide 
whether to take part.  Please take time to read the following information carefully and 
discuss it with others if you wish.  Ask us if there is anything that is not clear or if you 
would like more information. 
2. What is the purpose of the study? 
During pregnancy, the upper part of the womb (uterus) is relaxed while the lower part 
(cervix) is closed. In labour the upper part contracts and the lower part relaxes, 
allowing the baby to be born. If this occurs early, preterm birth results with major 
consequences for the baby. The drugs we use to treat premature labour are not very 
effective. In order to develop better drugs we need to understand how the womb 
contracts and relaxes. This study is investigating the effect of HDAC8 (an enzyme 
present in the womb).   
3. Why have I been chosen and do I have to take part? 
You have been chosen to take part because you are having a caesarean section.  It is 
up to you to decide whether or not to take part.  If you do decide to take part you will 
be asked to sign a consent form; a copy of your consent and this information sheet 
will be given to you to keep. If you decide to take part you are still free to withdraw at 
any time and without giving a reason.  A decision to withdraw, or a decision not to 
take part, will not affect the standard of the care you receive. 
 
4. What will happen to me if I take part? 
In order to undertake this study we need small samples of myometrium (the muscle 
layer of the womb). After the baby and placenta have been delivered a small piece of 
muscle (about the size of a pea) will be taken from the lower part of the womb (from 
the site where the womb was opened to deliver the baby).  Collecting the muscle 
sample adds less than a minute to the operation and will not affect your recovery in 
any way. 
5. What are the risks and benefits of taking part? 
Extensive experience of taking these samples suggests the procedure is not associated 
with any risk. You will not directly benefit from taking part in the study.  We will be 
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using the sample to study how the muscle contracts. This should help us understand 
why some women labour early and may allow us to develop better drugs to prevent 
premature birth.   
6. Will my taking part in this study be kept confidential? 
Participation in the study will be recorded in your hospital notes but no personal 
information will be kept by the research team.  
7. What will happen to the results of the research study? 
The study will take just over 3 years to complete.  We anticipate the results will be 
published in a medical journal. You will not be identified in any report or publication.  
8. What will happen if I don’t want to carry on with the study? 
If you withdraw from the study, we will destroy all your identifiable samples, but we 
will need to use the data collected up to your withdrawal. 
9.  What if there is a problem? 
In the event that something does go wrong and you are harmed during the research 
and this is due to someone’s negligence then you may have grounds for legal action 
for compensation against the Newcastle upon Tyne NHS Foundation Trust but you 
may have to pay your legal costs. If you have a concern about any aspect of this study, 
you should ask to speak to the researchers who will do their best to answer your 
questions. If you remain unhappy and wish to complain formally, you can do this 
through the NHS Complaints Procedure (or Private Institution). Details can be 
obtained from the hospital.   
10.  Who is organising and funding the research and who has reviewed the 
study? 
The study is funded by the Medical Research Council. The study has been approved 
by the Newcastle & North Tyneside Research Ethics Committee. It is being carried 
out by a team of researchers at Newcastle University. 
11. Contact for further information 
If you have any questions about the study please contact: Professor S. Robson (Tel: 
2824132)  
 
Thank you for reading this information sheet. 
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B.2 Placental consent forms 
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C Appendix C: Patient Information Form 
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D Appendix D: !-Toxin Export Licence 
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E Appendix E: Presentations and Publications 
E.1 Presentations and Awards 
 
June 2009:  Oral Presentation (40 minutes). Institute of Cellular Medicine 
Science Forum, Newcastle University. 
June 2009:  Oral Presentation (10 minutes). Alternative Muscle Conference, 
University of Manchester. Conference organised by PhD students 
for fellow PhD students and young PostDocs. 
November 2009: First Prize (£300), Oral Presentation (10 minutes). North-East 
Postgraduate Conference, Newcastle University.  
June 2010: Oral Presentation (10 minutes). Annual Physiological Society 
Meeting, University of Manchester.  Travel Grant obtained from 
the Physiological Society. 
June 2010: First Prize (£100), Poster Presentation. Annual Institute of 
Cellular Medicine Research Day, Newcastle University. 
July 2010: Poster Presentation. Vascular Biology Summer School, Bristol 
University. 
November 2010: Poster Presentation. Royal College of Obstetricians and 
Gynaecologists (RCOG) Annual Academic Meeting, RCOG, 
London. 
March 2011: Oral Presentation (25 minutes). Institute of Cellular Medicine 
Research Seminar, Newcastle University. 
April 2011: Oral Presentation (10 minutes). Northern Cardiac Research 
Group (NCRG) Meeting, Hull University. 
March 2012: Poster Presentation. 59th Annual Meeting for the Society for 
Gynecological Investigation, San Diego, CA, USA.  Travel 
Grants obtained from the Physiological Society and Newcastle 
University. 
 
E.2 Publications (scientific and non-scientific) 
 
A. C. Dordea, M. Sweeney, S. C. Robson, M. J. Taggart (2010), 8-br-cGMP-induced 
Ca2+-desensitisation mechanisms in human blood vessels – evidence of tissue 
specificity, Proc. Physiol Soc, 19, C136. Abstract. 
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A. C. Dordea, M. Sweeney, S.C. Robson, M.J. Taggart (2012), Human placental and 
myometrial arteries differ in their Ca2+-sensitivities of force production, Official J 
Soc Gynecol Invest, Suppl. Reprod Sciences, 19, T210. Abstract. 
A.C. Dordea (2012), Travel Grant Connections, Physiology News, Issue 87, Summer 
2012. Contribution about an International Meeting attended in San Diego, CA, March 
2012. 
A.C. Dordea (2012), Lab Profile: The Reproductive and Vascular Biology Group, 
Newcastle University, Physiology News, Issue 87, Summer 2012. Contribution about 
the research carried out in our laboratory. 
 
E.3 Society Affiliations 
 
2009 – Present: Affiliate member of the Physiological Society 
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